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INTrOduCTION 
Cancer and taxanes
Globally, 14.1 million people received a cancer diagnosis in 2012 (1). Cancer of the breast, 
prostate, lung, stomach and colorectal region are the most common malignancies in the Western 
world (1). For the treatment of these tumor types, the antineoplastic agents paclitaxel, docetaxel 
and, more recently, cabazitaxel are used. The collective term of these drugs is ‘Taxanes’, as paclitaxel 
and docetaxel were derived from different species of the pacific yew tree (Taxus brevifolia and Taxus 
baccata, respectively). Cabazitaxel is a semisynthetic dimethyloxy offshoot of docetaxel, with a change 
in the capacity to cross the blood-brain barrier and in the affinity for p-glycoprotein (2). Paclitaxel, 
docetaxel and cabazitaxel thus have common ground, despite their differences in chemical structure 
and their solvent.
Despite acceptable response rates, the use of taxanes has its downsides. Currently, the 
dosages of these drugs are determined using body surface area (3). However, taxanes have a small 
therapeutic window and a large inter-patient variability (IIV) in pharmacokinetics (PK) and toxicity 
(4). Patients are consequently at risk of receiving a higher or lower dose than optimally required. 
Because the PK of taxanes are associated with the toxicity and efficacy of these anti-cancer 
drugs, patients are at risk of insufficient efficacy and disproportionate toxicity (4,5). Toxicities as 
neutropenia, diarrhea, neurotoxicity, nausea and fatigue are common in taxane-treated patients. 
Hence, it is clinically relevant to be able to predict the exposure, efficacy and toxicity of taxanes, 
and to understand the corresponding mechanisms of factors influencing these endpoints. To 
improve current abilities in the management of taxane therapy, this thesis focuses on this topic. 
Effects of drug solvents on taxane pharmacokinetics
Because solubilizing taxanes in water is problematic, these drugs are formulated using the 
solubilizing agents Kolliphor EL (KEL; or Cremophor EL (CrEL)) and Polysorbate 80 (PS80). Though, 
both solvents were seen to affect the drug disposition of paclitaxel and docetaxel, respectively (6). 
This results in a great increase in systemic exposure to mainly paclitaxel. It was already shown that 
KEL inhibited the hepatic elimination of paclitaxel (7). As it is known that Organic Anion Transporting 
Polypeptide (OATP) 1B-type transporters are responsible for the hepatic uptake of taxanes (8), 
we hypothesized that CrEL and PS80 affected the uptake of taxanes by these transporters. These 
experiments and results are demonstrated in Chapter 2 of this thesis. 
Effects of genetic variation on taxane pharmacokinetics and toxicity
Genetic variation has also been studied as a potential factor influencing taxane PK and 
pharmacodynamics (PD) (9). This was most often done using a candidate gene approach. However, 
published results were contradictory. Genes involved in drug transport and metabolism could 
potentially affect taxane PK and PD.  In this thesis, we used the Drug Metabolizing Enzymes and 
Transporters platform, containing 1936 single nucleotide polymorphisms (SNPs) in 225 genes involved 
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in drug metabolism and transport to test this hypothesis. Using this platform, we aimed for the 
development of a genetic model predictive of paclitaxel and docetaxel-induced neutropenia and 
docetaxel clearance. This execution is described in Chapters 3 and 4.
Factors influencing docetaxel pharmacokinetics
As mentioned, a correlation exists between docetaxel exposure and efficacy. However, 
multiple factors hypothetically influence the pharmacokinetics of docetaxel considering inter-individual 
variability is high. In Chapter 5, we reviewed the literature and focused on factors influencing the 
pharmacokinetics of docetaxel such as gender, hormonal status and co-medication. 
Effects of other drugs on cabazitaxel pharmacokinetics and toxicity
 Docetaxel is among other indications used for the first line treatment of patients with 
metastatic castration resistant prostate cancer (mCRPC). A second line substitute that prolonged 
overall survival had been lacking for many years until cabazitaxel was registered in 2011 (10). Soon 
after its registration, novel androgen receptor targeted drugs (ART) abiraterone and enzalutamide also 
became available for the treatment of mCRPC. These drugs were demonstrated to be effective in both 
the pre-docetaxel and post-docetaxel setting (11-14). However, the efficacy of docetaxel in mCRPC 
patients was diminished after treatment with abiraterone (15). Preclinical studies demonstrated 
cross-resistance between enzalutamide and docetaxel in vivo, possibly explaining the reduced effect 
of docetaxel after abiraterone. We have investigated the effects of preceding ART on the efficacy of 
cabazitaxel in Chapter 6.
As mentioned, cabazitaxel is able to prolong survival of patients suffering from metastatic 
castration resistance prostate cancer. Unfortunately, in the registration study, half of the cabazitaxel-
treated patients suffered from cabazitaxel-induced diarrhea (10). Six percent of these patients 
suffered from severe diarrhea, resulting in hospital admittance (10). To decrease the incidence and 
severity of cabazitaxel-induced diarrhea we developed a large randomized controlled trial looking into 
the hypothesis that the anti-inflammatory drug budesonide would be able to decrease the incidence 
and severity of cabazitaxel-induced diarrhea (Chapter 8). To investigate whether budesonide would 
influence the pharmacokinetics of cabazitaxel, we first performed a pharmacokinetic study preceding 
the clinical trial as described in Chapter 8. In Chapter 7, we demonstrate a validated assay that is able 
to determine cabazitaxel concentrations in human plasma. 
The goal of this thesis was to improve current abilities in the management of taxane therapy 
using interventional and pharmacological approaches. Thereby aiming for providing patients with an 
optimally effective therapy, while reducing toxicity. This thesis sheds new light on factors influencing 
the pharmacokinetics and pharmacodynamics of the taxanes paclitaxel, docetaxel and cabazitaxel, 
further optimizing taxane therapy. 
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Part I 
Paclitaxel
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Chapter 2 
Influence of Drug Formulation on 
OATP1B-Mediated Transport of Paclitaxel
A.J.M. Nieuweboer, S. Hu, C. Gui, B. Hagenbuch, I.M. Ghobadi Moghaddam-Helmantel, A.A. Gibson, P. 
de Bruijn, A.H.J. Mathijssen and A. Sparreboom. 
Cancer Research. 2014 Jun 1;74(11):3137-45.
16
AbsTrACT 
 Taxane antineoplastic agents are extensively taken up into hepatocytes by OATP1B-type 
transporters before metabolism and excretion. Because the biodistributional properties imposed 
upon these agents by different solubilizers drive clinically important pharmacodynamic endpoints, we 
tested the hypothesis that the in vitro and in vivo interaction of taxanes with OATP1B transporters is 
affected by the choice of drug delivery system. Transport of paclitaxel, docetaxel, and cabazitaxel was 
studied in vitro using various cell lines transfected with OATP1B1, OATP1B3, or the rodent equivalent 
OATP1B2. Pharmacokinetic studies were done in wild-type and OATP1B2-knockout mice in the 
presence or absence of polysorbate 80 (PS80) or Kolliphor EL (formerly Cremophor EL; CrEL). Paclitaxel 
and docetaxel, but not cabazitaxel, were transported substrates of OATP1B1, OATP1B3, and OATP1B2, 
and these in vitro transport processes were strongly reduced in the presence of clinically relevant 
concentrations of PS80 and CrEL. When paclitaxel was administered without any solubilizers, deficiency 
of OATP1B2 in mice was associated with a significantly decreased systemic clearance because of a 
liver distribution defect (P = 0.000484).  However, this genotype dependence of paclitaxel clearance 
was masked in the presence of PS80 or CrEL because of significant inhibition of OATP1B2-mediated 
hepatocellular uptake of the drug (P < 0.05). Our findings confirm the importance of OATP1B-type 
transporters in the hepatic elimination of taxanes and indicate that this process can be inhibited by 
PS80 and CrEL. These results suggest that the likelihood of drug-drug interactions mediated by these 
transporters is strongly dependent on the selected taxane solubilizer. 
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INTrOduCTION
The nonionic surfactants Kolliphor EL (formerly Cremophor EL; CrEL) and polysorbate 80 
(Tween 80; PS80) are widely used to solubilize drugs, including the taxane-based antineoplastic 
agents paclitaxel (1), docetaxel (2), and cabazitaxel (3). A wealth of experimental data has indicated 
that these solubilizers are biologically and pharmacologically active compounds, and their use as 
drug formulation vehicles has been implicated in clinically important toxic side effects such as acute 
hypersensitivity reactions (4). CrEL and PS80 have also been found to influence the disposition of 
solubilized drugs administered intravenously (5).  This is particularly striking in the case of paclitaxel 
formulated in CrEL, where the overall resulting effect is a highly increased systemic exposure to 
paclitaxel (6), which is dependent on the dose and time-varying blood concentrations of the solubilizer 
(7). Kinetic experiments (8, 9) and model-based predictions (10, 11) have revealed that paclitaxel 
undergoes reversible partitioning into a circulating surfactant microemulsion that acts as a nano-sink 
and reduces the fraction of free drug available for extravascular distribution.
In line with these predictions, it was demonstrated that CrEL can inhibit the hepatic 
elimination of paclitaxel in the isolated perfused rat liver, the main organ of elimination (12), by 
preventing the drug from reaching sites of metabolism and excretion (13). This process is believed 
to be primarily mediated by the organic anion-transporting polypeptides OATP1B3 (in humans; refs 
14 and 15) and OATP1B2 (in rodents; refs 16 and 17), which are uptake transporters localized to the 
basolateral membrane of hepatocytes (18). To add further to the complexity of the carrier-mediated 
disposition properties of paclitaxel, CrEL was found to strongly inhibit the uptake of OATP1B3 substrates 
in vitro into cells overexpressing the transporter (19). However, the mechanistic basis underlying this 
observation, as well as its in vivo relevance, remains unclear.
Because the biodistributional properties imposed upon taxanes by different solubilizers 
drive clinically-important pharmacodynamic endpoints that further depend, at least in part, on 
whether or not the pharmacokinetics of carrier-released (free) drug is formulation-dependent 
(10), we here tested the hypothesis that the in vitro and in vivo interaction of paclitaxel with 
OATP1B-type transporters is affected by the choice of a particular drug delivery system. 
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MATerIAls ANd MeThOds 
In vitro transport studies
 Xenopus laevis oocytes injected with OATP1B1, OATP1B3, or rat OATP1B2 cRNA along with 
water-injected controls were obtained from BD Biosciences. The transporter nomenclature used 
throughout is based on recent recommendations proposed by Hagenbuch and Stieger (20). The 
transporter-expressing oocytes were functionally characterized by assessing the uptake of estrone-
3-sulfate (2 µmol/L) by OATP1B1 and OATP1B2, and of estradiol-17β-D-glucuronide (2 µmol/L) by 
OATP1B3. Human embryonal kidney (HEK293) cells overexpressing OATP1B1, OATP1B3, or OATP1B2 
have been described previously (21). The Chinese hamster ovary (CHO) cells expressing OATP1B1 or 
OATP1B3 were generated as follows.  The open reading frames of the two transporters (22) were PCR 
amplified in order to introduce a 6-His tag at the C-terminal end. The amplicons were ligated into 
pcDNA5/FRT, and after verifying the sequences, Flp-In-CHO cells were transfected with the plasmids in 
the presence of pOG44 following the manufacturer’s protocols (Life Technologies). Cells were selected 
with hygromycin B (600 µg/mL) and single clones were isolated by limited dilution. Overexpression of 
transporters was confirmed using TaqMan probes (Applied Biosystems). The cell culture conditions 
and details of accumulation experiments for [3H]paclitaxel (specific activity, 25.6 Ci/mmol; Vitrax) and 
[3H]docetaxel (specific activity, 60.0 Ci/mmol; American RadioChemicals) were described earlier (21). 
Radioactivity was quantified by liquid scintillation counting using a LS 6500 Counter (Beckman). 
Intracellular concentrations of cabazitaxel were measured by liquid chromatography-
tandem mass spectrometry (LC/MS-MS), as described (23). Total protein was measured using a 
Pierce BCA Protein Assay Kit (Thermo Scientific) and quantified using a Biotek µQuant microplate 
spectrophotometer.  Drug uptake results were normalized to total protein content and then to data 
obtained in cells carrying an empty vector plasmid, which was set to 100%.
Animal experiments
 Wild-type and OATP1B2 knockout [OATP1B2(-/-)] mice, both on a DBA/1lacJ background, 
between 8 and 12 weeks of age, were housed in a temperature-controlled environment with a 12-hour 
light cycle.  Experiments were approved by the Institutional Animal Care and Use Committee of St. Jude 
Children’s Research Hospital.  All mice received a standard diet and water ad libitum and were fasted 
3 hours before drug administration.  Paclitaxel was formulated in CrEL-ethanol (1:1, v/v; Taxol; Bristol-
Myers Squibb), PS80-ethanol (1:1, v/v) or as an albumin-bound nanoparticle (nab-paclitaxel; ABI-007; 
Abraxane; Celgene) without either CrEL or PS80.  These solutions were diluted in normal saline and 
administered by intravenous bolus in the tail vain at a dose of 10 mg/kg.  Docetaxel (Taxotere; Sanofi-
Aventis) and cabazitaxel (Jevtana; Sanofi-Aventis) were formulated in PS80-ethanol (1:1, v/v), diluted 
in normal saline (docetaxel) or 5% dextrose in water (cabazitaxel), and then administered by tail vein 
injection at a dose of 10 mg/kg. 
In all experiments, at select time points after drug administration, blood samples (30 μL 
each) were taken from individual mice at 3.5, 7.5, and 15 min from the submandibular vein using 
a lancet, and at 30 and 60 min from the retro-orbital venous plexus using a capillary. A final blood 
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draw was obtained at 120 minutes by a cardiac puncture using a syringe and needle. Isoflurane was 
used as an anesthetic. The total blood volume collected during the procedure from each mouse was 
150 μL. All blood samples were centrifuged at 1,500 × g for 5 minutes, and plasma was separated 
and stored at -80oC until analysis. Livers, kidneys, and small intestines were collected from the same 
animals at 120 min. The lumen of small intestines were purged using saline to remove remaining 
content. A separate group of mice was euthanized by CO2 asphyxiation at 5 min and the same tissues 
were immediately collected and flash-frozen on dry ice. To prevent continuing metabolic activity, 
liver tissues were snap-frozen using liquid nitrogen. All tissue specimens were stored at -80°C until 
further processing, as described (21).  Samples were analyzed by LC/MS-MS (see Supplementary 
Methods for details; ref 24), and noncompartmental parameters were calculated using WinNonlin 
6.2 software (Pharsight).  Concentrations in tissue were corrected for contaminating plasma (25). 
 
Statistical considerations
 All data are presented as mean ± SD.  Statistical analyses were done using SPSS version 20 
(SPSS), and P < 0.05 was regarded as statistically significant. Student’s t-test (2 groups) or one-way 
ANOVA (>2 groups) was used for statistical analysis on in vitro uptake data, plasma pharmacokinetic 
parameters, and tissue concentrations.  
 
resulTs 
Paclitaxel transport in vitro.
 Although previous in vitro studies have consistently identified paclitaxel as a potent inhibitor 
of OATP1B1- (22, 26) and OATP1B3-mediated transport (22, 27, 28), the actual transport of paclitaxel 
itself by these transporters remains controversial (14, 28-30). The presented methodological details 
were selected on the basis of existing literature in order to clarify the reported discrepancies in taxane 
transport by OATPS. In line with these conflicting data, we found that the interaction of paclitaxel with 
human OATP1B1 and OATP1B3 was dependent on cell context, with both proteins being able to take 
up paclitaxel when expressed in HEK293 cells or CHO cells, but no noticeable transport occurring by 
OATP1B1 expressed in X. laevis oocytes (Fig. 1A). Paclitaxel was also found to be transported into cells 
expressing mouse OATP1B2 or rat OATP1B2 (Fig. 1B), as predicted from studies done in isolated rat 
hepatocytes (31).  
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figure 1.  In vitro transport studies of paclitaxel. A, the uptake of paclitaxel by human OATP1B1 and human OATP1B3 
was assessed in OATP1B1 and OATP1B3-injected X. laevis oocytes (paclitaxel concentration, 2 µmol/L; 30 minute 
incubations), HEK293 cells (2 µmol/L; 30 minutes) and CHO cells (1 µmol/L; 2 minutes) and their respective vector 
controls (VC). b, the uptake of paclitaxel by mouse OATP1B2 transfected in HEK293 cells (0.1 µmol/L; 15 minutes) 
or rat OATP1B2 transfected in Xenopus laevis oocytes (2 µmol/L; 30 minutes). C, the uptake of paclitaxel by human 
OATP1B1, human OATP1B3 in CHO cells (1 µmol; 2 minutes), or mouse OATP1B2 in HEK293 cells (0.1 µmol/L; 15 
minutes) was evaluated in the presence of different concentrations of PS80.  d, the uptake of paclitaxel by human 
OATP1B1, human OATP1B3 in CHO cells (1 µmol/L; 2 minutes), or mouse OATP1B2 in HEK293 cells (0.1 µmol/L; 
15 minutes) was evaluated in the presence of either CrEL (1%, w/v) or PS80 (1%, w/v), with results normalized to 
transporter-specific uptake.  Data are presented as the mean percentage of uptake values in the VC cells (bars) for 
4 to 16 observations per condition, along with SD (error bars).  *, a statistically significant difference compared with 
VC (P < 0.05). 
In the absence of solubilizers, the transport of paclitaxel into CHO cells transfected with 
OATP1B1 or OATP1B3 was found to be time-dependent and saturable (Fig. 2) with a Michaelis-Menten 
constant (Km) of 0.408 ± 0.190 µmol/L and 2.36 ± 1.40 µmol/L, respectively, and a maximum velocity 
(Vmax) of 22.1 ± 3.20 pmol/mg/min and 14.2 ± 5.26 pmol/mg/min, respectively, which values are 
similar to those reported previously for docetaxel (21).  
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figure 2. In vitro transport of paclitaxel by OATP1B1 and OATP1B3. (A) Time-dependence of transport by OATP1B1 
(A) and OATP1B3 (b) and concentration-dependence of transport by OATP1B1 (C) and OATP1B3 (d) was evaluated 
in transfected CHO cells, where data represent the mean of 2 to 4 independent experiments in cells stably 
expressing OATP1B1, OATP1B3, or in control cells (VC), and the net difference. In panels (A) and (b), the paclitaxel 
concentration was 0.5 µmol.  In panels (C) and (d), the incubation time was 1 min.  Km denotes the Michaelis-
Menten constant, and Vmax the maximum velocity. Error bars represent the standard error.  Data in panels (C) and 
(d) were previously reported in De Graan et al. (21).
Next, we evaluated the ability of CrEL and PS80 to inhibit the intracellular accumulation 
of paclitaxel into CHO cells overexpressing human OATP1B1, human OATP1B3, or mouse OATP1B2. 
Recently, it was reported that the effect of CrEL on the uptake of several substrates by OATP1B2, 
OATP1B1, or OATP1B3 was dose dependent (19). Similar to these findings, we found that PS80 
also inhibited paclitaxel uptake in a concentration-dependent manner (Fig. 1C), which is in line 
with our observation that PS80 also affects the transporter-mediated uptake of docetaxel (21). 
The mechanism by which CrEL and PS80 inhibit OATP1B-type transporters is unclear and requires 
additional investigation. After correcting for non-specific inhibition of paclitaxel uptake occurring in 
cells transfected with an empty expression plasmid because of drug trapping in solubilizer micelles 
(Fig. 3), CrEL directly inhibited the transporters in decreasing order of potency OATP1B3 > OATP1B2 > 
OATP1B1, whereas PS80 inhibited all transporters to a similar extent (Fig. 1D).  
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figure 3. The uptake of paclitaxel by human OATP1B1, human OATP1B3 in CHO cells (1 µmol; 2-min), or mouse 
OATP1B2 in HEK293 cells (0.1 µmol; 15-min) evaluated in the absence (none) or presence of 1% (w/v) Cremophor 
EL (CrEL).  Data are presented relative to the mean percentage of uptake values in the vector control (VC) cells 
(bars) in the absence of CrEL for 4-16 observations per condition, along with SD (error bars).
Paclitaxel tissue distribution studies in vivo.
We next evaluated the possible importance of these transporters for paclitaxel disposition in 
mice with a genetic deletion of OATP1B2 [OATP1B2(-/-) mice]. Early after administration (5 minutes) 
of paclitaxel as an albumin-bound nanoparticle (nab-paclitaxel) in the absence of a solubilizer, uptake 
into the liver was dramatically decreased in OATP1B2(-/-) mice (Fig. 4A). This finding suggests that 
immediately after infusion paclitaxel uptake into the liver is mainly transporter-mediated, and is 
consistent with the notion that the amorphous nab-paclitaxel nanoparticles rapidly dissolve into 
soluble albumin-paclitaxel complexes with a size similar to that of native albumin, with no nanoparticles 
detected at any time point post infusion (32).  Therefore, phagocytosis-based uptake mechanisms 
in the liver involving the reticulo-endothelial system, which are relevant to the biodistribution of 
paclitaxel nanoparticles that remain stable in the circulation (33), are not contributing in the case of 
nab-paclitaxel.
As predicted based on the in vitro inhibition data, the differences in uptake of paclitaxel into 
the liver between wild-type and OATP1B2(-/-) mice were much less pronounced in the presence of 
PS80 or CrEL. In particular, the liver uptake in wild-type mice receiving paclitaxel formulated in PS80 
was similar to that observed in OATP1B2(-/-) mice receiving the drug without solubilizers, whereas 
uptake was further reduced by about two-fold in the presence of CrEL (Fig. 4A). Over time, the 
formulation-dependent differences in liver uptake normalized to control levels for the PS80 group (Fig. 
4B), but remained noticeably reduced in the presence of CrEL. This is consistent with the fact that PS80 
is very rapidly cleared, with plasma levels becoming undetectable within 15 minutes after intravenous 
administration (34), whereas the half-life of CrEL amounts to >17 hours (6).
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figure 4.  Influence of paclitaxel formulation and OATP1B2-deficiency on paclitaxel distribution. Paclitaxel was 
formulated as nab-paclitaxel in the absence of PS80 or CrEL, PS80, or CrEL (see Materials and Methods for details), 
and total paclitaxel levels were determined in wild-type and OATP1B2(-/-) mice at 5 minutes and 2 hours after 
intravenous injection in liver (A and b), kidney (C and d), and intestine (e and f).  Tissue levels were normalized 
to the corresponding plasma concentration (5 minute data) or the AUC from time 0 to 2 hours (2 hour data). Data 
are presented as the mean (bars) of four observations per condition per time point, along with SD (error bars).  *, 
a statistically significant difference compared with the corresponding wild-type group (P < 0.05); **, a statistically 
significant difference compared with the other formulations (P < 0.05).
Interestingly, a similar solubilizer-, time-, and genotype-dependent distribution of paclitaxel 
was observed for uptake into kidney (Fig. 4C and D) and intestine (Fig. 4E and F).  The significant 
reduction of paclitaxel administered without a solubilizer (i.e., nab-paclitaxel) in the kidneys of 
OATP1B2(-/-) mice at 5 minutes after drug administration is possibly the result of low expression 
of OATP1B2 in renal cells of mice (35), and a similar phenotype has been reported previously for 
the OATP1B2 substrate, hydroxyurea (36).  The concentrations of paclitaxel in the intestine after the 
administration of nab-paclitaxel were not dependent on OATP1B2 genotype at the early time point, 
where appearance of the drug likely reflects direct intestinal secretion (37).  At the 2-hour time point, 
the higher levels in the intestine are presumably the result of hepatobiliary secretion becoming an 
increasingly dominant contributor to the elimination of paclitaxel.  
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Effects of formulation and transport on taxane clearance in vivo.
As anticipated from the tissue distribution findings, the plasma concentration-time profiles of 
paclitaxel were inversely related to corresponding drug levels in liver, and concentrations in plasma 
were consistently higher by 5-to 7-fold for the CrEL-containing formulation compared with the other 
groups (Fig. 5A and B).  The notion that the slow clearance of paclitaxel administered in CrEL is due 
to a distribution defect rather than an event occurring in the terminal elimination phase is also 
consistent with the observed terminal half-lives of paclitaxel that were not significantly dependent on 
the formulation or genotype (Table 1).
After the administration of nab-paclitaxel, the peak plasma concentration of paclitaxel 
was significantly increased in OATP1B2(-/-) mice, and this genotype dependence was nullified in 
the presence of PS80 or CrEL (Fig. 5C).  Based on total area under the curve (AUC), a significant but 
blunted influence of genotype was still noted for PS80-based formulation, but not for CrEL (Fig. 5D). 
Because the same PS80 formulation is used in the clinical preparation of docetaxel and cabazitaxel, 
we also evaluated the comparative plasma pharmacokinetic properties of the two other approved 
taxanes in the same mouse model.  Studies performed in transfected cells confirmed that, like 
paclitaxel, docetaxel is a transported substrate of OATP1B2 (21), but this was not noted under the 
experimental conditions applied for cabazitaxel (Fig. 6A).  The lack of transport of cabazitaxel by 
OATP1B2 is somewhat surprising considering its structural similarity with docetaxel, both having a 
10-deacetylbaccatin III backbone (3), and because cabazitaxel has been reported to inhibit OATP1B1 
and OATP1B3, albeit at relatively high concentrations (Jevtana prescribing information, see: http://
products .sanofi.us/jevtana/ jevtana.pdf).  As expected based on the in vitro studies, the AUC (Fig. 6B) 
and plasma levels at the time points evaluated were significantly increased in the absence of OATP1B2 
for paclitaxel (formulated in PS80; Fig. 6C) and docetaxel (Fig. 6D), but not for cabazitaxel (Fig. 6E).
Table 1.  Plasma pharmacokinetic parameters of paclitaxel (10 mg/kg) in mice using different formulations.*
Solubilizer Mouse Cmax AUC CL T1/2
genotype    (μg/ml) (µg×h/ml) (L/h/kg) (h)
None OATP1B2(-/-) 9.37 ± 3.46 8.51 ± 4.32          1.36 ± 0.493      1.64 ± 0.668      
None Wildtype 4.61 ± 0.608 3.44 ± 0.394        2.38 ± 1.26        1.70 ± 0.427      
PS80 OATP1B2(-/-) 14.0 ± 3.12 6.93 ± 0.832        1.26 ± 0.454      1.06 ± 0.265      
PS80 Wildtype 12.4 ± 3.53 4.83 ± 0.761        1.94 ± 0.479      1.07 ± 0.230      
CrEL OATP1B2(-/-) 36.9 ± 10.9 25.6 ± 5.23        0.406 ± 0.0962    1.39 ± 0.294      
CrEL Wildtype 35.8 ± 8.60 18.8 ± 4.90          0.565 ± 0.174      1.30 ± 0.365      
* Data represent mean ± SD. Abbreviations: PS80, polysorbate 80; CrEL, Kolliphor EL (formerly Cremophor EL); 
AUC, area under the curve; CL, systemic clearance; T1/2, half-life of the terminal phase; Cmax, peak plasma 
concentration. Note: ‘None’ refers to nab-paclitaxel.
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figure 5.  Influence of formulation and OATP1B2-deficiency on paclitaxel plasma pharmacokinetics. Paclitaxel 
was formulated as nab-paclitaxel in the absence of PS80 or CrEL, in PS80, or in CrEL (see Materials and Methods 
for details), and total paclitaxel levels were determined in wildtype (A) and OATP1B2(-/-) mice (b) at in plasma 
samples taken at serial time points after dosing (5-120 minutes). The resulting concentration-time profiles were 
used to derived peak plasma concentrations (Cmax) (C) and area under the curve (AUC) (d).  Data are presented 
as the mean (symbols or bars) of four observations per condition per time point, along with SD (error bars).  *, a 
statistically significant difference compared with the corresponding wild-type group (P < 0.05); **, a statistically 
significant difference compared with the other formulations (P < 0.05).
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figure 6.  Comparative effects of formulation and OATP1B2-deficiency on transport of paclitaxel, docetaxel, 
and cabazitaxel. A, the uptake of paclitaxel, docetaxel, and cabazitaxel by mouse OATP1B2  was evaluated in 
transfected HEK293 cells (0.1 µmol/L; 15 minutes).  Data are presented as the mean percentage of uptake 
values in the VC cells (bars) for 4 to 11 observations per condition, along with SD (error bars). *, a statistically 
significant difference compared with VC (P < 0.05). b, AUC of paclitaxel in wild-type and OATP1B2(-/-) mice 
following administration of paclitaxel, docetaxel, or cabazitaxel, all formulated in PS80 (see Materials and Methods 
for details), along with the corresponding plasma concentration-time profiles for paclitaxel (C), docetaxel (d), 
and cabazitaxel (e).  Data are presented as the mean (bars or symbols) of four observations per condition per 
time point, along with SD (error bars).  *, a statistically significant difference compared with the corresponding 
wildtype group (P < 0.05); **,  a statistically significant difference compared with the other formulations (P < 0.05). 
 
dIsCussION
This study adds to a growing body of knowledge that solute carriers belonging to the OATP1B 
family can have a dramatic impact on the hepatocellular accumulation and systemic clearance of 
structurally diverse anticancer drugs.  Using an array of in vitro transport assays, including intracellular 
accumulation studies in multiple-transfected model systems, paclitaxel was confirmed to be a high-
affinity substrate for both OATP1B1 and OATP1B3.  We found that the interaction of paclitaxel with 
OATP1B1 and OATP1B3 was strongly dependent on cell context, and this has obvious implications 
for future screening strategies aimed at identifying novel substrates for these transporters.  The 
relatively low Km observed for paclitaxel transport by OATP1B1 suggests that this route of entry 
into hepatocytes may be saturated first, and this is consistent with results obtained in humanized 
transgenic mice indicating that OATP1B1 does not substantially contribute to paclitaxel transport 
in vivo (15), when administered at an intravenous dose of 10 mg/kg.  Indeed, the Km for OATP1B1 
of 0.408 µmol/L is substantially lower than the peak plasma concentration of unbound paclitaxel in 
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patients receiving nab-paclitaxel at the recommended dose of 260 mg/m2 (on average, 1.50 µmol/L), 
but much higher than that observed for paclitaxel in CrEL at 175 mg/m2 (on average, 0.143 µmol/L; ref. 
38). This suggests that the contribution of OATP1B1 to the disposition of paclitaxel in patients is likely 
to be dependent on the prescribed product, in addition to the total dose and duration of infusion.
Our in vitro studies also confirmed that paclitaxel and docetaxel, but not cabazitaxel, are 
transported substrates of mouse OATP1B2 and, for paclitaxel, rat OATP1B2, the amino acid sequence 
of which is 81% identical to that of the murine transporter. Moreover, the rodent OATP1B2 transporters 
share more than 60% amino acid sequence homology to the two human isoforms, and on the basis 
of their shared basolateral localization in hepatocytes and overlapping substrate specificity (39), it is 
possible that, in the context of paclitaxel, the rodent OATP1B2 fulfills the same function in the liver 
as OATP1B1 and OATP1B3 in humans.  Based on this premise, we evaluated the pharmacokinetic 
properties of paclitaxel in a mouse model with a genetic deletion of OATP1B2.  One possible limitation 
of this model is the fact that, unlike in humans, mouse hepatocytes express multiple members of 
OATP1A subfamily, related transporters that can potentially provide compensatory restoration of 
function when OATP1B2 is lost (40).  Despite this limitation, compared to wild-type mice, the systemic 
exposure to nab-paclitaxel, administered without PS80 or CrEL, in the OATP1B2(-/-) mice was increased 
by 2.5-fold.  Our previously reported gene expression profiling and enzyme activity measurements in 
liver samples exclude alterations in alternate transport mechanisms or metabolic pathways as a likely 
cause of the delayed clearance phenotype in OATP1B2(-/-) mice (20).  Thus, these findings suggest that 
OATP1B2-mediated transport of paclitaxel is an important process in the elimination of this drug in 
mice, depending on the solubilizer used for drug formulation.
We previously reported that the presence of PS80, the pharmaceutical vehicle used to 
solubilize docetaxel in clinical preparations, even in relatively low amounts, can completely nullify the 
genotype-dependent transport of docetaxel by OATP1B1 (21), and similar findings have been reported 
for CrEL, used in one of the clinical preparations of paclitaxel (19).  Based on our current in vitro and 
subsequent confirmatory in vivo studies, it appears that the interaction of paclitaxel with OATP1B2 is 
strongly diminished in the presence of PS80 and CrEL in a fashion that is consistent with the known 
disposition properties of these respective solubilizers.  It is interesting to note that a previous study 
demonstrated that mice deficient in all Oatp1a and Oatp1b genes display a rather modest increase 
(<2-fold) in concentrations of paclitaxel in plasma following intravenous administration of a PS80-
based formulation that is very similar to our present findings (17).  These authors speculated that 
the lack of differences in plasma levels of paclitaxel early after its administration (up to 3.5-minutes) 
may be because of saturation of Oatp1a/Oatp1b-mediated liver uptake, and that this distribution 
process is predominantly dependent on other uptake mechanisms.  Our current findings now provide 
an alternative explanation, where the initially high levels of PS80 in plasma can cause both temporary 
partitioning into a circulating PS80 microemulsion as well as directly inhibit the transporters required 
for hepatocellular uptake.  These two mechanisms combined likely also explain the results obtained for 
paclitaxel in the presence of CrEL, although here the former mechanism clearly remains the dominant 
contributor to the overall disposition phenotypes.
The present observation that PS80 and CrEL can directly inhibit OATP1B-type transporters 
suggests that the pharmacokinetic profile of carrier-released (free) paclitaxel is not formulation 
2
28
independent. This finding contrasts previously made assumptions (10), and may have important 
ramification for a proper interpretation of the clinical pharmacology of paclitaxel.  Firstly, we previously 
found that several common, naturally occurring genetic variants in OATP1B3 with impaired function were 
not associated with the pharmacokinetics of paclitaxel in a cohort of 90 patients with cancer receiving 
the drug in a CrEL-based formulation (16).  This somewhat unexpected observation is consistent with our 
current findings in that the interaction of paclitaxel with OATP1B3 may be masked by CrEL irrespective 
of an individual’s genotypic constitution.  It also suggests that the impact of reduced function variants of 
OATP1B1 and/or OATP1B3 on the clearance of paclitaxel may be much more pronounced for CrEL-free 
formulations of the drug, such as nab-paclitaxel.
Secondly, it can be postulated that intrinsic physiologic and environmental variables influencing 
OATP1B1- or OATP1B3-mediated uptake of paclitaxel into hepatocytes may have a more profound 
influence on drug clearance for formulations lacking solubilizers.  For example, substrates of OATP1B1 
and OATP1B3 for which the liver is the main organ of elimination are highly liable to drug interactions 
associated with these transporters (41, 42). Although formal drug interaction studies have not been 
performed to date with nab-paclitaxel, our present findings strongly suggest that interactions at the 
level of hepatocellular uptake mechanisms would be exacerbated with a formulation like nab-paclitaxel. 
Conversely, CrEL may act as a perpetrator in known pharmacokinetic interactions involving other OATP1B 
substrates coadministered with paclitaxel in Phase I clinical trials (reviewed in ref. 4), such as etoposide 
(43), docetaxel (44), oxaliplatin (45), and SN-38 (46).
 Thirdly, OATP1B1 is expressed at relatively high levels in tumors of the colon, endometrium, 
oesophagus, lung, prostate, stomach, testis, and bladder, and both OATP1B1 and OATP1B3 contribute 
to the in vitro cytotoxicity of paclitaxel in ovarian cancer cells (29). Although systemic exposure to free 
paclitaxel is believed to be the dominant driver of drug-induced cytotoxicity at tumor sites (10), it is 
conceivable that these transporters can contribute directly to tumoral uptake and that this process can be 
inhibited by solubilizers such as PS80 and CrEL, leading to diminished antitumor activity.  This possibility 
would be consistent with available clinical data on the comparative efficacy of the various paclitaxel 
formulations (reviewed in ref.10), and with preclinical findings suggesting that (i) the absorption rate 
constant of paclitaxel uptake into tumors is dramatically decreased in the presence of CrEL compared with 
nab-paclitaxel (47), and (ii) a tumor-delivery mechanism exists for nab-paclitaxel that is independent of 
SPARC (48), a matricellular glycoprotein produced by tumors and/or neighbouring stroma that facilitates 
the intracellular accumulation of intact albumin nanoparticles (49).
Collectively, our findings demonstrate the importance of OATP1B-type solute carriers in the hepatic 
elimination of paclitaxel, and indicate that solubilizers used in clinical preparations of this agent can inhibit 
this process in a time-dependent fashion. These results offer a mechanistic basis for previously reported 
interrelationships of taxane disposition with PS80 and CrEL, and suggest that the likelihood of drug-drug 
interactions mediated by these transporters is strongly dependent on the selected paclitaxel formulation.
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suPPleMeNTAry MeThOds 
Determination of paclitaxel and cabazitaxel concentrations
Paclitaxel and cabazitaxel were quantified using validated methods involving reversed-phase 
liquid chromatography coupled to tandem mass-spectrometric detection (LC-MS/MS). Sample extracts 
were injected onto an Alltima HP C18 HL 3-µm column (50×2.1mm internal diameter, Alltech Applied 
Science) by a Waters 2795 Separation Module.  The mobile phase for determination of paclitaxel was 
composed of acetonitrile and water containing formic acid (0.1% v/v), and was delivered using linear 
gradient settings at a flow rate of 0.2 ml/min.  Detection was performed with a MicroMass Quatro 
Micro triple-quadrupole mass spectrometer (Waters) in the positive ion mode.  The electrospray 
ionization was set at 3.8 kV and the cone voltage at 18 V.  The dwell times were set at 150 ms and 
the inter-channel delay at 50 ms.  A multiple-reaction monitoring (MRM) mode was applied for the 
quantitation with the following parameters: m/z 854>286, collision energy at 20 eV for paclitaxel 
and m/z 859>291, collision energy at 20 eV for the internal standard, paclitaxel-d5.  The collision cell 
pressure was set at ~4×10-3 mbar (argon). Samples for the quantitation of paclitaxel were prepared 
by extraction of 100-µl aliquots with 200-µl of an acetonitrile solution of the internal standard, and 
1 ml of n-butylchloride. After vigorously mixing and centrifugation for 10 min at 18,000 g, the clear 
supernatant was evaporated at a temperature of 70°C. The residue was dissolved in 150 µl of a mixture 
of acetonitrile-water-formic acid (40:60:0.1, v/v/v), from which aliquots of 5 µL were injected into the 
LC-MS/MS-system. The lower limit of quantitation (LLQ) for paclitaxel was determined to be 20.0 ng/
mL, and the calibration curve ranged from 20.0 to 1,000 ng/ml.  The within-run and between-run 
precisions were within 7.14%, while the accuracy ranged from 88.5 to 94.1%.
The mobile phase for determination of cabazitaxel was composed of acetonitrile and water 
containing ammonium formate (0.2% v/v), and was delivered using linear gradient settings at a flow 
rate of 0.2 ml/min.  Detection was performed with a MicroMass Quatro Micro triple-quadrupole mass 
spectrometer (Waters) in the positive ion mode.  The electrospray ionization was set at 3.5 kV and the 
cone voltage at 20V.  The dwell times were set at 150 ms and the inter-channel delay at 50 ms.  The 
MRM mode was applied for the quantitation with the following parameters: m/z 836>555, collision 
energy at 10 eV for cabazitaxel and m/z 842>561, collision energy at 10 eV for the internal standard, 
cabazitaxel-2H6. The collision cell pressure was set at ~4×10
-3 mbar (argon). Samples for the quantitation 
of cabazitaxel were prepared by extraction of 100-µl aliquots with 20 µl of ammonium hydroxide (4%), 
100 µl of an internal standard solution in acetonitrile and 1 ml of n-butylchloride.  After vigorously mixing 
and centrifugation for 10 min at 18,000 g, the clear supernatant was evaporated at a temperature of 
70°C under a stream of nitrogen. The residue was dissolved in 100 µl of a mixture of acetonitrile-water-
ammonium formate (40:60:0.2, v/v/v), from which aliquots of 10 µl were injected into the LC-MS/MS-
system.  The LLQ for cabazitaxel was determined to be 1.00 ng/ml, and two separate calibration curves 
were used for drug quantitation, one in the concentration range of 1.00 to 100 ng/mL, and another in the 
concentration range of 40.0 to 4,000 ng/ml.  For the former, the within-run and between-run precisions 
were within 8.75%, while the accuracy ranged from 88.5 to 94.1%.  For the latter, the within-run and 
between-run precisions were within 4.99%, while the accuracy ranged from 95.8 to 100.3%.
2
33
Disruption of mouse tissues
Tissue samples were kept frozen at -70ºC until the time of processing. All organis were 
diluted in blank (drug-free) human plasma (1:4, w/v) in a 2-ml Eppendorf vial.  Next, a 5-mm stainless 
steel bead (Qiagen) was added, and the samples were homogenized with a Tissuelyser (Qiagen), and 
processed for 4 min at 40 Hz.  Finally, the beads were removed and the homogenized samples were 
stored at -70ºC until analysis by LC-MS/MS as described above for plasma samples.
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AbstrAct
The use of paclitaxel in cancer treatment is limited by paclitaxel-induced neutropenia. We 
investigated the ability of genetic variation in drug-metabolizing enzymes and transporters to predict 
hematological toxicity. Using a discovery and validation approach, we identified a pharmacogenetic 
predictive model for neutropenia. For this, a drug-metabolizing enzymes and transporters plus DNA 
chip was used, which contains 1936 SNPs in 225 metabolic enzyme and drug-transporter genes. Our 10-
SNP model in 279 paclitaxel-dosed patients reached 43% sensitivity in the validation cohort. Analysis 
in 3-weekly treated patients only resulted in improved sensitivity of 79%, with a specificity of 33%. 
None of our models reached statistical significance. Our drug-metabolizing enzymes and transporter-
based SNP-models are currently of limited value for predicting paclitaxel-induced neutropenia in 
clinical practice.  
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IntroductIon
Paclitaxel is an antineoplastic drug, used for the treatment of several types of cancer such 
as non-small-cell lung cancer and ovarian cancer (1, 2). Regarding its metabolism, it is known that 
the uptake of paclitaxel in the liver occurs through 1B-type organic anion transporters (3, 4). Hepatic 
metabolism is thereafter performed by cytochrome (CYP) P450 enzymes CYP3A4 and CYP2C8 (5, 6). 
Subsequently, paclitaxel is effluxed out of the hepatocytes by the transporters ABCB1 and ABCC2 
(7, 8). Besides for hepatobiliary secretion, ABCB1 and ABCC2 are also responsible for the intestinal 
secretion of paclitaxel (5, 9). 
The pharmacokinetics and thus the exposure to paclitaxel has a high inter-individual variability, 
which is reflected in the incidence and severity of paclitaxel-induced toxicities (10). A correlation exists 
between these highly variable pharmacokinetics and paclitaxel-induced toxicities (11, 12). Neurotoxicity 
and neutropenia are paclitaxel’s main dose limiting toxicities. In this, neutropenia reduces the 
effectiveness of the immune system and increases the risk of severe bacterial infections (12). 
It is clinically relevant to predict which patients are predisposed for severe paclitaxel-induced 
toxicity. One aspect is predicting paclitaxel pharmacokinetics.  The role of ‘pharmaco’-genetics 
however is less broadly explored. Using a candidate gene approach, a limited number of SNPs has 
been identified to be associated with pharmacokinetics and paclitaxel-induced-toxicity (13, 14). For 
a multi-gene approach, the Affymetrix Drug Metabolizing Enzymes and Transporters (DMET) Plus 
Premier Pack (Affymetrix, CA, USA) was used previously. Using the DMET approach, genetic variation 
correlated with specific chemotherapy-induced toxicity such as gastrointestinal toxicity in colorectal 
cancer patients and osteonecrosis of the jaw in multiple myeloma patients could be identified (15-
17). This suggests that the DMET platform has a great potential in explaining chemotherapy-induced 
toxicity. 
We hypothesize that variation in genes not thought to be primarily involved in paclitaxel 
pharmacokinetics but still related to drug metabolism could be helpful for predicting neutropenia 
(defined as an absolute neutrophil count (ANC) <1x109/L) and leukopenia (defined as an absolute 
white blood cell count (WBC) <2x109/L). By using the Affymetrix DMET Plus Platform, we investigated 
whether polymorphisms in genes that are involved in drug metabolism and transport could predict 
neutropenia. 
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PAtIents And Methods 
Patients 
Patients treated with paclitaxel for solid tumors (Table 1) were included in a prospective 
pharmacological study (enumerated as NTR2311 at www.trialregister.nl). Patients were above the 
age of 18 and had a confirmed diagnosis of malignancy (cytologically or histologically proven). In 
addition, patients’ WHO Performance Score had to be 0 or 1 and hematopoietic, renal and hepatic 
functions should be adequate according to the product information of paclitaxel (18). Strong inducers 
and inhibitors of CYP2C8 and CYP3A4 were prohibited (19). Patients were treated in a combination 
regimen in which they started with weekly courses and then switched to a 3-weekly schedule, a weekly 
regimen, or a 3-weekly regimen. Throughout the whole period of paclitaxel treatment, neutrophil 
and leukocyte count values were scored. ANC and WBC values have been determined following the 
hospitals’ diagnostic protocols. These data have been collected from patient charts retrospectively. 
The lowest ANC or WBC score was determined throughout all paclitaxel cycles. Methods of the 
obtaining of pharmacokinetic data as well as the calculation of pharmacokinetic parameters were 
previously described by de Graan et al. (20). The Medical Ethical Committee of the Erasmus University 
Medical Center in Rotterdam, The Netherlands, approved this trial (MEC2003.264) and all procedures 
were done according to the declaration of Helsinki.
SNP analysis 
Genetic variant analysis was performed as described previously by de Graan et al. (20). 
Summarizing, whole blood was drawn from all patients and from this blood, genomic DNA was isolated 
using MagnaPure LC (Roche Diagnostics GmbH) according to the instructions of the manufacturer. 
Genotyping was done using the Affymetrix DMET Plus Premier Pack according to the descriptions of 
Dumaual et al. (21). As a measure of quality and reliable readability, the genotypes of all studied SNPs 
were stated as either ‘call’ or ‘no call’. A sample showing a call rate below 90% was removed from the 
analysis. Also, patients with missing clinical data (e.g. ANC values) were excluded. 
Predictive model design
Genotypes were disqualified from the data analysis when the same in all patients or not 
in Hardy Weinberg Equilibrium (HWE) (P>0.05). All 1936 genetic variants on 225 genes involved in 
metabolism or transport were statistically tested as described previously (20). Patients receiving 
treatment every 3-weeks (n=76) were grouped into a high and low risk group based on their nadir ANC. 
Patients were labelled as high risk for neutropenia if the ANC nadir was below the value of 1x109/L, 
otherwise as low risk. Patients with a nadir WBC <2x109/L were considered as high risk for leukopenia, 
otherwise as low risk. For both groups separately, patients were randomly divided into a discovery 
and a validation cohort. Because of the explorative character of this analysis, the total cohort was split 
into a discovery and a validation cohort, despite the knowledge that paclitaxel-induced neutropenia 
is schedule dependent. 
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Table 1. Patient characteristics of the total cohort
Total  
cohort
Discovery 
cohort
Validation 
cohort
Discovery 
cohort
Validation 
cohort
ANC<1x109/l ANC<1x109/l WbC<2x109/l WbC<2x109/l
Number of patients 
(n)
279 140 139 140 139
Male 146 69 77 72 74
Female 133 71 62 68 65
Mean age, years 
(range)
60.7 (19-82) 60.6 (19-82) 60.6 (26-82) 61.5 (27-82) 59.7 (18-79)
Cancer Type
Oesophagus (%) 152 (54.5) 78 (55.7) 73 (52.5) 76 (54.3) 76 (54.7)
Ovarian (%) 42 (15.1) 24 (17.1) 19 (13.7) 22 (15.7) 20 (14.4)
Cervix (%) 19 (6.8) 11 (7.9) 8 (5.8) 10 (7.1) 9 (6.5)
Endometrium (%) 18 (6.5) 9 (6.4) 9 (6.5) 10(7.1) 8 (5.8)
Mamma (%) 12 (4.3) 6 (4.3) 6 (4.3) 6 (4.3) 6 (4.3)
Rest (%) 36 (12.9) 12 (8.6) 24 (17.3) 16 (11.4) 20 (14.4)
Nadir endpoint*, 
mean (range)
1.59 (0.05-10.0) 1.59 (0.05-7.3) 1.58 (0.1-10.0) 2.89 (0.05-10.2) 2.70 (0.34-7.7)
Cytotoxic comedication (n) 
cisplatin  (%) 37 (13.2) 17 (12.1) 20 (14.2) 16 (11.4) 21 (14.9)
carboplatin  (%) 228 (81.1) 116 (82.9) 112 (79.4) 121 (86.4) 109 (77.3)
bleomycin  (%) 2 (0.7) 1 (0.7) 1 (0.7) 0 (0) 2 (1.4)
ifosfamide  (%) 2 (0.7) 0 (0) 2 (1.4) 0 (0) 2 (1.4)
sorafenib  (%) 1 (0.4) 0 (0) 1 (0.7) 0 (0) 1 (0.7)
trastuzumab  (%) 4 (1.4) 2 (0.7) 2 (1.4) 2 (0.7) 2 (1.4)
none  (%) 7 (2.5) 4 (2.9) 3 (2.2) 1 (0.7) 4 (2.8)
Data are represented as absolute numbers unless stated otherwise. By ‘endpoint’* is meant ANC (value x109/L) or 
WBC (value x109/L) , depending on the analysis. Abbreviations: absolute neutrophil count (ANC), white blood cell 
count (WBC). One patient was treated with the combination cisplatin & ifosfamide and one patient was treated 
with the combination carboplatin & sorafenib. These patients were separately mentioned for both drugs in the 
combination. 
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In the discovery samples, the conditional probability for each SNP was calculated for each 
variant using this formula: P (A|B)= P (A&B) / P (B). In the case of ANC nadir being the endpoint: A 
indicates an ANC nadir below the value of 1x109/L  (high risk) and B stands for the genotype. This 
formula gives the probability of a patient having an ANC nadir below the value of 1x109/L, given the 
manifestation of a certain genotype (wild-type (WT); heterozygous (HTZ), homozygous (HOZ)).  This 
gives a probability for each possible genotype of each SNP, which is incorporated in the prediction 
analysis as a weight.  
 SNPs were selected if the following selection criteria were met: WT, HTZ and HOZ genotype 
had to be represented at least five times, the difference in probability of WT and HOZ > 0.2, and both 
the probability for WT and HOZ should be at least 10% higher than the ‘standard risk’. This risk was 
derived from the clinical data of all patients; for example, considering ANC, 45 out of 76 patients show 
a nadir ANC <1x109/L, thus a ‘standard risk’ of 59.2%. To obtain a final selection of SNPs, all SNPs 
showing the exact same genotype in all patients in the discovery cohort were excluded.  Deciding 
which of the SNPs had to be included was based on the highest probability in WT/HOZ genotypes. The 
probabilities of the final list of SNPs were used as weights in the analysis to predict the samples in the 
validation cohort. 
Prediction of the validation samples 
A total probability weighted score was determined for every individual patient by adding up all 
probabilities of the SNPs in the model. In case the DMET chip was unable to call the genotype for a SNP in a 
particular patient, the standard risk was used. In a ROC-curve, the scores of the patients in the discovery 
cohort were associated with the risk for neutropenia. Here, a threshold was selected at which all or most 
patients having a nadir ANC<1x109/L were included. In the validation cohort, the probability-weighted 
scores were also calculated and then compared with the threshold chosen in the discovery cohort. The 
validation cohort samples were predicted as high or low risk. Finally, these predictions were matched 
with the actual nadir ANC to make apparent how many of these samples were predicted correctly. 
Statistics
All analyses were done using STATA version 13 (StataCorp LP, TX, USA). Data are presented 
as means with ranges, unless stated otherwise. P-values are two-sided and statistically significant 
was defined as p-value <0.05.  Dissimilarities amongst both patient cohorts were studied using the 
Chi-square test or the Mann-Whitney test, depending on whether variables were categorical of 
continuous. The influence of covariables on the association between the prediction model and a 
patient being at risk for an ANC count below 1x109/L was tested by logistic regression. To associate 
ANC as continuous variable with a SNP, a test for trend across ordered groups was used, which is an 
extension of the Wilcoxon rank-sum test (22). Because these are exploratory analyses, no correction 
for false discovery rate was made. 
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results 
Correlation between neutropenia and clearance of paclitaxel
Pharmacokinetic data of 251 patients was available. Patients with an ANC nadir <1x109/L had a 
significantly lower clearance of paclitaxel than patients with normal or high ANC nadirs (P<0.0001, Figure 1). 
 
figure 1. Clearance (L/h) of patients with ANC nadirs <1x109/L and patients with ANC nadirs ≥1x109/L. Outliers >1.5 
and <3 times the Inter Quartile Range (IQR) are represented by a plus sign (+), outliers >3 IQR are shown as a cross 
sign (x). ANC: absolute neutrophil count.
Trend test
ANC levels (treated as a continuous variable) were correlated with the SNPs that were in 
HWE, using a test for trend across ordered groups in the total cohort of patients.  In total, 23 SNPs 
were found to be associated with ANC levels (Table 2). 
The same analysis was done after dividing the patients into two groups according to their 
treatment regimen (weekly and 3-weekly treated patients). The SNP rs9285726 in MAT1A (Figure 2) 
was the only SNP leading to a significant difference in ANC nadirs between SNP variant and wildtype 
(WT) patients in both weekly and 3-weekly treated patients (P<0.03). Patients with the variant SNP 
had higher ANC nadirs than patients with the wild-type genotype. 
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Table 2. 23 SNPs significantly associated (P<0.05) with ANC<1*109/l in the total cohort
Common Name sNP Id rs Change P-value
SLC7A7_39780A>G(K509K) rs1061040 A/G 0.011
SLC13A1_1911>(rs2204295) rs2204295 G/C 0.012
SLC5A6_>(R94R) rs56970590 A/G 0.013
CYP4F11_78A>G(G26G) rs2305801 G/A 0.020
MAT1A_14030>(rs9285726) rs9285726 T/A 0.020
SLC15A1_66322G>A(S616S) rs8187840 G/A 0.020
ABCG1_60972>(rs3788007) rs3788007 G/A 0.022
CHST2_2082>(rs6664) rs6664 C/T 0.023
SLC10A1_225G>A(T75T) rs4646285 G/A 0.023
SLC5A6_7914>(rs7081) rs7081 G/A 0.024
CHST13_6702>(rs4305381) rs4305381 A/C 0.029
GSTP1_2265C>T(A114V) rs1138272 C/T 0.031
CYP39A1_56503T>A(N324K) rs7761731 A/T 0.033
CYP51A1_>(S437P) rs59683852 C/T 0.033
SLC16A1_>(rs12727968) rs12727968 C/A 0.033
SULT2B1_23737C>T(P40P) rs2544794 C/T 0.034
PPARD_-21172>(rs3798343) rs3798343 C/G 0.036
CHST5_-386>(rs2550915) rs2550915 C/G 0.037
SULT1A2_A3_>(rs11150564) rs11150564 C/T 0.037
SLC15A1_28672G>A(S117N) rs2297322 A/G 0.041
CYP4F11_10505T>C(C276R) rs8104361 C/T 0.042
ABCC6_65693G>A(R1268Q) rs2238472 G/A 0.044
ADH5_-159>(rs1154400) rs1154400 G/A 0.044
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figure 2. Nadir absolute neutrophil count per genotype of the SNP rs9285726 on the gene MAT1A. On the x-axis, 
wild-type genotype is shown as WT, the heterozygous variant genotype as HTZ and the homozygous variant 
genotype as HOZ. (A) The nadir ANC per genotype is shown for the patients treated in a weekly regimen. (B) The 
nadir ANC per genotype is shown for the patients treated in a 3-weekly regimen. Outliers >1.5 and <3 times the 
Inter Quartile Range (IQR) are represented by a plus sign (+), outliers >3 Inter Quartile Range are shown as a cross 
sign (x). ANC: absolute neutrophil count. 
 
Identification of patients at high risk for an absolute neutrophil count <1x109/L in the total cohort
Using the cut-off value of ANC <1x109/L (decision limit for antibiotic treatment), a total of 
279 patients were included in the discovery analysis (146 males and 133 females). The mean ANC 
nadir (lowest value during treatment) was 1.5x109/L (range 0.05 – 7.3x109/L) with 116 patients (42%) 
showing a nadir ANC <1x109/L. Age was not significantly associated with ANC nadir <1x109/L (Mann-
Whitney P=0.09), but in females the incidence of an ANC nadir <1x109/L was higher than in men 
(48% vs. 36% respectively; P=0.03). Subsequently, the total group of patients was randomly split into 
a discovery (n=140) and a validation cohort (n=139). Both cohorts were checked for bias in age and 
gender. Patient characteristics were comparable in both cohorts (Table 1). Treatment with cytotoxic 
comedication was not significantly different between the discovery and validation cohorts for each 
endpoint (P≥0.4).
In the discovery and the validation cohort, a comparable proportion of patients (58/140 
(21%) and 58/139 (21%) respectively) had an ANC nadir <1x109/L (defined as high risk patients). 
In the discovery cohort, SNPs associated with high risk were identified and combined in a genetic 
profile containing 10 SNPs: ABCC4 rs2274405, ABCC6 rs2238472, ABP1 rs4725373, CHST10 rs1530030, 
CYP11B1 rs5303, CYP2B6 rs2279344, GSTP1 rs1695, SLC13A1 rs2204295, SLC6A6 rs9036 and VKORC1 
rs8050894. A ROC curve of the discovery cohort was generated and 90% sensitivity was defined as the 
cut-off point (Figure 3). This cut-off was chosen because it gave the most optimal balance between 
specificity and sensitivity. Patients with a probability score above the cut-off value were defined as high-
risk patients. Hereafter, we validated the predictive SNP-model using the validation cohort, consisting 
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of both 1-weekly and 3-weekly dosing regimen patients. Here, 25 out of 58 patients having a true ANC 
nadir<1x109/L were identified, resulting in a sensitivity of 43%. Specificity was 68%, identifying 55 out 
of 81 patients with an ANC nadir >1x109/L; the positive predictive value (PPV) was 49%. The Chi-square 
test of the 2x2 table containing predicted ANC nadirs versus the true nadir level was not statistically 
significant (P=0.18).
 
figure 3. Receiver operation curve of the predictive model for absolute neutrophil count <1x109/L in the 
discovery samples of the total cohort of patients. This is a representation of the ability of the predictive model 
to distinguish between patients with nadir absolute neutrophil counts (ANCs) below and above the value of 
<1x109/L. Here, the true positives (sensitivity, y-axis) are set out against the false positives (1-sensitivity, x-axis) 
at several different cut-off points. The single thin line represents an example in which no distinguishing ability 
is seen for a test. The boxes (score sum) represent the developed predictive model for predicting ANC <1x109/L. 
 
Identification of patients at high risk for a white blood cell count <2x109/l in the total cohort
Next to neutropenia, leukopenia is often seen in paclitaxel-treated cancer patients. 
Therefore, a similar approach was used to predict which patients would be at high risk for WBC 
values below 2x109/L after paclitaxel infusion. Again, the cohort was split into a discovery (n=140) 
and a validation cohort (n=139). In the discovery set, 37 patients had a WBC nadir <2x109/L and in the 
validation set this number of patients was 36. SNPs included in the WBC predictive genetic model are: 
CHST1 rs750398, SLC22A11 rs2078267, SLCO3A1 rs2283458, SULT1A1 rs9282861, CYP4F8 rs4646523, 
SULT2A1 rs296365, ABCC5 rs7636910, SLC22A7 rs2270860, SLC22A7 rs2242416. None of the identified 
SNPs were similar to the SNPs found in the analysis for ANC nadirs. In this case, the closest data-point 
on the ROC-curve to 90% sensitivity was chosen (identification of 33/37 low nadir WBC patients) to be 
the cut-off point in the discovery cohort. Patients with a probability score above this cut-off point were 
predicted as patients with a WBC <2x109/L. Sensitivity of this model was 56%, specificity was 38% and 
PPV was 24%. This model was however not statistically significant.
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Identification of 3-weekly treated patients at high risk for an absolute neutrophil count <1x109/l 
Patients treated with a 3-weekly paclitaxel regimen received higher doses of paclitaxel 
than patients treated with a weekly regimen. These patients were therefore seen to drop below the 
ANC value of 1x109/L more often than the weekly treated patients. Therefore, this subgroup (n=76) 
was tested separately and split in a discovery cohort (n=38) and a validation cohort (n=38). In the 
discovery cohort, 22/38 (58%) had an ANC nadir <1x109/L and in the validation cohort, 23/38 (60%) 
patients had an ANC nadir <1x109/L (Table 3). The following 19 SNPs were identified for inclusion in 
the genetic model for predicting neutropenia in 3-weekly treated patients: ABCB11 rs2287622, ABCC6 
rs2238472, ALB rs3756067, CBR3 rs1056892, CYP2B6 rs4803418, CYP2D6 rs1800716|rs3892097, 
CYP2F1 rs305968, CYP4F1 rs3765070, FMO3 rs2266782, GSTA4 rs405729, GSTM5 rs11807, GSTZ1 
rs3177427, NAT2 rs1799930, SLC16A1 rs1049434, SLC22A11 rs2078267, SLC22A2 rs624249, SLC5A6 
rs1395, SLC7A7 rs2281677, and SULT1A2 rs11150564. The ROC-curve cut-off point was set at 100% 
sensitivity because of the shape of this particular ROC-curve; in other words, the 90% sensitivity point 
in the ROC-curve had the same specificity as at 100% sensitivity, and thus the highest sensitivity was 
chosen.  Patients with a probability score above this value were defined as patients with an ANC 
<1x109/L. Sensitivity of this model was 79%: 18/23 true neutropenic patients had been identified 
as patients with ANC <1x109/L. Specificity was 33% and the PPV was 64%. The Odds Ratio (OR) in 
the logistic regression on the ‘predicted ANC<1x109/L’ versus ‘true ANC<1x109/L’ was 1.8 (P=0.43), 
although this difference did not reach statistical significance.
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dIscussIon 
Out of the total number of SNPs in HWE, we created a list of SNPs statistically significantly 
associated (P<0.05) with severe neutropenia (ANC <1x109/L). Our final list consisted out of 23 SNPs 
(Table 2). SNPs in the SLC gene family were best associated with neutropenia. The SNP rs776173 
(CYP39A1) also came forward in this list (Figure 4), and was previously shown to be associated with the 
incidence of docetaxel induced grade 4 neutropenia, tested in 42 Japanese patients (P=0.049, OR=9.0) 
Table 3. Patient characteristics of patients treated in a 3-weekly schedule
Discovery cohort Validation cohort
ANC<1x109/l ANC<1x109/l
Number of patients (n) 38 38
Male 8 8
Female 30 30
Mean age, years (range) 58.2 (27-82) 57.2 (18-76)
Cancer Type
Oesophagus (%) 1 (0.7) 0 (0)
Ovarian (%) 15 (39.5) 17 (44.7)
Cervix  (%) 3 (7.9) 1 (2.6)
Endometrium  (%) 7 (18.4) 8 (21.1)
Mamma  (%) 1 (2.6) 1 (2.6)
Rest  (%) 11 (28.9) 11 (28.9)
Nadir ANC, mean (range) 1.5 (0.05-10.0) 1.6 (0.05-5.5)
Cytotoxic comedication (n)
cisplatin  (%) 10 (25.6) 9 (23.1)
carboplatin  (%) 26 (66.7) 27 (69.2)
bleomycin  (%) 0 (0) 2 (5.1)
ifosfamide  (%) 1 (2.6) 1 (2.6)
sorafenib  (%) 1 (2.6) 0 (0)
none  (%) 1 (2.6) 0 (0)
Data are represented as absolute numbers unless stated otherwise. Abbreviations: Absolute neutrophil 
count (ANC). One patient was treated with the combination cisplatin & ifosfamide and one patient was 
treated with the combination carboplatin & sorafenib. These patients were separately mentioned for both 
drugs in the combination. 
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(23). In that study, 28 SNPs were associated with docetaxel AUC (P<0.05). The association between 
these 28 SNPs and neutrophil counts were validated in the remaining 32 patients (23). Only rs776173 
(CYP39A1) was significantly associated with grade 4 neutropenia. The validation of this particular SNP 
in our analysis shows that this SNP might be of clinical relevance, despite the fact this SNP was not 
found to be in any of our predicted models. The exclusion of this particular SNP in an early phase of 
the analyses could have been based on the fact this SNP had a lower p-value in our population than 
another SNP in the same gene. The other 22 SNPs in our list (Table 2) were not previously associated 
with toxicities of taxanes.  
 
 
 
 
 
 
figure 4. Total cohort nadir absolute neutrophil count per genotype of the SNP 7761731 on the gene 
CYP39A1. On the x-axis, wild-type genotype is shown as WT, the heterozygous variant genotype as HTZ and 
the homozygous variant genotype as HOZ. Outliers >1.5 and <3 times the Inter Quartile Range (IQR) are 
represented by a plus sign (+),outliers >3 IQR are shown as a cross sign (x). ANC: absolute neutrophil count. 
With the use of the Affymetrix DMETPlus Premier Pack, we have also identified three predictive 
models that could either predict leukopenia or neutropenia. Using the total cohort of patients treated 
with paclitaxel in different regimen, leukopenia was predicted in the validation cohort by a nine SNP 
profile with a sensitivity of 56%, and neutropenia was predicted by a 10 SNP profile with a sensitivity 
of 43%. Additionally, a 19 SNP model was developed for predicting neutropenia in the 3-weekly treated 
patients only. One of these 19 SNPs was located in the ABCB11 gene (BSEP/PFIC2/SPGP), a gene encoding 
a drug transporter previously found to play a role in paclitaxel resistance (24). This model had an improved 
sensitivity of 79%, but was not statistically significant (P<0.05). One SNP, rs9285726 in MAT1A, was 
significantly associated with neutropenia in both 3-weekly treated patients and weekly-treated patients.
SNPs in some of the same genes as found in the previously published DMET paper were 
again identified in our analyses (20). For example, in our predictive model for ANC in the total cohort 
of patients, SNPs in the genes SLC6A6 (rs9036) and VKORC1 (rs8050894) were identified. These genes, 
however not the same SNPs, were also described in our model predicting paclitaxel clearance (20). 
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This paper by de Graan et al. has also described the following genes that have also been identified 
in this analysis: SLC22A11 (rs2078267) and GSTZ1 (rs3177427). In our model, rs2078267 in SLC22A11 
was identified to predict leukopenia in all patients and neutropenia in 3-weekly treated patients. 
rs3177427 in GSTZ1 was selected to predicted neutropenia in the 3-weekly treated patients. To sum, 
SNPs in SLC22A11, GSTZ1, SLC6A6 and VKORC1 were found in the analysis on predicting paclitaxel 
clearance as well as toxicity. However, not all selected SNPs are identical in both analyses. The 
exclusion of these SNPs because of neutral criteria such as a lower P-value for this SNP than another 
SNP in the same gene or a larger amount of missing data could have caused this. Interestingly, also 
SNPs in OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3), drug transporters that were described to be 
involved in hepatic uptake of paclitaxel (3, 4), did not show up in the top genes in our analyses, for 
which we do not have a clear explanation. The hypothesis free analysis using an exploratory and a 
validation cohort seems to be a more open approach than candidate gene analysis, but may suffer 
from chance findings, which is intended to be counteracted by using exploratory and validation 
cohorts. The fact that also only few SNPs from our recent models do overlap the models focusing on 
paclitaxel pharmacokinetics that have previously been developed by de Graan et al. (20), strengthens 
the idea that factors influencing pharmacodynamics and pharmacokinetics do not always overlap. 
For gaining an adequate predictive model with high clinical impact, the model would ideally have 
a high sensitivity as well as a high specificity, aiming for the correct identification of all patients at 
high risk for neutropenia (ANC <1x109/L). A wrongful recognition of a low risk patient as a high-risk 
patient would not have immediate serious medical consequences. On the other hand, addressing 
a high-risk patient as a low risk patient could have more serious consequences, but is analogous to 
the current standard of practice; that is, patients are hospitalized upon showing neutropenia and/
or neutropenic fever. Being able to identify high-risk patients would mean that all of these patients 
would receive proper follow-up in the weeks after paclitaxel administration and could hypothetically 
receive a lower dose of paclitaxel than their genetically different equals. Before this could be clinical 
practice, the correlation between a lower dose and treatment outcome has to be addressed. 
Patients at low risk for neutropenia could be send home for a longer period, with less frequent 
outpatient visits. This would decrease patient burden and would also decrease health care costs. 
 
 
conclusIons
We found a 10-SNP model in 279 paclitaxel-dosed patients reaching 43% sensitivity in the 
validation cohort for predicting hematological toxicity. Analysis in 3-weekly-treated patients resulted 
in improved sensitivity of 79%, with a specificity of 33%, although both approaches did not lead to 
statistically significant models. Therefore, we assume that variation in genes that are involved in 
drug metabolism and transport only partly covers the inter-individual variability in hematological 
toxicity (25). SNPs in genes not involved in drug metabolism or transport or additional factors as 
the environment could also contribute in developing paclitaxel-induced hematological toxicity. 
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Future PersPectIve
To reduce patient burden and health care costs, it is crucial to be able to predict which 
patients will suffer from neutropenia and associated complications. Our predictive genetic models 
reached acceptable sensitivity, but unfortunately did not reach statistical significance. In future studies 
aiming for similar purposes, large homogeneous subgroups of patients should be used for gaining 
optimal sensitivity. As it seems that variation in genes involved in drug metabolism and transport 
only partially explains the inter-individual variability in hematological toxicity, additional factors such 
as environmental factors (i.e., co-medication) should be investigated and potentially included in 
future models. To add, the SNPs rs9285726 in MAT1A and rs776173 in CYP39A1 deserve additional 
investigation since these were shown to be associated with neutropenia and need further validation. 
In particular, this last mentioned SNP in CYP39A1 might be clinically relevant, as this SNP had already 
been found to be associated with taxane-induced neutropenia. 
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AbsTrACT
Docetaxel is used for treatment of several solid malignancies. In this study, we aimed for 
predicting docetaxel clearance and docetaxel-induced neutropenia by developing several genetic 
models. Therefore, pharmacokinetic data and absolute neutrophil counts (ANCs) of 213 docetaxel-
treated cancer patients were collected. Next, patients were genotyped for 1936 Single Nucleotide 
Polymorphisms (SNPs) in 225 genes using the Drug-Metabolizing Enzymes and Transporters (DMET) 
platform and thereafter split into two cohorts. The combination of SNPs that best predicted severe 
neutropenia or low clearance was selected in one cohort and validated in the other. Patients with 
severe neutropenia had lower docetaxel clearance than patients with ANCs in the normal range 
(P=0.01). Severe neutropenia was predicted with 70% sensitivity. True low clearance (1SD<mean 
clearance) was identified in 80% of cases. These models however did not reach statistical significance. 
To improve the predictive value of these models, the addition of non-genetic influencing factors is 
needed.  
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INTrOduCTION
Neutropenia is one of docetaxels’ main dose limiting toxicities, which may cause neutropenic 
fever, subsequent dose reductions and early discontinuation of treatment. Dose calculation of docetaxel 
is currently solely based on a patients weight and length (body surface area) (1). Unfortunately, due 
to a wide variation in docetaxel exposure between patients this dosing strategy does not give much, if 
any, information on the actual systemic exposure to docetaxel in an individual patient (2). It is known 
that the risk of drug-related toxicities is correlated with the exposure to docetaxel, but is also highly 
variable (3). Therefore, it is still difficult to predict which patients will suffer from severe toxicity. 
 It is highly relevant to determine which factors are associated with the variability in docetaxel 
exposure and toxicity. Multiple environmental factors (that is, smoking behaviour, co-medication and 
adenoviruses), intrinsic factors (that is, gender and age) have been explored for their effects on the 
variation between patients in pharmacokinetics or pharmacodynamics (4-14). Besides these factors, 
a limited amount of genetic variants was studied for their role in this pharmacologic variability and 
differences in patients’ predisposition for toxicities (15). However, the results of these studies have 
often been conflicting. 
If it would be possible to better understand and predict the inter-patient variability in 
exposure and toxicity of docetaxel, dosing docetaxel could be individualized. As a result, physicians 
may attempt to administer a higher dose, within the dose-range of the therapeutic window, to 
individual patients with a potentially higher chance of obtaining anti-tumor efficacy.  
In the current project, we studied the correlations between the risk of severe neutropenia 
(absolute neutrophil count (ANC) nadir <1x109/L or grade 3 neutropenia according to the 
Common Terminology Criteria for Adverse Events v.4.0) (http://www.eortc.be/services/doc/ ctc/
CTCAE_4.03_2010-06-14_ QuickReference_5x7.pdf) and the exposure to docetaxel in a large set 
of docetaxel-treated cancer patients, of which the majority was treated in a 3-weekly regimen. In 
addition, we investigated the effects of pharmacogenetic variability on the inter-patient variability 
in docetaxel exposure and docetaxel-induced severe neutropenia. Because previous candidate gene 
approaches did not give a final answer on this question, we here used the Drug-Metabolizing Enzymes 
and Transporters (DMET) platform, which enables us to simultaneously study 1936 single nucleotide 
polymorphisms (SNPs) on 225 genes involved in drug transport and metabolism. Subsequently, we 
aimed for developing genetic models to predict the risk of severe neutropenia and a low docetaxel 
clearance during docetaxel therapy. 
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MeThOds 
Patient inclusion
All 240 Caucasian cancer patients who have given written informed consent (between 
June 2004 and January 2014) for a pharmacokinetic study (Dutch Trial Registry number NTR2311 at 
www.trialregister.nl) were included in the current study. This study was carried out according to the 
declaration of Helsinki and had been approved by the Medical Ethical Board of the Erasmus Medical 
Center, Rotterdam, the Netherlands. All patients were receiving docetaxel for solid malignancies. 
Patients were treated in different treatment regimens. As shown in Table 1, the majority of patients 
were treated with 75mg/m2 or 100mg/m2 docetaxel every three weeks. Patients with a World Health 
Organization performance status ≥2 and the intake of strong CYP3A4 inducers or inhibitors were 
excluded (http://medicine.iup ui.edu/clinpharm/ddis/main-table/). 
Renal and hepatic function had to be sufficient according to hospital protocol. Neutrophil 
counts had to be >1.5 x 109/L for docetaxel administration according to the product information of 
docetaxel (16). Neutrophil blood counts were drawn according to the physician’s assessment.
Table 1. Patient characteristics
docetaxel-induced neutropenia low docetaxel clearance
Identification 
cohort
Validation 
cohort
Identification 
cohort
Validation 
cohort
Number of patients 98 99 96 98
Male (n, %) 37 (38%) 38 (38%) 41 (44%) 37 (38%)
Female (n, %) 61 (62%) 61 (62%) 55 (56%) 61(62%)
Premenopausal 19 (31%) 20 (33%) 18 (33%) 18 (29%)
Postmenopausal 36 (59%) 35 (57%) 31 (58%) 39 (64%)
Unknown 6 (10%) 6 (10%) 5 (9%) 4 (7%)
Mean age, years (range) 56 (17-80) 54 (24-79) 58 (17-80) 56 (24-79)
Cancer Type (n, %)
Breast 56 (57%) 53 (54%) 45 (47%) 56 (57%)
Prostate 24 (25%) 21 (21%) 29 (30%) 6 (7%)
Melanoma 3 (3%) 6 (6%) 5(5%) 21 (21%)
Head/neck 3 (3%) 3 (3%) 1 (1%) 3 (3%)
Sarcoma 1 (1%) 6 (6%) 4(4%) 4 (4%)
Lung 1 (1%) 4 (4%) 0 (0%) 3 (3%)
Rest 10 (10%) 6 (6%) 12 (13%) 5 (5%)
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Pharmacogenetic and pharmacokinetic analyses 
Pharmacogenetic and pharmacokinetic analyses were performed as described previously 
(17). For pharmacokinetic purposes, patients were sampled using a validated limited sampling strategy 
during at least one of the cycles with docetaxel (18). As an anti-coagulant, lithium heparin was used 
in all collected tubes. Pharmacokinetic measurements and sample handling was done as described 
before by de Graan et al. (19).  
For pharmacogenetic purposes, patients were genotyped using whole blood. The MagnaPure 
LC (Roche Diagnostics GmbH, Mannheim Germany) was used for DNA isolation and the DMET Plus 
Premier Pack (DMET, Affymetrix, Santa Clara, CA, USA) was used for genotyping (17, 20). All 1936 
SNPs were run simultaneously on this chip. The quality and trustworthiness of these genotypes was 
indicated by the “call-rate”. When the call-rate for a sample was below 90%, this sample was removed 
from the analysis. Patients with missing neutrophil counts, pharmacokinetic data, or neurotoxicity 
data were excluded from the analysis of that particular topic.
Regimen (n, %)
Weekly 1 (1%) 4 (4%) 1 (1%) 3 (3%)
3 weekly 82 (84%) 85 (86%) 84 (87%) 78 (80%)
Unknown or only 1 course 15 (15%) 10 (10%) 11 (12%) 17 (17%)
Median dose (n, %)
30 mg/m2 0 (0%) 5 (5%) 2 (2%) 3 (3%)
60 mg/m2 0 (0%) 2 (2%) 1 (1%) 1 (1%)
75 mg/m2 45 (46%) 43 (43%) 50 (52%) 40 (41%)
100 mg/m2 46 (47%) 46 (47%) 42 (44%) 45 (46%)
Unknown 1 (1%) 0 (0%) 0 (0%) 0 (0%)
Rest 6 (6%) 3 (3%) 1 (1%) 9 (9%)
ANC data
Patients with ANC <1x109/L 46 (47%) 46 (46%) 43 (45%) 42 (43%)
Patients with ANC ≥1x109/L 52 (53%) 53 (54%) 45 (47%) 48 (49%)
Unknown 0 (0%) 0 (0%) 8 (8%) 8 (8%)
Mean clearance (range) 45.2 (16.2-95.9) 44.7 (13.0-76.9) 45.6 (16.2-95.9) 44.1 (13.0-76.9)
Abbreviations: ANC: absolute neutrophil count
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Associations between docetaxel clearance and severe docetaxel-induced neutropenia
Neutrophil counts and neurotoxicity data were collected from patients’ charts. Treating 
physicians had scored the neurotoxicity grade according to the common terminology criteria for 
adverse events (CTCAE) versions 2 to 4 (http://www.eortc.be/services/doc/ctc/CTCAE _4.03_ 2010-
06-14_QuickReference_5x7.pfd). 
Genetic model for predicting low absolute neutrophil counts
Patients were clustered in a ‘high risk’ and ‘low risk’ group according to their nadir ANC; with 
a nadir <1.0x109/L used to label patients as ‘high risk’. All 197 patients for whom ANC (nadir) data were 
available were included in this analysis and randomly separated in an identification cohort (n=98) and a 
validation cohort (n=99). To exclude as much patient bound bias as possible, the cohorts were checked 
for bias in age, gender, and smoking status using the Chi-square test. For all patients, genotyping 
was done for 1936 SNPs in 225 genes that are involved in drug metabolism and/or drug transport 
using the DMET Plus Premier Pack (Affymetrix) according to former descriptions (17). SNPs of which 
only one genotype was observed in all patients (n= 985) and SNPs that were not in Hardy-Weinberg 
Equilibrium (P<0.05) (n=131) were excluded from the analysis. This resulted in 815 remaining SNPs. 
The genotypes of the SNPs were analysed in the identification cohort using conditional probability as 
previously described (17). This means that the probability of a patient of having severe neutropenia 
is calculated, given the manifestation of a particular genotype for a certain SNP. Thus, for each SNP, 
three probabilities (wildtype, heterozygous and homozygous genotype) were calculated. To select 
SNPs for inclusion in the profile, the following criteria were used: the probabilities of the wildtype and 
homozygous genotype had to be 15% higher than the standard risk of developing severe neutropenia. 
This standard risk was defined as the proportion of patients in the identification set showing a risk of 
severe neutropenia and was calculated to be 47% (46 out of 98 patients). We were aiming for finding 
SNPs that predicted the risk for a particular patient of severe neutropenia better than the overall risk 
of 47%. Next, the difference in probability score between WT and HOZ had to be >20%. SNPs reaching 
these criteria were checked for collinearity, i.e. all patients in the identification set having the same 
genotype for that SNP. If collinearity existed, one of the SNPs was randomly selected to be used, or in 
case of missing calls in one of the SNPs, the SNP with the most observations was kept. 
The probabilities were subsequently used as weight in the analysis for predicting severe 
neutropenia. A score for each sample was calculated as the sum of probabilities of the SNPs in the profile. 
This score was associated with the ‘high risk’ or ‘low risk’ status of the patients in the identification set 
by using a receiver operation curve. In this curve, the capability of the predictive model for predicting 
severe neutropenia was made visual. A threshold was selected, based on the desired sensitivity in the 
identification set. Next, the probability scores for the patients in the validation cohort were calculated 
and compared with this threshold. Patients with a value above this threshold were predicted as ‘high 
risk’ patients, thus at risk for severe neutropenia. The predictions were matched with the ANC status 
and the sensitivity, specificity and positive predictive value were then calculated.
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A genetic model for predicting low docetaxel clearance
A similar process as described for the nadir ANC was used to generate a model for the 
prediction of low docetaxel clearance. Here, low clearance was defined as clearance 1 standard 
deviation below the mean. This applied to 30 patients. Of all 194 patients with available data, patients 
were again split in an identification cohort and a validation cohort. Both cohorts were checked for 
bias in age, gender and smoking status. Both the discovery and validation cohort comprised 15 
patients with low clearance. Identifying relevant SNPs associated with low clearance, calculation of 
the probability score, selecting the threshold and predicting the samples in the validation cohort 
were done as described for the nadir ANC model. Conditional probability was again used to select the 
relevant SNPs in the identification cohort as earlier described.
Statistics 
SPSS version 21 (SPSS Inc.) and STATA version 13 (StatCorp LP, TX, USA) were used to 
perform the statistical analyses. A P-value <0.05 was defined to be statistically significant and data 
are shown as a mean with a range. The predictive value of genetic profiling on severe docetaxel-
related neutropenia was considered as the primary endpoint. Secondary endpoints were the 
associations between docetaxel pharmacokinetics and neurotoxicity and severe docetaxel-induced 
neutropenia. In univariate analysis of SNP versus endpoints, no adjustments for multiple testing 
were made in view of the exploratory nature of the analysis. Comparisons between a category 
and continuous variable where tested using the Mann-Whitney test in case of 2 groups, in case 
of multiple groups the Kruskal-Wallis rank test was used. For comparisons between groups the 
Chi-square test was used. If the number of observations was too low to use the Chi-square test, a 
Fisher’s exact test was used. To associate ANC as continuous variable with a SNP, a test for trend 
across ordered groups was used, which is an extension of the Wilcoxon rank-sum test (21).  
 
 
resulTs 
Association between docetaxel clearance and severe docetaxel-induced neutropenia
A total of 213 patients had been genotyped and had demographic data available. A trend 
was seen between low clearance and severe neutropenia in the total population of which these data 
were available (n=202, P=0.056) when using the definition of low clearance being 1 standard deviation 
below the mean clearance (Table 2). However, in females only (n=73) it was seen that low clearance 
was associated with severe neutropenia (P=0.003), possibly indicating that females are more sensitive 
to higher docetaxel concentrations than male patients. Pharmacokinetic data were available for 194 
of the genotyped patients. Of these 194 patients, 30 patients (15%) had a defined low clearance (1 SD 
< mean CL). For 197 of the total 213 patients, nadir ANC data were available. Of these 197 patients, 
92 patients (47%) had severe neutropenia. Patients with severe neutropenia had a lower docetaxel 
clearance than patients with an ANC ≥1.0x109/L (mean difference=5.0 L/h, P=0.01). Neurotoxicity was 
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not significantly associated with docetaxel clearance (P=0.6) (Table 2). Neurotoxicity was seen in 66 
out of these 125 patients (53%) of whom 15 had grade 2/3 neurotoxicity. Neurotoxicity was also not 
significantly associated with the cumulative dose of docetaxel (P=0.5).
 
 
Association between docetaxel exposure and severe docetaxel-induced neutropenia
For analyzing the association between the area under the curve (AUC) of docetaxel and 
severe neutropenia and neurotoxicity, patients receiving 30mg/m2 docetaxel were excluded. We found 
that patients with severe neutropenia had a significantly higher docetaxel AUC than patients without 
severe neutropenia (n=196, P=0.008). Neurotoxicity was not correlated with the AUC of docetaxel 
(n=122, P=0.9).
Model for predicting severe neutropenia
In both the identification cohort (n=98) and the validation cohort (n=99), 46 patients (47%) 
had severe neutropenia. Patient characteristics in the identification cohort were similar to those in 
the validation cohort (n=99) (Table 1). There were no significant differences between the numbers of 
patients that smoked cigarettes in both cohorts. No differences in age (P=0.2) and gender (P=0.9) were 
seen in the two cohorts. In the identification cohort, 24 SNPs have been selected for inclusion in the 
predictive profile according to the criteria described in the method section (Table 3).
A probability score was calculated for all patients in the identification cohort, and the value 
for the prediction threshold was chosen where 90% of patients in the identification cohort with severe 
neutropenia showed scores above that particular threshold (Figure 1). Thus, the threshold was chosen 
to result in 90% sensitivity in the identification cohort (Figure 1). Next, the probability score of the 
patients in the validation cohort were calculated and – using the selected threshold – patients were 
predicted as high or low risk of severe neutropenia. In the validation cohort, the profile showed a 
Table 2. Correlations between clearance and docetaxel-induced toxicities
ANC ANC Count (*109/l) Patients (n) high Cl *1 (n) low Cl *1  (n) P-value
≥ 1 106 96 10
< 1 96 78 18 0.056
Neurotoxicity Grade Patients (n) Mean Cl (range)
0 59 46.5 (16.2-84.0)
1 51 46.8 (20.3-95.9)
2 15 47.7 (22.0-62.7) 0.627
ANC: absolute neutrophil count, *1 High CL: CL ≠1SD < mean CL, *1 Low CL: CL 1SD, Mean CL: in L/h
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sensitivity of 70%, specificity of 21% and a positive predictive value of 43% (P=0.27). In total, 32 out of 
46 patients with severe neutropenia were correctly predicted. 
Table 3. sNP model for predicting docetaxel-induced neutropenia
rs sNP Id Gene Common name Allele change
rs12248560 CYP2C19 CYP2C19_-806>(rs12248560) C/T
rs2852425 NNMT NNMT_15229>(rs2852425) T/C
rs818202 CDA CDA_1169>(rs818202) G/A
rs2020861 FMO2 FMO2_13733A>G(S195S) C/T
rs7512785 FMO2 FMO2_24435>(rs7512785) C/T
rs7515157 FMO2 FMO2_24625>(rs7515157) T/C
rs131713 ARSA ARSA_>(rs131713) C/T
rs3770602 ABCB11 ABCB11_-7056>(rs3770602) T/C
rs3832043 UGT1A9 UGT1A9_>(rs3832043) -/T
rs6759892 UGT1A9 UGT1A9_>(rs6759892) G/T
rs7586110 UGTA1A1 UGT1A1_>(rs7586110) T/G
rs13197674 GSTA4 GSTA4_-1366>(rs13197674) G/A
rs8192879 CYP7A1 CYP7A1_9082>(rs8192879) G/A
rs1138541 SLCO5A1 SLCO5A1_160281>(rs1138541) A/G
rs4149057 SLCO1B1 SLCO1B1_37091T>C(L191L) T/C
rs1339067 SLC15A1 SLC15A1_48241T>C(A449A) C/T
rs8187758 SLC28A1 SLC28A1_17884C>A(Q237K) C/A
rs2305367 SLC28A1 SLC28A1_45450G>A(K383K) A/G
rs1060463 CYP4F11 CYP4F11_20043G>A(D446N) G/A
rs2228099 ARNT ARNT_40155G>C(V189V) C/G
rs1051740 EPHX1 EPHX1_3203T>C(Y113H) C/T
rs3749442 ABCC5 ABCC5_71596C>T(L1208L) C/T
rs272893 SLC22A4 SLC22A4_32753T>C(I306T) T/C
rs1050152 SLC22A4 SLC22A4_46011C>T(L503F) C/T
SNPs: single nucleotide polymorphisms
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figure 1. The ROC-curve for the genetic model for predicting neutropenia. This curve represents the true positives 
and the false positives at different cut-offs. The line from the left lower corner to the right upper corner is an 
example of a test with no distinctive ability. The curve of boxes (score sum) represents the ROC-curve of the genetic 
model predictive for ANCs <1.0x109/L.
A genetic model for predicting low docetaxel clearance
For this analysis, the total cohort of 194 patients for whom clearance data were available 
was split into an identification cohort (n=96) and a validation cohort (n=98). The cohorts were found 
similar regarding age, gender and smoking status. Both groups contained 15 patients (15% and 16% 
respectively) with a defined low clearance (1 SD < mean). By using conditional probability, 14 SNPs 
were selected in the patients from the identification cohort (Table 4). A cut-off point closest to reach 
a sensitivity of 90% to predict low clearance in the identification cohort was chosen, and similarly as 
described for neutropenia, the selected SNPs were subsequently validated in the validation cohort. 
The patients with a probability score above the cut-off point were predicted to have low docetaxel 
clearance. For this SNP-based profile, the sensitivity was 80%, the specificity was 35% and the positive 
predictive value was 18% (P=0.26). 
Significant SNPs associated with neutropenia or low docetaxel clearance
When analysing the genotypes from all patients of whom ANC nadir data were available, 31 
SNPs were statistically significantly associated with severe neutropenia (P<0.05, test for trend, Table 
5). Thirty-three SNPs were associated with low docetaxel clearance (P<0.05, test for trend) in the 
patients for whom pharmacokinetic data were available (Table 6). Only rs1881668 in SULT1E1 was 
found associated with both severe neutropenia and low docetaxel clearance. 
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Table 4. sNP model for predicting low docetaxel clearance
rs Id sNP Gene Common Name Allele Change
rs2242046 SLC28A1 SLC28A1_47738G>A(D521N) G/A
rs3743369 SLCO3A1 SLCO3A1_>(rs3743369) A/G
rs11859842 SULT1A2 SULT1A2_A3_>(rs11859842) A/G
rs2479390 GSTM5 GSTM5_1141>(rs2479390) A/G
rs3788010 ABCG1 ABCG1_76650>(rs3788010) A/G
rs1044317 ABCG1 ABCG1_40560>(rs1044317) A/G
rs1541290 ABCG1 ABCG1_>(rs1541290) A/G
rs6759892 UGT1A9 UGT1A9_>(rs6759892) G/T
rs3814055 NR1I12 NR1I2_-26063>(rs3814055) C/T
rs7662029 UGT2B7 UGT2B7_-327>(rs7662029) A/G
rs3756067 ALB ALB_-400>(rs3756067) A/G
rs405729 GSTA4 GSTA4_16261>(rs405729) A/G
rs2292334 SLC22A3 SLC22A3_88737G>A(A411A) G/A
rs1208 NAT2 NAT2_803G>A(R268K) A/G
SNPs: single nucleotide polymorphisms
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Table 5. significant sNPs associated with severe neutropenia
rs Id sNP Gene Common Name Allele Change p-value
rs1050152 SLC22A4 SLC22A4_46011C>T(L503F) C/T 0.001
rs1800822 FMO3 FMO3_15136C>T(S147S) C/T 0.004
rs1799814 CYP1A1 CYP1A1_2452C>A(T461N) C/A 0.014
rs2305367 SLC28A1 SLC28A1_45450G>A(K383K) A/G 0.016
rs1202283 ABCB4 ABCB4_22490C>T(N168N) T/C 0.016
rs1060253 SLC7A5 SLC7A5_36891>(rs1060253) C/G 0.017
rs6915115 PPARD PPARD_-19920>(rs6915115) C/T 0.018
rs3765070 CYP4F11 CYP4F11_4927T>C(I106I) C/T 0.019
rs4148271 UGT2B15 UGT2B15_328324>(rs4148271) T/A 0.021
rs6755571 UGT1A4 UGT1A4_>(rs6755571) C/A 0.022
rs272879 SLC22A4 SLC22A4_40237C>G(T394T) G/C 0.023
rs909530 FMO3 FMO3_21375C>T(N285N) C/T 0.024
rs1060463 CYP4F11 CYP4F11_20043G>A(D446N) G/A 0.026
rs3786362 TYMS TYMS_4505A>G(E127E) A/G 0.027
rs272893 SCL22A4 SLC22A4_32753T>C(I306T) T/C 0.027
rs7483 GSTM3 GSTM3_3209G>A(V224I) A/G 0.030
rs2274407 ABCC4 ABCC4_94534G>T(R304S) G/T 0.033
s1881668 SULT1E1 SULT1E1_-2094>(rs1881668) C/G 0.034
rs854560 PON PON1_7704T>G(L55V) T/A 0.037
rs2140516 SLC13A1 SLC13A1_30767A>G(N174S) A/G 0.037
rs17102596 MAT1A MAT1A_14007>(rs17102596) A/G 0.040
rs6577 GSTA2 GSTA2_7331A>C(E210A) A/C 0.040
rs1803684 GSTA2 GSTA2_-10>(rs1803684) C/G 0.040
rs7748890 GSTA5 GSTA5_-3506>(rs7748890) C/T 0.040
rs1736565 FMO6 FMO6_>(rs1736565) C/T 0.042
rs818202 CDA CDA_1169>(rs818202) G/A 0.043
rs82693844 CSHT9 CHST9_-66>(rs28693844) T/C 0.046
rs16947 CYP2D6 CYP2D6_2851T>C(C296R) T/C 0.047
rs17596954 GSTM5 GSTM5_2656T>C(L128L) C/T 0.048
rs7087728 MAT1A MAT1A_15710>(rs7087728) T/C 0.050
rs8187832 SLC15A1 SLC15A1_64082C>T(N509N) C/T 0.050
SNPs: single nucleotide polymorphisms
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Table 6. significant sNPs associated with low docetaxel clearance
rs Id sNP Gene Common Name Allele Change p-value
rs8192868 TBXAS1 TBXAS1_186455G>A(E450K) A/G 0.001
rs3822172 SULT1E1 SULT1E1_-478>(rs3822172) A/G 0.002
rs7512785 FMO2 FMO2_24435>(rs7512785) C/T 0.005
rs7515157 FMO2 FMO2_24625>(rs7515157) T/C 0.005
rs3736599 SULT1E1 SULT1E1_-2459>(rs3736599) G/A 0.007
rs2835286 CBR3 CBR3_10872>(rs2835286) A/G 0.011
rs2020869 FMO2 FMO2_23300>(rs2020869) A/G 0.011
rs1801282 PPARG PPARG_-28080>(rs1801282) C/G 0.011
rs7853758 SLC28A3 SLC28A3_54623C>T(L461L) T/C 0.011
rs13197674 GSTA4 GSTA4_-1366>(rs13197674) G/A 0.012
rs12208357 SLC22A1 SLC22A1_181C>T(R61C) C/T 0.012
rs683369 SLC22A1 SLC22A1_8237G>C(L160F) C/G 0.012
rs2231142 ABCG2 ABCG2_8825C>A(Q141K) C/A 0.014
rs2297322 SLC15A1 SLC15A1_28672G>A(S117N) A/G 0.014
rs6196 NR3C1 NR3C1_118915T>C(N766N) T/C 0.015
rs1883322 PPARD PPARD_-9059>(rs1883322) T/C 0.016
rs2214102 ABCB1 ABCB1_-1>(rs2214102) A/G 0.018
rs207440 XDH XDH_75121G>A(E1239E) A/G 0.021
rs2237667 PPARD PPARD_-6341>(rs2267667) G/C 0.023
rs3322 RALBP1 RALBP1_23648>(rs3322) A/G 0.024
rs7751481 PPARD PPARD_-7112>(rs7751481) G/A 0.025
rs506008 GSTM4 GSTM4_2688T>C(F178F) T/C 0.026
rs2072671 CDA CDA_79A>C(K27Q) C/A 0.029
rs3749442 ABCC5 ABCC5_71596C>T(L1208L) C/T 0.031
rs305968 CYP2F1 CYP2F1_96G>A(P32P) G/A 0.032
rs6906237 PPARD PPARD_-3339>(rs6906237) A/C 0.032
rs1881668 SULT1E1 SULT1E1_-2094>(rs1881668) C/G 0.033
rs41507953 EPHX2 EPHX2_9780A>G(K55R) A/G 0.034
rs909921 TPSG1 TPSG1_1450>(rs909921) G/A 0.038
rs17863783 UGT1A6 UGT1A6_>(rs17863783) G/T 0.046
unknown CYP2C8 CYP2C8_2189A>-(unk1) -/A 0.047
rs1049434 SLC16A1 SLC16A1_15385T>A(D490E) A/T 0.048
rs7867504 SCL28A3 SLC28A3_35313A>G(T89T) G/A 0.050
SNPs: single nucleotide polymorphisms
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dIsCussION
In this study, almost 50% of the included patients had severe neutropenia, confirming that 
neutropenia is indeed a frequently occurring side effect of docetaxel therapy, potentially leading to 
neutropenic fever, which is of great clinical relevance. As expected, patients with severe neutropenia 
had a significantly lower docetaxel clearance than patients with ANCs ≥1.0x109/L. For predicting severe 
neutropenia, we developed a DMET-based 24-SNP model with a sensitivity of 70%. Unfortunately, 
this model did not reach the significance level. Also, a 14-SNP model was developed for predicting 
low docetaxel clearance with 80% sensitivity. Again however, this model did not reach statistical 
significance. This indicates that the 1936 SNPs in the 225 genes on the DMET chip are probably not 
(fully) representative for explaining inter-patient variation in docetaxel clearance and neutropenia in 
our identification and validation sets. Despite the large cohort of patients studied, a lack of power due 
to sample size cannot be excluded as a reason for not reaching statistical significance. Another reason 
for this might be the impact of non-genetic variables such as gender, castration status, menopausal 
status and drug-drug interactions on inter-individual variability in pharmacokinetics as well as toxicity 
(22-24). For neutropenia, previous cytotoxic treatment might also influence the severity of toxicity, as 
it theoretically changes the bone marrow ‘reserve’. 
A trend was seen for the association between low clearance and severe neutropenia in 
the total population when defining low clearance as clearance that is 1 standard deviation below 
the mean clearance in this population. When looking at absolute numbers, we found that 18 out of 
28 low clearance patients had neutropenia (64%), which is more than the standard risk for severe 
neutropenia that we observed in our total patient population (47%). Nonetheless, patients who do not 
easily clear docetaxel are not always prone for neutropenia, suggesting that other mechanisms may 
also be involved in the development of this dose-limiting side effect (25). When separately analyzing 
only female patients, low clearance was significantly associated with severe neutropenia. This may 
suggest that female patients might be more sensitive to higher docetaxel concentrations than male 
patients. However, this difference may also be caused by the fact that female breast cancer patients 
tend to get higher doses than most male patients. It yet remains unclear if rs1881668 in SULT1E1, a 
protein that plays a role in the levels of oestrogens, which was found associated with both neutropenia 
and low docetaxel clearance, may partly be responsible for this gender based difference (26).
 Interestingly, neurotoxicity was not associated with docetaxel clearance, contrary to 
the related taxane paclitaxel (27). A SNP recently correlated to paclitaxel-induced neurotoxicity 
(CYP3A4*22) was not available on the DMET chip, so a potential relationship is not excluded. Also, the 
incidence of docetaxel-induced neuropathy seems to be lower than that of paclitaxel, although the 
cohorts of patients were not fully comparable (28, 29). The effects of co-prescribed anti-cancer agents 
on neurotoxicity seem limited because the majority of patients received docetaxel mono-therapy. The 
fact that neurotoxicity was not significantly correlated with the cumulative dose of docetaxel might 
be due to the fact that only 18 out of 137 patients that this data was available for suffered from grade 
2/3 neurotoxicity. 
 Some of the identified SNPs in the developed models have also been previously described in 
the context of toxicity, clearance and taxane therapy. In the gene FMO3 for example, the SNP rs909530 
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is previously identified to be associated with docetaxel-induced febrile neutropenia and a reduction in 
neutrophil count cycle (from cycle 1 to cycle 2) in a group of 100 Lebanese cancer patients (30). In that 
study, also rs1065852 in CYP2D6 was identified to be associated with febrile neutropenia. We found 
another variation (rs16947) in CYP2D6 to be associated with severe neutropenia, suggesting a possible 
role of this phase I enzyme in the existence of docetaxel-related neutropenia. Other SNPs identified in 
that study did not come up in our analysis and vice versa (30). The different ethnic background of the 
included patients in these studies may have played a role. 
 We found that rs13197674 in the glutathione S-transferase gene (GSTA4) was associated 
with low docetaxel clearance. This SNP had already been described to be associated with low paclitaxel 
clearance (17). The GSTA4 gene is involved in the defence against by-products of oxidative metabolism 
(31). Two other SNPs on GSTA4 have also been described to be associated with docetaxel clearance 
(32). Next to the SNP in GSTA4, SNPs in the genes CDA (cytadine transaminase), EPHX2 (epoxide 
hydroxylase 2) and SLC22A1 (solute carrier family 22 member A1) were also previously found to be 
associated with low paclitaxel clearance (17). In addition, variation in the CDA gene had been correlated 
with haematological toxicity in gemcitabine patients (33). We however, did not find the same SNPs. 
Differences in the incidences of these genotypes make it possible that SNPs in this analysis have been 
excluded based on a lack of variety or for example not being in Hardy-Weinberg Equilibrium. However, 
different SNPs could have similar effects on the function of a gene. The value of these findings thus lies 
in the apparent importance of these particular genes in taxane pharmacokinetics. 
The limited effects of genetic variation on docetaxel clearance are, most likely, attributed 
to masking effects of other factors influencing docetaxel PK. Dividing the cohorts based on patients’ 
gender could possibly improve results (9, 23). However, limited amounts of patients do not allow such 
subset analyses. Endocrine factors, among other factors, such as menopausal status and castration 
status might also influence docetaxel PK, and therefore mask underlying genetic effects (23, 25). 
In conclusion, the majority of patients at a higher risk for severe neutropenia and low 
docetaxel clearance could be identified using models based on genetic variation. However, in this study 
these models did not reach statistically significance, indicating that variation in the DMET genes is (at 
most) of limited value for explaining inter-patient variability in severe docetaxel-induced neutropenia 
and docetaxel clearance. Our findings indicate that new predictive models need to be developed 
combining genetic, environmental and intrinsic factors in sufficiently sized and homogeneous patient 
cohorts. 
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AbsTrACT
Docetaxel is a frequently used chemotherapeutic agent in the treatment of solid cancers. 
Because of the large inter-individual variability (IIV) in the pharmacokinetics (PK) of docetaxel, it is 
challenging to determine the optimal dose in individual patients in order to achieve optimal efficacy 
and acceptable toxicity. Despite the established correlation between systemic docetaxel exposure and 
efficacy, the precise factors influencing docetaxel PK are not yet completely understood. This review 
article highlights currently known factors that influence docetaxel PK, and focuses on those that 
are clinically relevant. For example, liver impairment should be taken into account when calculating 
docetaxel dosages as this may decrease docetaxel clearance. In addition, drug-drug interactions may 
be of distinct clinical importance when using docetaxel. Particularly, drugs strongly inhibiting CYP3A4 
such as ketoconazole should not be concurrently administered without dose modification, as they may 
decrease the clearance of docetaxel. Gender, castration status, and menopausal status might be of 
importance as potential factors influencing docetaxel PK. The role of pharmacogenetics in predicting 
docetaxel PK is still limited, since no polymorphisms of clinical importance have yet been established.
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INTrOduCTION
Docetaxel is approved for the treatment of several solid malignancies, including non-small 
cell lung cancer (NSCLC), metastatic castration resistant prostate cancer (mCRPC), breast cancer and 
head and neck cancer (1,2). Most of these cancers typically occur in elderly people, who may have 
comorbidities, organ dysfunction and are using various medications. The pharmacokinetics (PK) of 
docetaxel are highly variable, ranging from 30-45% (3). Therefore, it is challenging to predict toxicity 
and antitumor activity of docetaxel in individual patients. Ideally, patients would be individually dosed 
to prevent toxicity and improve the efficacy of docetaxel.
It is believed that the systemic exposure to a drug like docetaxel is related to its efficacy 
(4). This was also shown by Bruno et al., who found that the area under the plasma-concentration 
time curve (AUC) of the initial course of docetaxel was a predictor of time to progression in NSCLC 
patients (5). Also, a decreased clearance (CL) increased the risk of grade 4 and febrile neutropenia (6). 
Knowledge of factors that are of importance for PK variability could therefore lead to the optimization 
of docetaxel therapy. 
Several studies have focused on determining factors that may influence docetaxel PK, aiming 
for better prediction of toxicity and exposure to docetaxel (see Figure 1). This excessive sum of studies 
makes it difficult to extract clinically relevant findings for usage in daily clinical practice. Hence, no 
label changes for docetaxel dosing have been made in the last decade although the current dosing 
strategy using body surface area (BSA) has been criticized, as this dosing strategy does not reduce 
the inter-individual variability (IIV) in docetaxel PK to an absolute minimum, since it does not account 
for other factors influencing docetaxel PK. This review article gives a comprehensive summary on the 
currently available and clinically relevant factors influencing docetaxel PK that can aid in individualizing 
docetaxel therapy in current clinical practice.  
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figure 1. Factors influencing docetaxel pharmacokinetics. Co-medication and the use of complementary alternative 
medicines (CAMs) impact docetaxel PK in a clinically relevant way and should be taken into account when optimizing 
docetaxel treatment. In addition, patient related factors such as liver impairment, gender and hormonal status 
could  potentially influence docetaxel PK. 
 
druG TrANsPOrTers INVOlVed IN dOCeTAxel PhArMACOlOGy 
Drug transporters and docetaxel pharmacokinetics
The activity of docetaxel-transporters could be altered due to drug-drug interactions, which 
potentially influences the PK of docetaxel. The largest family of drug transporters consists out of passive 
transporters: the solute carriers (SLCs), which cover 48% of the total amount of transporters. Docetaxel 
is a known substrate of SLC22A7 (7), SLCO1B1 (8), SLCO1B3 (9), SLC22A7 (7) and possibly SLCO1A2 
(7,10). Besides SLCs, members of the ATP-binding cassette (ABC) transporters are extensively studied 
with regard to multidrug resistance and the PK of several anticancer drugs. Docetaxel is known to be 
transported by ABCB1 (ATP-binding cassette transporter B1, p-glycoprotein (p-gp)) [11]{Manzo, 2012 
#2255}, ABCC2 (canalicular multispecific organic anion transporter 1 (cMOAT), MRP2) (12) and ABCC10 
(multidrug resistance-associated protein 7 (MRP7)) (13).
 
Absorption
The gastro-intestinal absorption of docetaxel is limited. This is because ABCB1 directly excretes 
docetaxel into the intestinal lumen or bile (14). Moreover, docetaxel‘ s bioavailability is greatly reduced 
by the liver‘s first pass effect (15). Docetaxel is currently only being administered intravenously. As 
oral administrations of docetaxel could be more patient friendly, research is ongoing to improve the 
bioavailability of docetaxel (16,17).
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Tissue distribution and accumulation
Over ninety percent of docetaxel is bound to plasma proteins (1). Because of its lipophilic 
properties, docetaxel has a large distribution volume, indicating accumulation in several tissues (1). 
Based on a bio-distribution study in cancer patients, a high uptake of [11C]-docetaxel in the liver and 
gall bladder was seen, while there w as fewer uptake in the small intestines, kidney, bone marrow, 
lungs and bladder (18). Uptake of docetaxel in the brain was limited, resulting from an effective 
blood brain barrier containing efflux transporters like ABCB1 and ABCC2 (19).  
 
 
Docetaxel metabolism and excretion 
Hepatic uptake
Docetaxel is metabolized in the liver (Figure 2). Uptake is facilitated via uptake transporters 
such as Organic Anion Transporting Peptides (OATP) 1B1 and OATP1B3, which belong to the SLC family. 
These transporters mediate the uptake of docetaxel from sinusoidal blood into the hepatocytes (8-10). 
Iusuf and colleagues recently found that OATP1A2 was also involved in the in vivo uptake of docetaxel 
(10). Animal studies with the OATP1B3/OATP1B1 orthologue OATP1B2 showed that the CL of docetaxel 
is substantially decreased in OATP1B2 knockout mice (8, 10, 20, 21) in a manner that resembles 
drug phenotypes observed in mice with a deficiency of metabolic Cyp3a activity (22). Therefore, co-
medication that inhibits both OATP1B1 and 1B3 should only be used with caution in combination with 
docetaxel. Also, we previously found that docetaxel’s formulation vehicle polysorbate 80 could inhibit 
the uptake of docetaxel via interaction with OATP1B1 and OATP1B3 (8, 21). 
figure 2. A schematic overview of docetaxel metabolism. Docetaxel is transported from the blood into the 
hepatocytes by OATP1B1 and OATP1B3. CYP3A4, and to a lesser extend CYP3A5, are responsible for the metabolism 
of docetaxel. ABCB1 and ABCC2 are accountable for the transport from hepatocyte into the bile canalicus. 
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Metabolism of docetaxel
Docetaxel is mainly metabolized via CYP3A4 and to a lesser extent by CYP3A5, and is processed into four 
metabolites (Figure 2) (23). A methyl group of docetaxel is oxidized into a primary alcohol forming metabolite 
M2. Further oxidation of M2 leads to formation of unstable metabolites of the alcohol that will lead to 
diastereoisomers (M1/M3) and a ketone metabolite (M4) (24). There are no indications that docetaxel-
metabolites undergo phase II metabolism. All four metabolites showed limited anti-tumor activity (25), 
which suggests that the metabolism of docetaxel is the main contributor in the inactivation of the drug. 
Excretion of docetaxel
Docetaxel and its metabolites are mainly excreted into bile via ABCB1 and ABCC2 mediated 
transport (11,12). Tumor cells can also express ABCB1 what will cause efflux of docetaxel and thus 
possible docetaxel-resistance. Therefore, clinical studies were designed to combine ABCB1-inhibitors 
in combination with docetaxel therapy. The first studies focused on PK interactions between ABCB1 
inhibitors and docetaxel but did not show any interactions on PK level (26-28), indicating that the role 
of the ABCB1 transporter in the elimination of docetaxel is probably not the most dominant. 
PhArMACOkINeTIC druG INTerACTIONs 
Cancer patients use numerous drugs for the treatment of chemotherapy related side effects, 
comorbidities, and the management of cancer related pain. Therefore, studying pharmacokinetic 
drug-drug interactions is highly clinically important. As docetaxel has a narrow therapeutic window, 
pharmacokinetic interactions with drugs for supportive care as well as with complementary alternative 
medicines (CAMs) are of great clinical relevance for its pharmacodynamics. According to FDA guidelines, 
drug-drug interactions are generally considered clinically relevant when the difference in exposure 
after the addition of the co-medication of subject is 25% or more (29). As the IIV of docetaxel already 
ranges from 30-45%, it is therefore challenging to identify clinically relevant drug-drug interactions. 
 
Interactions with anti-cancer agents  
The concurrent use of anti-cancer drugs is common in the treatment of many tumor types. 
Current regulations regarding the clinical implementation of new anti-cancer regimens oblige extensive 
Phase I studies looking into synergistic effects and pharmacokinetic interactions. Here, we will not 
focus on possible synergistic effect of combination strategies, but only review pharmacokinetic effects 
and adverse events. In Table 1, an overview of studied anti-cancer drug combinations is given (30-51). 
Docetaxel CL decreased with 50% when topotecan was administered on day 1-4 preceding 
the administration of docetaxel (42). This resulted in increased neutropenia. The combination 
docetaxel and everolimus was associated with severe neutropenia and wide variation in the CL of 
both drugs (48). Authors state that concomitant treatment with these drugs is unpredictable due to a 
large variability in the CL of both drugs (48).
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Table 1. drug-drug interactions with anti-cancer drugs
drugs Interaction* effect ref
Cytostatics
Cisplatin no [30]
Estramustine no [31]
5-FU no [32]
Capecitabine no [33]
Irinotecan no [34]
Carboplatin no [35]
Gemcitabine no [36]
Methotrexate no [37]
Cisplatin and 5-FU no [38]
Vinorelbine no [39]
Doxorubicin yes DTX followed by doxorubicin: duration grade 4 neutropenia [40]
Ifosfamide yes DTX preceding ifosfamide: ↓ AUC ifosfamide [41]
On DTX AUC: no effect
Topotecan yes Topotecan 1-4 days before DTX: DTX CL 50% ↓ [42]
Paclitaxel yes No effect DTX on paclitaxel [43]
DTX before paclitaxel: nadir ANC ↓
Protein kinase inhibitors
Lapatinib no [44]
Sunitinib no [45]
Imatinib no Inhibits CYP3A4, no effect on DTX CL [46]
Erlotinib yes Substantial toxicity, not related to PK [47]
Everolimus yes Substantial neutropenia and highly variable CL [48]
Monoclonal antibodies
Pertuzumab no [49]
Other
Amifostine no [50]
Bortezomib no [51]
*clinically relevant interaction, DTX=docetaxel, AUC= area under the curve, CL=clearance, 
ANC= absolute neutrophil count, PK=pharmacokinetics, Ref=reference
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The combination docetaxel-erlotinib was associated with severe toxicity, without a significant 
change in PK (47). In contrast, in a phase I and PK study on the combination of docetaxel and pazopanib, a 
lower docetaxel CL was found due to pazopanib co-treatment (52). This probably results from OATP1B1 and 
CYP3A4 inhibition. For doxorubicin holds that when given before the administration of docetaxel instead 
of after the administration, a longer duration of grade 4 neutropenia was seen (40). The AUC of ifosfamide 
decreased when the administration was preceded by docetaxel (41). 
 
Interactions with supportive medication 
Patients may receive co-medication for treatment-associated side-effects such as nausea and 
vomiting. These toxicities can often be well treated with anti-emetic prophylaxis. Aprepitant was shown 
to inhibit CYP3A4 and induce CYP2C9 (53). Therefore, this drug could hypothetically decrease docetaxel 
CL (54). However, neither aprepitant nor other studied antiemetic drugs showed a clinically relevant 
interaction with docetaxel so far (see Table 2) and can therefore be safely used in docetaxel-treated patients 
(55-57). Besides regular drugs for the management of nausea and vomiting, cannabis was demonstrated to 
be effective and was approved by the FDA (58). No effects on docetaxel PK were demonstrated (59). 
Interactions with Complementary Alternative Medicines (CAMs) 
It is estimated that 40% of cancer patients seek relieve from anticancer therapy related adverse 
events by using complementary alternative medicine (CAMs) (60).  Herbal and dietary supplements mostly 
influence the PK of docetaxel via CYP3A4, drug transporters and other metabolic pathways, thereby again 
potentially influencing toxicity and therapeutic efficacy (61). Patients should thus be well counseled if 
preference to CAMs is given in supportive care. Here, we discuss frequently used CAMs in cancer patients 
with regard to docetaxel PK (Table 2). 
In breast cancer patients, a trend towards reduced docetaxel CL was found for patients using 
600 mg of garlic twice daily for 12 consecutive days (62). In addition, St. John’s wort was found to decrease 
docetaxel AUC from 3,035 ± 756 to 2,682 ± 717 ng h/mL, indicating that concomitant use of docetaxel 
and St. John’s wort could diminish clinical efficacy and should thus be avoided (63). Echinacea purpurea 
also induces CYP3A4 activity, but does not influence docetaxel PK (64). This is consistent with earlier 
observations that the administration of other CYP3A4-inducing medications, such as dexamethasone, does 
not substantially alter the clearance of docetaxel (14). These collective observations are congruent with the 
supposition that, since >90% of the docetaxel dose is already metabolized by CYP3A enzymes in a normal 
(uninduced) state, induction of this route is unlikely to result in a further substantial increase in the extent 
to which the drug undergoes metabolic inactivation.
Preclinical studies suggested that components in grape seed, green tea and milk thistle potentially 
inhibit CYP3A4 activity, which could alter docetaxel PK. This however needs further validation in clinical 
setting (29). To note, caution is warranted when interpreting the results of studies on CAMs, as various 
(non-standardized) formulations with different concentrations of the active compound are available and 
used (65). Concentrations of the active compound in these varying formulations could differ and similarities 
in study outcome could be masked. 
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Table 2. drug-drug interactions with co-administered medication
subject Co-administration endpoint Interaction* effect ref
Co-medication Dexamethason CL no [6]
premedication
Ketoconazole CL yes 50% CL ↓ [66]
PK yes
40% CL ↓, no difference 
in AUC
[3]
Polysorbate 80 CL and Fu yes
Fu P80 treated samples  > 
Fu pretreatment samples
[81]
CL yes
↑ P80 AUC associated 
with  ↓  unboud DTX CL
[79]
Supportive therapy Aprepitant PK no [55]
Granisetron PK no [56]
Cannabis PK no [59]
Casopitant PK no [57]
CAMs Echinacea purpurea PK no [64]
St. John’s worth PK yes
increases AUC and 
decrease CL
[63]
Garlic CL no
trend towards decreased 
CL
[62]
*clinically relevant interaction, CL=clearance, PK=pharmacokinetics, AUC=area under the curve, Fu=unbound 
docetaxel, P80=polysorbate 80, DTX=docetaxel, Ref=reference
5
80
Interactions with co-medication
Ketoconazole, used for the treatment of fungal infections, is a strong inhibitor of CYP3A4. 
Co-administration of ketoconazole decreased docetaxel CL with 40-50% (Table 2) (3, 66).  Also, 
ketoconazole co-administration increased the IIV of docetaxel CL around 8% (3) and should therefore 
be avoided. Pre-medication with dexamethasone did not show an association with docetaxel PK (6). 
To sum, for safe and optimal care, clinicians should be aware of drug-drug interactions and 
take these into account when administering docetaxel to patients as these interactions influence both 
PK and pharmacodynamics. 
 
PATIeNT fACTOrs
In addition to drug-drug interactions, patient related factors might play a role in the large 
pharmacokinetic IIV of docetaxel. Some factors have been studied extensively and are discussed below. 
 
Gender, age and ethnicity
The effects of gender on docetaxel metabolism have been investigated in multiple studies 
and the results are indistinct (8, 9, 67). A previous study found that females had a 35% lower docetaxel 
CL than males and a gender effect on docetaxel metabolism was suggested (9) while others observed 
no clear effect of gender on docetaxel PK (8, 67). This might be due to underlying and masking factors, 
as hormonal factors such as menopausal status and castration status may play a role in the discrepancy 
regarding the effect of gender, masking potential clinically relevant effects. 
Age is of insignificant influence on docetaxel PK (9, 67-71). Docetaxel CL and its variability 
was not altered in elderly patients compared to younger patients (70).
Regarding ethnicity, Japanese patients are usually treated with a lower dose than patients 
in Western countries. This resulted from different recommended phase II doses during early drug 
development, due to differences in (dose-limiting) toxicity between Asian and non-Asian patients (72). 
However, no statistically significant differences in docetaxel CL were seen when races were compared, 
suggesting that ethnicity does not substantially contribute in explaining the large docetaxel IIV (73, 74). 
hormonal status
The influence of castration status on docetaxel PK was investigated in 30 men with mCRPC 
(Table 3) (7). It was shown that castration status did not modify CYP3A levels, confirming earlier findings 
(75). However, castrated males showed increased docetaxel CL and a 2-fold decrease in AUC compared 
to non-castrated patients. These findings were further supported by studies in rodents, where castrated 
rats had reduced docetaxel peak concentrations (7). The increased expression of hepatic rOatp2 
(slc22a7) was reported as a potential explanation for this finding (7). This increase in rOatp2 expression 
was hypothesized to result in increased hepatic docetaxel uptake and thus in increased metabolism.
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Menopausal status was shown to affect docetaxel PK with premenopausal woman having a 
lower AUC (4124 µg h/l, n=53) than postmenopausal woman (4598 µg h/l, n=33) [76]. This study also 
showed that docetaxel AUC was significantly different in 40 pre-menopausal and post-menopausal 
women carrying the same C3435T genotype (CC), with a lower AUC in premenopausal woman (76). 
No effect was seen in woman with other genotypes. Castration status and menopausal status could 
thus potentially be part of the underlying mechanisms explaining the discrepancy in the influence of 
gender on docetaxel PK. At this point, the influence of menopausal and castration status has to be 
validated in larger cohorts and is not yet usable in a clinical setting. 
 
Obesity
 When separating patients into quartiles based on their BSA, the mean docetaxel CL was highest 
in the highest BSA quadrant and lowest in the lowest BSA quadrant (69). In patients with a BSA > 2m2, a 
33% increase in docetaxel CL was seen compared to patients with a BSA ≤ 2m2 (68). A BMI of ≥ 30 kg/m2 was 
not associated with higher docetaxel CL (68, 77). Thus, no dose adaptations need to be made for obesity. 
However, extensively obese patients with a BSA > 2 m2 had an increased docetaxel CL and may need a 
higher dose than patients with a BSA ≤ 2 m2. This hypothesis however needs validation in larger cohorts. 
liver impairment
Liver impairment was shown to decrease docetaxel CL (Table 3) (78-80). Minami and 
colleagues demonstrated that patients with grade 2 and 3 elevations of transaminases at baseline 
together with alkaline phosphatase elevation had around a 30% decrease of docetaxel CL (78). Their 
advice was to consider a 20-40% dose reduction for patients with a grade 2 and 3 transaminase 
increase in combination with alkaline phosphatase elevation.
 
Plasma proteins
Plasma proteins are seen as possible determinants for docetaxel PK, as docetaxel is highly bound 
to proteins. Some studies looked into the relation between α 1-acid glycoprotein (AAG) and docetaxel PK 
(54, 79, 81, 82) (see Table 3). Ambiguous results were found. This discrepancy could possibly be caused 
by the fact that unbound docetaxel CL was used to test a possible correlation with AAG concentrations, 
which eliminates the effect of protein binding as a confounder (79). Also, AAG is an acute phase reactant, 
which could mask a potential effect. It is also known that in critically ill patients, albumin levels are 
low due to altered distribution between intravascular and extra vascular compartments (83). Decreased 
albumin levels thus might make up for the increase of AAG, explaining why no effect is seen in some of 
the studies that focus on AAG only. As also the expression of CYP3A4 is decreased during inflammatory 
response, the question rises whether AAG is mechanistically responsible for changes in PK or that 
increased levels of AAG are only a sign of ongoing inflammatory response, decreasing CYP3A4 activity 
(84). Currently, no definite clinical actions can be taken based on baseline plasma protein values. 
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eNVIrONMeNTAl fACTOrs
In addition to patient related factors, environmental factors may play a role in docetaxel PK. 
Smoking has been studied as such and demonstrated to have no effect on docetaxel PK (85). However, 
the incidence of grade 4 neutropenia was lower in smokers who were treated with docetaxel (35%) than 
in non-smokers (52%) (85). One of the supposed mechanisms for this effect is that patients inhale small 
particles when smoking, which could result in IL-6 and granulocyte macrophage colony stimulating factor 
release, that encourages the proliferation of pre-cursors in the bone marrow (86-88). Thus, the effect of 
smoking on docetaxel PK seems to be limited and at this point, the advantages of quitting smoking still 
seem to offset the possible protective effect on hematological toxicity. 
 
CuRRENT AlTERNATIvES FOR BSA-BASED DOSING
The BSA-based formula does not account for the factors described in the previous paragraph that 
potentially influence the PK of docetaxel, such as obesity, gender, hormonal status and liver impairment. To 
improve individualized dosing of docetaxel, other strategies have been studied and will be discussed here. 
 
Therapeutic drug monitoring
A priori therapeutic drug monitoring (TDM) is a tool for calculating the optimal dose of a drug 
(4). Generally, drugs with a narrow therapeutic window and an existing correlation between toxicity and 
exposure may be suited for such an approach. Since docetaxel matches these criteria, docetaxel dosing 
could hypothetically be individualized by using TDM. To investigate this hypothesis, a TDM strategy was 
developed using a validated limited sampling model based on Bayesian analysis. Using TDM, the IIV 
in PK decreased significantly with 39% (89). Unfortunately, the incidence of hematological toxicity was 
not different in TDM dosed patients from patients that had been dosed using BSA. Despite the fact 
that relatively cheap immuno-assays for determining docetaxel plasma concentrations are currently 
(commercially) available, a problem of TDM is that it is still time-consuming for both patients and 
professionals. 
bsA dose banding 
To improve the current BSA strategy, it was recently suggested that dose-banding could be an 
alternative (90). A limited amount of predefined BSA ranges was used to determine an initial docetaxel 
dose and for adaptation of the dose in patients with extreme BSA values. This strategy was feasible, since 
the difference in the calculated docetaxel dosage was marginal compared to regular BSA dosing. This 
strategy has the potential to simplify pharmacy processes and to improve patient safety (90). 
Probe-drug phenotyping
As an alternative for accounting for individual factors influencing docetaxel PK, researchers 
tried to predict CYP3A4 activity as a measure for docetaxel CL with the use of probes, such as 
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antipyrine, midazolam and erythromycin (9, 54, 67, 82, 91). The erythromycin breath test, antipyrine 
CL, dexamethasone CL and midazolam exposure tests were demonstrated to be successful in predicting 
CYP3A4 activity and thereby docetaxel PK (9, 54, 67, 92, 93). To add, urinary 6-beta-hydroxy cortisol was 
used in a formula for the estimation of docetaxel CL (91). Compared with BSA-based dosing, using this 
method these researchers were able to reduce docetaxel’s IIV significantly. However, the complexity 
of such methods, the interaction with several other mechanisms such as docetaxel transport and for 
example the interference with polysorbate 80, currently obstruct clinical application of these strategies 
(8, 79, 81, 94). 
 
Pharmacogenetics
The effect of genetic variation on docetaxel PK has been studied extensively (see Table 4, 
refs. 8, 9, 62, 67, 73, 75, 95-100). Some of the studied single nucleotide polymorphisms (SNPs) have 
been associated with docetaxel PK alteration. For example, the SNP rs12762549 in ABCC2 resulted in a 
significantly decreased docetaxel CL (98). A 50% increase in docetaxel CL was seen in patients carrying 
one *1A allele (rs776746) in CYP3A5 (9). When carrying both CYP3A4 *1B and CYP3A5 *1/*3 alleles 
an increase in docetaxel CL was seen, as well as for carrying both CYP3A4 *1B and CYP3A5 *1A alleles 
(9, 95). Contradictory results have been shown for SNPs in ABCB1 (rs1128563, 1236C>T) and SLCO1B3 
(rs11045585, IVS12-5676A>G) (8, 9, 97-99). For clinical applicability, these SNPs have to be validated 
in larger cohorts, possibly using genome wide association studies next to the usual candidate gene 
approach. 
 
reCOMMeNdATIONs
The high IIV in the PK of docetaxel renders it difficult to accurately choose an individual dose 
resulting in optimal docetaxel exposure, leading to efficacy at the cost of acceptable toxicity. Today, only 
BSA is used for calculating docetaxel dosages. However, this method does not fully reduce the high IIV 
of docetaxel PK to an absolute minimum. Unfortunately, no superior alternatives for the current dosing 
strategy are presently available. A new dosing strategy could therefore use some additional, and clinically 
applicable, tools for decreasing IIV and individualizing docetaxel treatment. Tools for such a strategy 
could thus be demographic factors partly explaining docetaxel’ s high IIV in PK. 
From current knowledge, several recommendations can be given on factors influencing 
docetaxel PK in order to optimize docetaxel dosing. Liver impairment may decrease docetaxel CL, and 
should be taken into account. Also, hormonal status and gender may be of clinical relevance in future 
dosing strategies for docetaxel. 
Drug-drug interactions have been established and some are distinctly relevant. These 
interactions are most probably mediated by drug transporters and cytochrome P450 iso-enzymes. 
Therefore, notice should be taken when using CYP3A4 inhibiting drugs in combination with docetaxel. 
Interactions at the level of uptake transporters may also be of relevance, as these are likely influencing 
hepatic uptake of docetaxel and thus drug elimination. The role of pharmacogenetics is currently still 
limited, and special recommendations on preemptive genotyping cannot be given.
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AbsTrACT
The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) 
has expanded with the introduction of several new therapies. In this treatment continuum, it is unclear 
whether the efficacy of cabazitaxel is affected by prior novel androgen receptor targeted therapies 
(ART) such as abiraterone and enzalutamide. In this study, we investigated the influence of prior ART 
on the efficacy of cabazitaxel in men with mCRPC. Data from an ongoing multicenter, phase II trial 
were used comprising 114 men with mCRPC treated with cabazitaxel in the post-docetaxel setting. 
The primary endpoints of the current analysis were prostate-specific antigen (PSA) response (≥50%), 
and overall survival (OS). Univariate and multivariable analyses were conducted to investigate the 
influence of prior ART on the efficacy of cabazitaxel. From the 114 patients included in this analysis, 
44 men received prior ART and 70 men did not receive prior ART before treatment with cabazitaxel. 
PSA response rates while on cabazitaxel treatment were similar in patients with and without prior 
ART (34% versus 40%, respectively, P=0.53). Likewise, median OS was not significantly different 
between men with and without prior ART (13.0 versus 14.0 months, respectively, logrank P=0.65). In 
multivariable analysis, the only variables significantly associated with OS were performance status, 
serum albumin and alkaline phosphatase. Our study showed that prior treatment with ART may not 
influence the efficacy of cabazitaxel in men with mCRPC. With emerging evidence of cross-resistance 
in the treatment of mCRPC, cabazitaxel provides a good treatment option irrespective of prior ART.
6
97
INTrOduCTION 
The treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) 
has changed considerably over the past few years, with the introduction of several new drugs that 
provide substantial survival benefits (1-6). Cabazitaxel, abiraterone, enzalutamide and radium-223 all 
demonstrated to prolong life in the post-docetaxel setting and subsequently became approved for the 
treatment of this disease. Moreover, the novel androgen receptor (AR)-targeted therapies abiraterone 
and enzalutamide have shown survival improvement when used in chemotherapy-naïve mCRPC (5, 6). 
These advances also come with new challenges. Although there are emerging biomarkers such as the 
androgen receptor splice variant AR-V7 (7), no established biomarkers for treatment selection exist at 
the current time and the optimal treatment sequence in mCRPC is still undetermined. 
Retrospective series studies suggested that overall survival benefit obtained by the new 
therapies cannot be added up, as cross-resistance between docetaxel and AR-targeted agents has 
been observed (8-10). Reduced efficacy of docetaxel was observed in men with mCRPC who had 
previously been treated with abiraterone, suggesting clinical cross-resistance (8-10). In a post-
hoc analysis of the COU-AA-302 study, a prostate-specific antigen (PSA) response rate of 45% was 
observed in patients treated with taxane chemotherapy after abiraterone (11). This was slightly higher 
as compared to previous reports of docetaxel in this setting, with PSA response rates ranging from 26 
to 40% (8-10). However, the observed response rates were lower as compared with a contemporary 
cohort of abiraterone-naïve patients treated with docetaxel (PSA response rate ≥50%: 64%), which 
might support the hypothesis of cross-resistance (12). 
Preclinical studies revealed that the AR may confer cross-resistance between enzalutamide 
and docetaxel in vivo, which is induced by an overlapping working mechanism on AR nuclear 
translocation (13, 14). These findings are confirmed in clinical studies (15), and raise concern whether 
prior treatment with abiraterone or enzalutamide may affect the efficacy of subsequent cabazitaxel 
treatment. Emerging preclinical and retrospective clinical data suggested that cabazitaxel, in contrast 
to docetaxel, has sustained efficacy in men with mCRPC after prior abiraterone treatment (16, 17). 
In two retrospective studies, cabazitaxel efficacy after abiraterone treatment was investigated and 
compared to the TROPIC trial of cabazitaxel in abiraterone-naïve patients as an historical control group 
(2, 16, 17). These studies suggested retained efficacy of cabazitaxel after prior abiraterone, as the 
observed PSA response rates were similar when compared to the TROPIC trial. However, to date, the 
efficacy of cabazitaxel has never been directly compared between patients with and without prior 
abiraterone or enzalutamide, which limits clinical conclusions.
In the current study, we aimed to investigate the influence of prior novel AR-targeted therapy 
(ART) on the efficacy of cabazitaxel. For this purpose, we used data from a randomized phase II trial 
to directly compare clinical outcome and response to cabazitaxel in men with and without prior ART.
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PATIeNTs ANd MeThOds
Study population and data collection
CABARESC (Dutch Trial Registry number: NTR 2991, EudraCT number: 2011-003346-40) is 
an ongoing randomized, open-label, multicenter, phase II trial that was designed to investigate the 
effects of budesonide on cabazitaxel-induced diarrhea. The primary endpoint of the original study 
was the incidence of grade 2-4 diarrhea. In order to detect a reduction of 15% in grade 2-4 diarrhea a 
total sample size of 250 patients was planned for this study. Eligible men were randomized to either 
cabazitaxel (25 mg/m2) and prednisone (10 mg daily) plus oral budesonide (9 mg daily during 44 days), 
or standard cabazitaxel 25 mg/m2 plus prednisone (10 mg daily). It has been shown previously that 
budesonide does not affect the pharmacokinectics of cabazitaxel (18). 
Full inclusion and exclusion criteria of the CABARESC trial are shown in the Supplementary 
materials and methods. In brief, patients were eligible if they had mCRPC with documented disease 
progression during or after treatment with docetaxel, as defined by rising PSA levels, appearance 
of new lesions or documented disease progression based on CT scan or bone scan. Cabazitaxel 
treatment was continued until disease progression, unacceptable toxicity, or until 10 cycles have been 
administered. Administration of G-CSF was allowed during the study. Patients were randomly assigned 
to the treatment groups through a centralized stratified randomization process using the following 
stratification factors: center, age (≥65 versus <65 years) and previous radiotherapy (yes versus no). 
In this study, data were prospectively collected at baseline and for every cycle including: hematology 
and biochemistry laboratory values, performance status, age, prior treatment with ART, duration of 
treatment with ART, PSA values (every 3 weeks), and survival status. 
For the current unplanned analysis, we included patients who were randomized and went 
off-study between December 2011 and May 2014. As the CABARESC study is still recruiting, the 
primary endpoint of the original study (incidence of grade 2-4 diarrhea) was not reported, and no data 
per arm were analysed. The CABARESC study was approved by the institutional review board at each 
participating center. Written informed consent was obtained from all participants. The study protocol 
allowed for secondary analyses that do not involve the primary endpoint of the CABARESC study to be 
conducted before reporting of the original study.
Data collection and definitions 
The primary objective of the current analysis was to explore the influence of prior ART 
on the efficacy of cabazitaxel in men with mCRPC. Primary endpoints of this analysis were the 
proportion of patients with a ≥50% PSA response, and overall survival (OS). As a secondary endpoint, 
we investigated PSA progression-free survival (PSA-PFS). For the definition of PSA response and PSA-
PFS, Prostate Cancer Working Group 2 (PCWG2) criteria were used (19). As recommended by the 
PCWG2, PSA response was defined as ≥50% decline from baseline, and PSA progression as a 25% 
increase (and a minimum of 2 ng/ml) from baseline or nadir. In most cases this was confirmed by a 
second measurement; however confirmation was not routinely performed for all patients. A taxane 
induced PSA flare during the first 12 weeks of treatment was ignored (20). OS was defined by time 
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from randomization to death from any cause. Since bone scans and CT-scans were not performed 
according to regular intervals in the study protocol, we did not include radiological PFS in our analyses. 
Descriptive statistics were used to compare baseline characteristics in the ART pretreated 
versus non-pretreated patients, with statistical evaluation using Fisher’s exact test for categorical 
variables and Kruskal-Wallis test for continuous variables. OS and PSA-PFS were calculated using the 
Kaplan-Meier method with statistical evaluation by the logrank test. 
Model building and statistical considerations
We conducted univariate and multivariable Cox regression analyses including prior treatment 
with ART (yes/no) and duration of prior ART to investigate its effect on PSA response and OS of 
men treated with cabazitaxel. For this purpose, Cox proportional hazards models were constructed 
including established prognostic factors from the Halabi nomogram (21): baseline serum PSA, lactate 
dehydrogenase (LDH), albumin, alkaline phosphatase, hemoglobin, and performance status. The 
multivariable model was constructed using backward elimination at the 5% level. A log transformation 
was applied to variables with a non-normal distribution.
resulTs 
Baseline characteristics 
In the CABARESC trial, 141 patients were randomized and went off-study between December 
2011 and May 2014. Of these 141 patients, 27 men were excluded from analysis for the following 
reasons: five patients had missing PSA values at baseline, nine patients were randomized but never 
received cabazitaxel treatment due to rapid worsening of performance status or death, and 13 patients 
had received previous study treatment with orteronel (Figure 1). Patients who received prior orteronel 
were excluded from this analysis since this is not a clinically approved regimen in the treatment of 
mCRPC. All patients had received prior docetaxel chemotherapy. Forty-four out of 114 patients (39%) 
had received prior ART in the post-docetaxel setting, of whom 39 had received abiraterone, three had 
received enzalutamide, and two had received both abiraterone and enzalutamide. The remaining 70 
patients had received no prior ART before study treatment with cabazitaxel. 
Baseline characteristics of men with and without prior ART are shown in Table 1. Known 
prognostic variables were evenly distributed among subgroups, except for a significantly lower 
albumin level in men with prior ART (Table 1). The median number of cabazitaxel cycles received was 
six in the ART group, and five for men without prior ART.
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Table 1. Baseline characteristics of patients with and without prior novel AR targeted therapy.
Characteristic
Prior abiraterone or 
enzalutamide
No prior abiraterone or 
enzalutamide
P-value
Number of patients 44 70
Age, years, median (range) 69 (53-83) 68 (49-82) 0.093
WHO performance score n (%)
0 18 (41) 25 (36)
1 25 (57) 44 (63) 0.56
Missing 1 1
PSA, ng/ml, median (range) 210 (15-5000) 154 (12.5-4172) 0.25
LDH at baseline, median (range) 287 (90-724) 273 (38-1843) 0.83
Hemoglobin at baseline, mmol/L, 
median (range)
8 (6-10) 8 (5-9) 0.96
Alkaline phosphatase at baseline, IU/L, 
median (range)
124 (50-907) 126 (43-1023) 0.83
Albumin at baseline, g/L, median 
(range)
37 (26-46) 41 (25-49) 0.013
Duration of treatment with 
abiraterone/enzalutamide, months, 
median (range)
6.1 (0.9-22) -
PSA - prostate-specific antigen; LDH - Lactate Dehydrogenase
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figure 1. CONSORT diagram.
 
The influence of prior novel AR-targeted therapy on the efficacy of cabazitaxel
PSA response rates (≥50%) while on cabazitaxel treatment were similar in patients with and 
without prior ART (34% versus 40% respectively, P=0.53). Waterfall plots of the maximum PSA change 
while on cabazitaxel treatment for men with and without prior ART are shown in Figure 2. Likewise, 
median PSA-PFS was not significantly different between the two groups. Men who received prior ART 
had a median PSA-PFS of 4.8 months, versus 6.5 months for men without prior ART (logrank P=0.32) 
(Figure 3A). Median OS was similar for patients previously treated with ART versus patients who were 
not previously treated with ART, with a median OS of 13.0 versus 14.0 months respectively (logrank 
P=0.65) (Figure 3B). 
CABARESC study
Patients who were randomized and 
went off-study between December 
2011 and May 2014 (N=141)
N=9 never received study 
treatment
N=13 received previous 
treatment with orteronel
N=5 with missing baseline 
PSA values
N=44 received previous novel 
AR targeted therapy
N=41 abiraterone
N=5 enzalutamide
N=2  both
N=70 did not receive prior 
novel AR-targeted therapy
.
. .
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figure 2.  Waterfall plots of the maximum prostate-specific antigen (PSA) change from baseline during treatment 
with cabazitaxel in men with (A) and without (B) prior novel androgen receptor (AR)-targeted therapy.
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figure 3. Kaplan–Meier estimates of PSA progression-free survival (PSA-PFS) (A) and overall survival (OS) (B) in men 
treated with cabazitaxel with and without prior novel androgen receptor (AR)-targeted therapy.
univariable and multivariable analyses for OS and PSA response.
Factors significantly associated with OS in univariate analysis are shown in Table 2 and 
included performance status, alkaline phosphatase, albumin, hemoglobin and LDH at baseline. Prior 
ART and the duration of prior ART were not significantly associated with OS (hazard ratio (HR)=1.14; 
95% confidence interval (CI): 0.66-1.97, P=0.65 and HR=1.00; 95%CI: 0.92-1.09, P=0.98, respectively). 
From the significant variables in univariate analysis, a multivariate model for OS was constructed (Table 
2). The only variables significantly associated with OS in multivariable analysis were performance 
status, alkaline phosphatase and albumin at baseline. Univariate logistic regression analyses for PSA 
response (≥50%) are shown in Table 3. Prior ART or the duration of prior ART were not significantly 
associated with PSA response (OR=0.78; 95%CI: 0.35-1.70, P=0.53 and OR=1.00; 95%CI: 0.88-1.13, 
P=0.98, respectively). Baseline hemoglobin was the only variable that was significantly associated with 
PSA response. 
6
104
Table 2. univariate and multivariable analyses for OS 
univariate Multivariable
Variable Hazard Ratio (95% CI) P-Value Hazard Ratio (95% CI) P-Value
Age (≥ median) 1.01 (0.97-1.05) 0.71
WHO performance score (1 vs. 0) 1.83 (1.01-3.32) 0.039 2.23 (1.06-4.69) 0.035
Hemoglobin at baseline 0.68 (0.53-0.88) 0.005 0.88 (0.63-1.24) 0.47
PSA at baseline 1.12 (0.92-1.37) 0.26
Alkaline phosphatase at baseline 1.84 (1.31-2.60) <0.001 1.65 (1.06-2.57) 0.026
LDH at baseline 1.69 (1.02-2.81) 0.049 0.74 (0.42-1.29) 0.29
Albumin at baseline 0.90 (0.86-0.95) <0.001 0.87 (0.81-0.92) <0.001
Prior novel AR-targeted therapy (yes/no) 1.14 (0.66-1.97) 0.65
Duration of prior AR-targeted therapy 1.00 (0.92-1.09) 0.98
PSA - prostate-specific antigen; LDH - Lactate Dehydrogenase; AR – Androgen receptor
Table 3. univariate logistic regression analysis for PSA response (≥50%) 
univariate
Variable Odds ratio (95% CI) P-Value
Age 1.03 (0.98-1.09) 0.26
WHO performance score (1 vs. 0) 0.58 (0.26-1.25) 0.17
Hemoglobin at baseline 1.63 (1.06-2.50) 0.026
PSA at baseline 1.17 (0.88-1.56) 0.29
Alkaline phosphatase at baseline 0.64 (0.37-1.09) 0.11
LDH at baseline 0.68 (0.34-1.35) 0.27
Albumin at baseline 1.06 (0.99-1.14) 0.074
Prior novel AR-targeted therapy (yes/no) 0.78 (0.35-1.70) 0.53
Duration of prior AR-targeted therapy 1.00 (0.88-1.13) 0.98
PSA - prostate-specific antigen; LDH – Lactate Dehydrogenase; AR – Androgen receptor
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dIsCussION
In this study, prior ART did not influence the efficacy of cabazitaxel in patients with mCRPC. 
PSA response rates, OS and PSA-PFS were similar in patients with and without prior ART. The only 
variables significantly associated with OS were performance status, alkaline phosphatase and albumin 
at baseline. 
We used data from a prospective phase II trial to directly compare the efficacy of cabazitaxel in 
men who received prior ART versus men who did not receive prior ART. To date, only two retrospective 
studies have been published that investigated the response of patients treated with cabazitaxel after 
abiraterone, which were limited by the use of an historical control group (16, 17). In our study, we 
aimed to overcome this limitation by directly comparing clinical outcome and response to treatment 
with cabazitaxel between patients with and without prior ART, within the same study population. Our 
results strengthen the conclusions of the two previous studies (17, 18) and confirm activity and lack of 
cross-resistance for cabazitaxel after prior ART in men with mCRPC.
Our observed PSA response rates in ART pretreated men (36%) are in line with those 
reported by Pezaro et al. and Al Nakouzi et al., which ranged from 40 to 45% (16, 17). These findings 
are concordant with the TROPIC trial of cabazitaxel in ART-naïve men and with the ART-naïve patients 
in the current analysis, demonstrating PSA response to cabazitaxel in both second- and third line 
treatment for mCRPC (2). The only variable that was significantly associated with lower PSA response 
rates was haemoglobin (<median), which might reflect the worse prognostic features of this patient 
subgroup.
Taken together, these findings suggest that there might be no cross-resistance between ART 
and cabazitaxel. This is especially of interest, since an increasing number of reports have suggested 
impaired efficacy of docetaxel after abiraterone, suggesting cross-resistance with ART for this taxane 
(8-10). Clinical cross-resistance could be explained by preclinical data from our group that showed an 
overlapping working mechanism on AR-nuclear translocation for both abiraterone and enzalutamide, 
as well as docetaxel (13, 14). Docetaxel inhibited tumor growth and AR signalling in enzalutamide-
naïve tumors, but did not in enzalutamide-resistant tumors, demonstrating cross-resistance between 
enzalutamide and docetaxel in vivo. Interestingly, in this preclinical model, cross-resistance was not 
observed for cabazitaxel, that demonstrated sustained antitumor activity even in tumors previously 
treated with enzalutamide (13). In the current analysis we confirmed these preclinical findings, 
showing similar activity of cabazitaxel either when delivered before or after ART. An explanation 
for the lack of cross-resistance for cabazitaxel could be that cabazitaxel, in contrast to docetaxel, is 
less dependent on the AR for exerting its antitumor activity (11). Moreover, it has been shown that 
cabazitaxel supresses microtubule dynamics more potently as compared with docetaxel, with higher 
intratumoral concentrations, and stronger cytotoxic effects (22, 23).
The main strength of our study is the use of prospective trial data to directly compare 
the efficacy of cabazitaxel in patients who did and did not receive prior ART within the same study 
population. Thus far, this is the only study that directly compared the influence of prior ART (post-
docetaxel) on the efficacy of cabazitaxel. As an inherent limitation, the original CABARESC study was 
not designed for the aim of the current unplanned analysis and had a different primary endpoint. As a 
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result, this study might be underpowered to detect a potential significant difference between patients 
with and without prior ART. In addition, some parameters such as Gleason score and the duration of 
response to LHRH agonists/antagonists have not been captured in our database. However, it has been 
shown previously that tumor differentiation and the duration of response to prior LHRH agonists/
antagonists do not affect clinical outcome of men treated with cabazitaxel (24).
In conclusion, our study showed that prior treatment with ART may not influence the efficacy 
of cabazitaxel in men with mCRPC. With emerging evidence of cross-resistance between the currently 
available therapies in mCRPC, cabazitaxel provides a good treatment option both before and after 
novel AR-targeted therapies in the post-docetaxel setting.
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suPPleMeNTAry MATerIAls ANd MeThOds
Inclusion and exclusion criteria CABARESC study
Inclusion criteria:
• Metastatic castrate resistant prostate cancer (mCRPC) patients with documented disease 
progression, defined as: documented rising PSA levels (at least 2 consecutive rises in PSA over a 
reference value taken at least 1 week apart, or a PSA rise of ≥ 2.0 µg/l), appearance of new lesions 
or documented disease progression based on CT scan or bone scan.
• Previous treatment with a docetaxel-containing regimen
• Age ³ 18 years;
• WHO performance status £ 1 
• Adequate renal function (within 21 days before randomization) defined as serum creatinin ≤ 1.5 x 
ULN and/or calculated creatinin clearance ≥ 50ml/min, according to MDRD formula.
• Adequate hepatic functions (within 21 days before randomization) defined as: total bilirubin ≤ 
1.0 x ULN; alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) ≤2.5x ULN, in 
case of liver metastasis < 5 ULN; alkaline phosphatase (AF) < 5x ULN) In case of bone metastasis, 
AF < 10x ULN is accepted.
• Adequate hematological blood counts (within 21 days before randomization) defined as (absolute 
neutrophil count (ANC) ≥1.5 x 109/L and platelets ≥ 100 x 109/L);  
• Castration, either surgically or by continued LHRH agonist therapy 
• Written informed consent according to ICH-GCP
Exclusion criteria:
• Impossibility or unwillingness to take oral drugs
• Serious illness or medical unstable condition requiring treatment, brain metastases or history of 
psychiatric disorder that would prohibit the understanding and giving of informed consent.
• Use of medications or dietary supplements known to induce or inhibit CYP3A 
• Known hypersensitivity to corticosteroids 
• Any active systemic or local bacterial, viral, fungal - or yeast infection. 
• Ulcerative colitis, Crohn’s disease or celiac disease (active or in medical history)
• Ostomy
• Planned/active simultaneous yellow fever vaccine
• Geographical, psychological or other non-medical conditions interfering with follow-up 
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Chapter 7
Quantification of cabazitaxel in human plasma 
by liquid chromatography / triple-quadrupole 
mass spectrometry: a practical solution for 
non-specific binding
P. de Bruijn, A.M. de Graan, A.J.M. Nieuweboer, A.H.J. Mathijssen, M. Lam, R. de Wit, E.A.C. Wiemer 
and W. J. Loos
Journal of Pharmaceutical and Biomedical Analysis. 2012 Feb 5;59:117-22.
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AbsTrACT
A rapid and sensitive liquid chromatography/tandem mass spectrometry (LC-MS/MS) method 
has been developed and validated for the quantitative determination of cabazitaxel, a novel tubulin-
binding taxane, in 100 µl aliquots of human lithium heparinized plasma with deuterated cabazitaxel 
as internal standard. The sample extraction and cleaning-up involved a simple liquid-liquid extraction 
with 20 µL aliquots of 4% ammonium hydroxide, 100 µl aliquots of acetonitrile and 1 ml aliquots of 
n-butylchloride. Chromatographic separations were achieved on a reversed phase C18 column eluted 
at a flow-rate of 0.200 ml/min on a gradient of acetonitrile. The overall cycle time of the method 
was 5 min, with cabazitaxel eluting at 3.0 min. The multiple reaction monitoring transitions were 
set at 836>555 (m/z), and 842>561 (m/z) for cabazitaxel and the internal standard, respectively. The 
calibration curves were linear over the range of 1.00 to 100 ng/mL with the lower limit of quantitation 
validated at 1.00 ng/ml. The within-run and between-run precisions, also at the level of the LLQ, 
were within 8.75%, while the accuracy ranged from 88.5 to 94.1%. As dilution of samples prior to 
extraction resulted in a loss of cabazitaxel of approximately 6.5% per dilution step, a second calibration 
curve ranging 40.0 to 4000 ng/ml was validated and was also linear. The within-run and between-
run precisions in this range were within 4.99%, while the accuracy ranged from 95.8 to 100.3%. The 
method was successfully applied to samples derived from a clinical study.
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INTrOduCTION
 Acquired and intrinsic resistance to docetaxel and paclitaxel (i.e., the two approved first 
generation taxanes) is still an important concern in daily clinical practice. Therefore, the intravenously 
available semi-synthetic taxanes, cabazitaxel (Jevtana®; XRP6258; TXD258; RPR116258A) and larotaxel 
(RPR109881A) were selected for clinical development as a result of their efficacy in a broad range 
of cell-lines and tumor models of mouse and human origin. Also, both compounds showed greater 
potency than docetaxel in cell lines expressing the drug transporter p-glycoprotein (reviewed in (1-3)).
While larotaxel is currently still under clinical evaluation, cabazitaxel has been approved in 
the US by the Food and Drug Administration (FDA) in June 2010 (3) and in Europe by the European 
Medicines Agency (EMA) in January 2011 (4) in combination with prednisone for the treatment 
of patients with castration-resistant metastatic prostate cancer whose disease progresses after 
docetaxel treatment, based on the results of the TROPIC trail investigating cabazitaxel plus prednisone 
versus mitoxantrone plus prednisone following docetaxel failure (5). Cabazitaxel is currently being 
investigated in the setting of metastatic breast cancer progressing after taxane or anthracycline based 
chemotherapeutic regimens (6-7).
 A population pharmacokinetic model was developed using pharmacokinetic data from five 
different studies (4), from which two currently have been published as peer-reviewed manuscripts 
(7-8). The pharmacokinetics of cabazitaxel are linear in the studied dose-range of 10-30 mg/m2 given 
as 1 h infusions and are consistent with a three-compartment pharmacokinetic model with half lives 
in the initial, intermediate and terminal phase of approximately 4.4 minutes, 1.6 hours, and 95 hours 
respectively. The drug has a fast plasma clearance estimated to be 48.5 l/h in the studied population 
and has a large volume of distribution of 4870 l. The ex-vivo protein binding was 91.6%, mainly to 
albumin and lipoproteins, while the drug displays low binding to α1-acid glycoprotein. Cabazitaxel is 
extensively metabolized by cytochrome P450 iso-enzymes CYP3A4 and CYP3A5, with CYP2C8 playing 
a minor role in its metabolism. Cabazitaxel and its metabolites are mainly excreted via the feces (76% 
of the dose) and to a lesser extent through the urinary pathway (3.7% of the dose).  
 Neutropenia is the principle dose-limiting and most commonly observed toxicity in cabazitaxel 
treatment when administered as 1h infusion every 3 weeks (8). In the phase III trial comparing the 
efficacy of prednisone plus cabazitaxel to mitoxantrone, grade ≥3 neutropenia was observed in 82% of 
the patients in the cabazitaxel arm, with 8% of the patients experiencing febrile neutropenia (5). Of the 
non-hematological toxicities diarrhea is the most commonly observed side effect seen in this regimen 
(5, 8). Overall, diarrhea occurred in 47% of the patients with 6% experiencing grade ≥3 diarrhea (5). In 
a weekly schedule, diarrhea was even more pronounced and considered a dose-limited toxicity (9).
As cabazitaxel is a promising new anticancer agent for taxanes-resistant tumors, it is expected 
that numerous subsequent clinical studies investigating both single agent and cabazitaxel–based 
combinations will be initiated. For this purpose, quantitation of cabazitaxel is imperative.
To the best of our knowledge, no reports have been published describing a validated 
bioanalytical method for the quantitation of cabazitaxel. We have developed and validated a 
sensitive and selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay 
for cabazitaxel in human plasma, according to the Guidance for Industry, Bioanalytical Method 
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Validation, as specified by the FDA. In addition, we discuss the non-specific binding of cabazitaxel 
observed during sample preparation and provide a simple and practical solution to deal with this 
phenomenon during pharmacokinetic analysis.  
 
 
exPerIMeNTAl 
Chemicals
 Cabazitaxel (purity 92.9%) and the deuterated internal standard, 2H6-cabazitaxel (purity 
97.4%), were kindly supplied by Sanofi-Aventis (Frankfurt am Main, Germany). All chemicals were 
of analytical grade or higher. Acetonitrile, methanol and water were purchased from Biosolve BV 
(Valkenswaard, The Netherlands). Dimethyl sulfoxide, ammonium formate and n-butylchloride 
were from Sigma-Aldrich (Zwijndrecht, The Netherlands). Formic acid and ammonium hydroxide 
were obtained from J.T. Baker (Deventer, The Netherlands) and 2-propanol from Merck (Darmstadt, 
Germany). Blank lithium heparinized plasma was purchased from Biological Specialty Corporation 
(BSC, Colmar, PA, USA).
Preparation of stock solutions, calibration standards and quality control samples 
Cabazitaxel stock solutions were prepared at 1 mg/ml free base in dimethyl sulfoxide. Stock 
solutions were aliquotted and stored at T<-70°C. Separate stock solutions were prepared for the 
construction of the calibration curve standards and the pools of quality control samples. The internal 
standard stock solution was prepared at 1 mg/mL in dimethyl sulfoxide, which subsequently was 
aliquotted and stored at T<-70°C. Internal standard working solutions were prepared at concentrations 
of 100 and 1000 ng/ml in acetonitrile, which were stored at T<8°C for a maximum of 3 months.
Calibration standards were prepared in duplicate on the day of analysis, by addition of 10 µL 
aliquots of appropriate dilutions of cabazitaxel stock solution in acetonitrile/DMSO (1:1, v/v) to 190 µl 
aliquots of human lithium heparinized plasma with concentrations of  1.00, 2.50, 10.0, 25.0, 50.0, 75.0, 
90.0 and 100 ng/ml for quantitation of cabazitaxel in the concentration range of 1.00 to 100 ng/mL 
and  40.0, 120, 500, 1000, 2500, 3600 and 4000 ng/ml for concentrations of cabazitaxel in the range 
of  40.0 to 4000 ng/mL.
Pools of QC samples were prepared in human lithium heparinized plasma at 
concentrations of 1.00 ng/ml (lower limit of quantitation, LLQ), 3.00 ng/ml (QC Low), 40.0 ng/
ml (QC Middle) and 80.0 ng/ml (QC High) for calibration standard curve in the range of 1.00 to 
100 ng/ml and at 40.0 ng/ml (LLQ; i.e., QC Middle above), 120 ng/ml (QC Low), 1500 ng/ml (QC 
Middle) and 3000 ng/ml (QC High) for calibration standard curve in the range of 40.0 to 4000 ng/
ml. Pools of QC samples were aliquotted and stored at T<-70 and T<-20°C upon processing. 
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Sample preparation
For both calibration ranges, aliquots of 20 µl 4% ammonium hydroxide and 100 µl of internal 
standard working solution (100 ng/ml for the range of 1.00 - 100 ng/mL and 1000 ng/ml for the range 
of 40.0 – 4000 ng/ml) were added to 100 µl of plasma samples in 2 ml microcentrifuge tubes followed 
by 1 ml aliquots of n-butylchloride. Hereafter, the samples were vigorously mixed for 10 minutes and 
then centrifuged at 18000 x g at ambient temperature for 10 minutes. Aliquots of 1 ml of the organic 
phase were transferred into 4.5 ml glass tubes and evaporated under nitrogen at T=70°C. The residues 
were resuspended in 100 µL aliquots of acetonitrile/water/ammonium formate (40:60:0.2, v/v/v). 
After 5 minutes of centrifugation at 3000 x g, the supernatants were transferred into 350 µl 96-well 
plates, which were placed into the chilled (T=10°C) autosampler, from which aliquots of 50 µl were 
injected onto the HPLC column for the low-range method (1.00 – 100 ng/ml) and 10 µl for the high-
range method (40.0 – 4000 ng/ml).
Equipment
The LC-MS/MS system was purchased from Waters Chromatography B.V. (Etten-Leur, The 
Netherlands) and consisted of a Waters 2795 Separation Module coupled to a Quatro micro API 
Mass Spectrometer. The MassLynx V4.1 SCN627 software package was used for the acquisition and 
processing of data. Quantification was performed using QuanLynx as implemented in the MassLynx 
software.
Chromatographic conditions
Analytes were separated on an Alltima HP C18 HL column 3 µm, 50 mm x 2.1 mm, (Grace, 
Breda, The Netherlands) thermostatted at T=40°C. A gradient at a flow-rate of 0.20 ml/min was 
achieved with mobile phase A, composed of 2 mmol/L ammonium formate and mobile phase B, 
composed of acetonitrile. A linear gradient was used, with 50% to 15% mobile phase A, from 0 to 1.5 
minutes, followed by holding on 15% mobile phase A (i.e., 85% mobile phase B) for 1.5 minutes. This 
was succeeded by a linear gradient back to 50% mobile phase A from 3.0 to 3.1 minutes, which was 
held for 1.9 minute to re-equilibrate. The overall run time of the assay was 5 minutes. A pre-column 
volume of 300 µl was applied and a parallel injection was enabled. The needle wash solvent was 
composed of acetonitrile/methanol/water/2-propanol/formic acid (25:25:25:25:0.1, v/v/v/v/v). 
Mass spectrometry
Tandem mass spectrometry was performed in the positive ion electrospray ionization mode. 
Mass transitions of m/z were optimized for cabazitaxel and 2H6-cabazitaxel (internal standard) by 
infusion of the respective analytes in acetonitrile/water/formic acid (40:60:0.1, v/v/v) via a T-union. 
Optimal MS settings were manually adjusted. The desolvation gas was set at 800 L/hour and the cone 
gas at 25 l/h (nitrogen). The ionspray voltage was kept at 3.50 kV and the cone voltage at 20 V for 
cabazitaxel and 19 V for the IS, with a source temperature of T=120°C and desolvation temperature of 
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T=350°C. The dwell times were set at 150 ms and the inter-channel delay at 50 ms. Multiple reaction 
monitoring (MRM) mode was applied for the quantitation with the following parameters: m/z 836 > 
555, collision energy at 10 V for cabazitaxel and m/z 842 > 561, collision energy at 10 V for the internal 
standard (Figure 1). The collision cell pirani pressure was set at ~5e-3 mbar (argon). The column effluent 
was passed through the mass spectrometer and monitored between 2 and 4 minutes after start of MS 
method, 0-2 minutes and 4-5 minutes sent to waste.
 
figure 1. Mass spectrum and chemical structure of cabazitaxel. The asterisks represent the deuterium atoms in the 
stable labeled internal standard 2H6-cabazitaxel 
Quantitation
Calibration curves were generated using peak area ratios of cabazitaxel to internal standard 
2H6-cabazitaxel versus the known cabazitaxel concentrations with a linear regression analysis with a 
weighting scheme of 1/concentration for the low curve and 1/concentration2 for the high curve. 
Method validation
The quantitative LC-MS/MS method was validated in accordance with the Guidance for 
Industry, Bioanalytical Method Validation, as specified by the FDA (http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf).
Potential presence of endogenous contaminating compounds that may interfere with the 
analytical assay was determined by analyzing blank human lithium heparinized plasma samples of 
ten different lots. The following substances were investigated for interference with the analytical 
method: aprepitant, budesonide, dexamethasone, domperidon, granisetron, lorazepam, oxazepam, 
paracetamol and metoclopramide. All drugs have been dissolved/diluted in water to a concentration 
of 1 mg/ml followed by a 500-fold dilution in blank human lithium heparinized plasma. Aliquots 
have subsequently been diluted in plasma containing the different drugs to yield final cabazitaxel 
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concentrations of 8.00 and 50.0 ng/ml, which have been processed and compared to equal 
concentrations in blank human lithium heparinized plasma.
Accuracy (ACC), within-run precision (WRP) and the between-run precision (BRP) for both 
calibration curve ranges were determined by analyzing 5 replicates of pools of LLQ and QC samples 
independently over a three-run period, with the calibration curve standards processed in duplicate. 
The ACC, WRP and BRP at the level of the LLQ and QC samples were calculated by one-way analysis of 
variance, using the run as the variable as earlier described (10-11). 
For the validation of the LLQ, besides the validation of the pools as described above, blank 
human lithium heparinized plasma of 10 different donors were spiked at a concentration of 1.00 ng/ml 
and quantitated in a separate run. 
The evaluation of the matrix effect was tested by comparing the MS/MS response of cabazitaxel 
at a concentration of 3.00 and 80.0 ng/ml (for the low curve) and at 3000 ng/ml (for the high curve) 
spiked in triplicate in acetonitrile/water/formic acid (40:60:0.1, v/v/v) to the MS/MS responses of the 
analytes spiked in triplicate into extracts of blank human lithium heparinized plasma, as described 
recently (10, 12).
Extraction recovery was determined by comparing the MS/MS response of cabazitaxel at a 
concentration of 3.00 and 80.0 ng/ml (for the low curve) and at 3,000 ng/mL (for the high curve) spiked 
in triplicate into six different lots of blank lithium heparinized plasma before extraction, to the MS/MS 
responses of the analytes spiked in triplicate into extracts of blank human lithium heparinized plasma 
after extraction, corrected for the evaporated volume of organic phase (10, 12).
The stability of cabazitaxel in human lithium heparinized plasma was tested with QC low (3.00 
ng/ml) and both QC high (80.0 and 3000 ng/ml) at ambient temperature for a period of 18 hours as well 
as following 3 freeze-thaw cycles, in which the samples were thawed for at least 30 minutes followed by 
refreezing for at least 18 hours. Long-term stability at T<-20°C and T<-70°C in human lithium heparinized 
plasma has been investigated using the same QC samples as described above. Also the storage stability 
of processed samples in the autosampler was tested in triplicate at the concentration of QC low and 
both QC high. QC samples were processed in triplicate and repeatedly injected on different time points. 
Non-specific binding
 As during the initial method validation non-specific binding of cabazitaxel was observed 
(see results section), an experiment was conducted to establish the potential loss of cabazitaxel during 
sample dilution. QC high (80.0 ng/ml) was serially diluted (in triplicate) to 40.0, 20.0, 10.0 and 5.00 ng/
ml in blank plasma, subsequently processed and the individual accuracies estimated.
Application of method to clinical samples
To demonstrate the applicability of the validated bioanalytical method, blood samples 
were collected from seven patients enrolled in a clinical study in which cabazitaxel was administered 
intravenously over 60 minutes at a dose of 25mg/m2 (see www.trialregister.nl; NTR study number 2840). 
Twelve blood samples in the presence of lithium heparin as anticoagulant were obtained during the 
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first 24 h after administration. A last blood sample was drawn between day 7 and 9. Samples were 
processed within 15 minutes of collection to isolate the plasma, which was stored at T<-70°C before 
analysis as described. All patients provided written informed consent and the local institutional review 
boards approved the clinical protocol (MEC 2011-091).
 Individual pharmacokinetic parameters were estimated using non-compartmental analysis 
using the software program Phoenix WinNonLin 6.1 (Pharsight, Mountain View, CA). 
resulTs ANd dIsCussION 
lC-MS/MS conditions
Cabazitaxel belongs to the group of taxanes with a single protonation site located on the 
secondary amine of the side-chain. Optimal sensitivity was achieved by the addition of ammonium 
formate, presumably by generation of an intermediate ion [M + NH4+] which may dissociate into [M + 
H+] and ammonia during the electrospray process. Therefore, for optimal signals the mobile phase was 
composed of 2 mM aqueous ammonium formate and acetonitrile.  
The cabazitaxel product ion spectra (Figure 1) yielded abundant product ions suitable for 
use in multiple reaction monitoring. Main fragment m/z 555 resulted from the baccatin III core while 
m/z 523 is generated by loss of the methyl groups of the baccatin III core and m/z 433 was generated 
by loss of the benzoic acid from the baccatin III core. The product ion at m/z 555 was selected as the 
MRM ion for quantitation of cabazitaxel and the product ion at m/z 561 for its stable isotope labeled 
internal standard 2H6-cabazitaxel.
Cabazitaxel was separated from early eluting hydrophilic, potentially response-suppressing, 
matrix components by applying a step gradient. A relative short analysis time of 5 minutes, with 
cabazitaxel eluting at 3.0 minutes (Figure 2) was maintained.
figure 2. Representative chromatograms of (A) double blank processed plasma sample collected prior to the 
administration of 25 mg/m2 cabazitaxel, (B) plasma sample taken prior to the end of infusion containing 267 ng/
ml cabazitaxel and (C) plasma sample collected on day 7 containing 1.03 ng/ml cabazitaxel. Samples A and C are 
quantitated on the calibration curve in the range of 1.00 – 100 ng/ml cabazitaxel and sample B on the calibration 
curve in the range of 40.0 – 4000 ng/ml.
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figure 3. Linear correlation between the number of dilution steps and the observed accuracy of QC sample high 
spiked with 80.0 ng/ml cabazitaxel. Dilution “0” represents the accuracy following no dilution, “1” following 2-fold 
dilution in one step (i.e. 40.0 ng/ml), “2” following 4-fold dilution in 2 steps (i.e. 20.0 ng/ml),  “3” following 8-fold 
dilution in 3 steps (i.e. 40.0 ng/ml) and “4” following 16-fold dilution in 4 steps (i.e. 5.00 ng/ml). The equation of 
the linear curve is: y = -6.5 * x + 95.3, in which the -6.5 represents the loss of 6.5% of cabazitaxel per dilution step. 
 
Non-specific binding
During the initial method validation a QC diluted spiked at a concentration of 4000 ng/ml 
was included on the calibration curve standards in the range of 1.00 – 100 ng/ml. This QC sample 
was 50-fold diluted in blank plasma in 2-steps prior to extraction. The accuracy was below 85% during 
the first two validation runs. Therefore a new pool was prepared, which also failed for the accuracy. 
Non-specific binding is a well-known drawback of taxanes (13), therefore, non-specific binding during 
sample dilution was most likely the underlying explanation of the low accuracy of the diluted QC 
sample. This was investigated by serial dilution of the QC sample with a spiked concentration of 
80.0 ng/mL. As shown in Figure 3, the accuracy decreases linearly by 6.5% following each sequential 
dilution step. Addition of polysorbate 80 or Cremophor EL up to concentrations of 1% to overcome 
non-specific binding (13), did not result in increased accuracies. Also, accuracy could not be improved 
by using pipette tips and/or laboratory tubes of different materials and brands (data not shown). 
Eventually, validation of the method at a higher concentration range, to avoid additional steps 
in sample processing for samples in which the concentration exceeds the 100 ng/mL, was performed. 
The range of 40.0 to 4000 ng/ml was selected based on the available data of maximum concentrations 
of 535 ± 305 ng/mL following the administration of 25 mg/m2 cabazitaxel (8). 
Assay performance
The results of the method were linear (r ≥ 0.9987) in the concentration range of 1.00 to 100 
ng/ml as well as in the range of 40.0 to 4000 ng/ml (r ≥ 0.9950) in human lithium heparinized plasma. 
None of the potentially co-administrated drugs interfered with the quantitation of cabazitaxel. 
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The LLQ was validated at 1.00 ng/ml with the measured concentrations of cabazitaxel in 
nine out of ten independently spiked plasma samples falling within the acceptable range of accuracy 
of 80-100%. The average measured concentration in all ten samples was 0.940 ± 0.087 ng/mL. The 
within-run and between-run precisions and the accuracies at seven tested concentrations in human 
lithium heparinized plasma, including at the level of the LLQ, are summarized in Table 1. All fall within 
the accepted ranges as specified by the Food and Drug Administration.  
The mean measured extraction efficiencies for cabazitaxel were 92%, 100% and 106% at the 
concentrations of 3.00, 80.0 and 3000 ng/ml, respectively. The values for the matrix effect were 66%, 
72% and 86% at 3.00, 80.0 and 3000 ng/ml, respectively.
Cabazitaxel was stable in lithium heparinized plasma (i) at ambient temperature for at least 
18 hours, (ii) during three consecutive freeze-thaw cycles and (iii) at least 6 months when stored at 
T<–20°C and T<–70°C. As processed samples, cabazitaxel was stable for at least 20 hours in the chilled 
(T=10°C) autosampler (Table 2). 
Table 1. Calculations of the between-run and within-run precisions and the average accuracy of the llQ and 
QC samples1 
Sample Spiked GM ACC WRP BRP  n2
(ng/mL) (ng/mL)        (%)           (%)          (%)
Range 1.00 – 100 ng/mL
LLQ 1.00 0.885 88.5 8.75 5.98 13 of 15
Low 3.00 2.81 93.7 8.12 #3 13 of 15
Middle 40.0 37.3 93.3 2.94 #3 15 of 15
High 80.0 75.3 94.1 3.03 0.67 15 of 15
Range 40.0 – 4,000 ng/mL
LLQ 40.0 39.7 99.3 4.75 3.72 15 of 15
Low 120 119 99.2 4.15 3.29 15 of 15
Middle 1500 1504 100.3 4.99 #3 15 of 15
High 3000 2873 95.8 4.11 #3 15 of 15
Abbreviations: GM, grand mean; ACC, average accuracy; WRP, within-run precision; BRP, between-run precision
1,  n=5 in 3 separate runs
2, number of individual samples falling within acceptable range of accuracy of 85-115% (80-120% at LLQ)
3 , no additional variation observed by performing the assay in different runs.
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Clinical application 
As shown in Figure 4, plasma concentration versus time curves could be readily determined. 
The data indicate that the lower limit of quantitation of 1.00 ng/ml is sufficient for monitoring 
drug-plasma levels in samples obtained from patients treated with cabazitaxel at a dose of 25 mg/
m2. Preliminary pharmacokinetic data revealed maximum concentrations of 189 ± 14.7 ng/ml (n=7) 
and AUC(0-24h) values of 248 ± 31.9 ng*h/ml (n=7). We were able to quantitate concentrations up to 
7-9 days after administration with concentrations in the range of 1.03 to 1.25 ng/ml. The method is 
thus sensitive enough for pharmacokinetic analysis in clinical pharmacokinetic studies beyond 24h. 
Representative chromatograms are shown in Figure 2.
 
figure 4. Average plasma concentration-time profile of cabazitaxel in 7 patients following the administration of 25 
mg/m2 as a 1 h infusion in the first course. Open symbols represent individual concentration data. The solid line 
represents the fit according to a three-compartmental pharmacokinetic model (model 19 with 1/y2 weighting; 
Phoenix WinNonLin version 6.1; Pharsight, Mountain View, CA).
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Table 2. Stability of cabazitaxel
Condition (% to concentration at the initial time point)
3.00 ng/mL 80.0 ng/mL 3,000 ng/mL
Ambient temp (18h) 105 95.5 99.8
3 freeze/thaw cycles 100 103 100
Processed sample (T=10°C, 20h) 112 109 105
T<-20°C (6 months) 90.5 94.9 111
T<-70°C (6 months) 90.3 93.7 107
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CONClusION
A sensitive, selective, accurate and precise LC-MS/MS method has been developed and validated 
for the analysis of cabazitaxel in human heparinized plasma, which meets the current requirements of 
bioanalytical method validation. As sample dilution prior to extraction results in the loss of cabazitaxel, 
a secondary calibration range has been validated to avoid sample dilution. This method will prove to 
be a valuable tool for pharmacokinetic (interaction) studies with cabazitaxel. 
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AbsTrACT
Forty-seven percent of patients in the registration trial of cabazitaxel reported diarrhea of 
any grade (TROPIC, De Bono et al., Lancet 2010). The objective of this study was to investigate the 
effect of budesonide on the incidence and severity of cabazitaxel-induced diarrhea. An open-label, 
randomized, phase II multi-center trial was performed in metastatic castration resistant prostate 
cancer patients after docetaxel treatment between December 2011 and October 2015. Two hundred 
and forty-six metastatic castration resistant prostate cancer patients were randomized to receive 
standard of care cabazitaxel 25 mg/m2 Q3W plus prednisone 10 mg (group CABA) or same dose/
schedule of cabazitaxel with concomitant budesonide 9 mg QD during the first two treatment cycles 
(group BUD). The incidence and severity of diarrhea during the first two cycles of cabazitaxel was the 
primary outcome measure. An intention-to-treat principle was used. Chi-squared tests were used to 
compare incidence numbers. In the phase II trial, 227 patients were evaluable. Grade 2-3 diarrhea 
occurred in 35 patients (15%) and grade 4 diarrhea was not reported. The incidence of grade 2-3 
diarrhea was comparable in both treatment groups: 14 of 113 patients in group CABA (12%) versus 
21 of 114 patients in group BUD (18%) (P=0.21). Seven patients were admitted to the hospital with 
diarrhea (n=5 group CABA vs. n=2 group BUD). PSA response was seen in 30% of patients and not 
affected by budesonide co-administration (P=0.29). Other toxicities were also not affected by 
budesonide co-administration. Conclusive, the incidence of cabazitaxel-induced diarrhea was notably 
less than reported in the TROPIC trial and and appears manageable in routine practice. Budesonide 
co-administration did not influence the incidence of cabazitaxel-induced diarrhea. 
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INTrOduCTION
Several therapeutic options are available for the treatment of metastatic castration resistant 
prostate cancer (mCRPC). Cabazitaxel is currently approved for second line treatment of mCRPC after 
progression on docetaxel treatment. In the registration trial of cabazitaxel, diarrhea was reported in 
47% of patients (1). Six percent of patients had grade 3-4 diarrhea, requiring hospital admissions (1).
In order to avoid dose reductions of an effective regimen and to preserve the patients’ 
quality of life, we aimed to search for measures to reduce the incidence and severity of cabazitaxel-
induced diarrhea. It has previously been shown that co-administration of budesonide is able to reduce 
the incidence of diarrhea in irinotecan as well as in 5-FU-treated patients (2,3) Budesonide, a locally 
active corticosteroid, reduced diarrhea with ≥2 grades in 86% of irinotecan and 57% of 5-FU-treated 
patients that suffered from grade 3-4 diarrhea and did not respond to loperamide treatment (2). In 
the second study, budesonide co-administration in patients treated with irinotecan resulted in shorter 
and fewer periods of diarrhea compared to placebo (3). Budesonide has a 90% first pass effect and 
thus a low systemic availability, so little to none systemic toxicity can be expected from budesonide co-
administration. Based on these data, we assumed budesonide to be a safe and potent drug to prevent 
cabazitaxel-induced diarrhea. Since the co-administration of budesonide and cabazitaxel has never 
been tested, our study was conducted in two parts. First, we investigated the safety of budesonide on 
the pharmacokinetics (PK) of cabazitaxel in a limited-size cross-over trial, to exclude a negative effect 
of budesonide on cabazitaxel exposure. Next, a sufficiently powered randomized phase II setting was 
chosen to explore the effects of budesonide on cabazitaxel-induced diarrhea.  
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PATIeNTs ANd MeThOds
Phase II Trial
The randomized open-label phase II multicenter study was registered in the European 
Clinical Trials Database (no. 2011-003346-40) and in the Dutch Trial Registry (no. NTR2991). Only 
mCRPC patients with documented disease progression during or after docetaxel therapy were eligible 
for study participation. Disease progression was defined as at least two consecutive rises in PSA (taken 
≥1 week apart) or progression according to RECIST (version 1.1). Patients had to be ≥18 years of 
age. A World Health Organisation (WHO) performance status of ≥1 and adequate renal, hepatic and 
hematopoietic functions were required for study inclusion. Patients had to be able to take oral drugs. 
The use of strong CYP3A4 inhibitors or inducers was prohibited. 
Patients with an ostomy, ulcerative colitis, Crohn’s disease or celiac disease were excluded. 
For the stratification of patients, the following factors were used: age (≥65 versus <65 years), center of 
enrolment, and previous radiotherapy on back, abdomen or pelvis (yes versus no). 
Treatment
Patients were randomized to receive either standard of care cabazitaxel 25 mg/m2 3-weekly 
plus prednisone 10 mg (group CABA) or cabazitaxel with concomitant budesonide 9 mg daily added 
for the first two courses (group BUD) as diarrhea was expected to occur in the first two treatment 
cycles (1). Prednisone had to be started at least one week before the first cycle of cabazitaxel. Patients 
started budesonide two days before their first cabazitaxel administration and took budesonide one 
hour before breakfast. Cabazitaxel was continued for a maximum of 10 cycles for evaluation of 
toxicity, but could be continued beyond 10 cycles if in the interest of the patient, unless progression or 
unacceptable toxicity occurred. Standard premedication was given (1). In case of severe toxicity, one 
dose reduction of 20% (to 20 mg/m2) was allowed.  
Objectives and enpoints
Primary objective of this trial was to study the effects of budesonide co-treatment on the 
grade of cabazitaxel-induced diarrhea during the first two treatment cycles. Primary endpoint was 
the difference in the incidence of grade 2-4 diarrhea in the budesonide co-treated arm compared to 
the arm without budesonide. Secondary objectives were to study the effects of budesonide on other 
cabazitaxel-induced adverse events and the effects of cabazitaxel and budesonide on PSA response. 
PSA response was defined as a >50% change in PSA after start of treatment with cabazitaxel. PSA at 
baseline was considered the last measured PSA value before start of cabazitaxel treatment. 
Data acquisition
Patients kept a diary on their stools, co-medication and adverse events during the first two 
cabazitaxel cycles. Loperamide use in case of diarrhea was accepted according to regular protocol. 
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Prior to each treatment cycle PSA was measured, and adverse events were monitored. Common 
Terminology Criteria for Adverse Events (CTCAE) versions 2-4 were used. 
Statistics for the Phase II trial analyses
The incidence of grade 2-4 diarrhea in the CABA group was estimated to be 25%. A reduction 
of 15% in the BUD group was considered clinically relevant and a two-sided significance level of α = 0.05 
and a power of 80% was defined. Power calculation showed that 113 evaluable patients per treatment 
arm were required. After the first 57 evaluable patients in each arm were included, an interim analysis 
was performed. If the percentage of patients with grade 3-4 diarrhea in the budesonide group would 
exceed the incidence observed in the control group by 15% the study would end for reasons of futility. 
Since the PK study had shown no drug interaction and the cabazitaxel dose and regimen was identical 
in the two treatment arms the study was not powered to test for differences in anti-tumor efficacy (4).
The results of the primary endpoint of the phase II study were based on the information 
reported by physicians on the adverse event forms. Analyses were done according an ‘intention-to-
treat’ principle. The incidences of adverse events were compared between both treatment arms using 
a Chi-squared test. 
Pharmacokinetic Study
In a randomized cross-over PK study, we investigated the effects of budesonide on the 
exposure to cabazitaxel. It was registered in the Dutch Trial Registry (no. NTR2840). Inclusion criteria 
were similar as those described above. Chemotherapy or radiotherapy <4 weeks before start with 
cabazitaxel was prohibited.
Patients were randomized to receive standard of care cabazitaxel 25mg/m2 Q3W plus 
prednisone 10 mg without budesonide in course 1 and with daily 9 mg budesonide (3 capsules of 3 
mg) in course 2. In group B, budesonide was added to the cycles of cabazitaxel in the opposite order. 
Patients as well as their treating physicians, documented diarrhea and other (serious) adverse events 
in a diary or patient record.
Pharmacokinetic sampling and analysis
Cabazitaxel PK sampling was performed prior to infusion, 30 minutes after start and 5 minutes 
before stop of the infusion. Post-infusion, samples were drawn at 5 minutes, 15 minutes, 30 minutes, 
1 hour (h), 2h, 4h, 6h, 11h and 23h. Samples were collected in the presence of lithium heparin and 
processed to plasma which were thereafter added into polypropylene tubes and stored at <-70°C 
until the time of analysis. Analyses were done using a validated LC-MS/MS method as described by de 
Bruijn et al. (5). Area under the curves from 0 to 24 hours (AUC 0-24h) were estimated doing a non-
compartmental analysis using Phoenix v 6.1 (Pharsight, Mountain View, CA). 
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Statistics for pharmacokinetic analyses
Patients were considered evaluable for analysis when two cabazitaxel courses had been 
administered and PK sampling was performed adequately. A difference in PK was defined as a 
difference in cabazitaxel area under the curve (AUC) of >20%. Based on a power analysis assuming 
an inter-individual variability in cabazitaxel PK of 20% and a power of 80%, with a 2-sided P-value of 
≤ 0.05, a sample size of 18 patients was calculated. A Student’s t-test was used for statistical testing.
Both the PK study and the randomized phase II study were approved by the ethics committee of the 
Erasmus University Medical Center as well as approved by the local committees of the participating 
hospitals and performed according to the values of the Declaration of Helsinki. Informed consent was 
obtained in all patients.
resulTs
Patient and treatment characteristics in the Phase II trial
Between December 2011 and October 2015, 246 patients were included in 22 different 
hospitals in the Netherlands (see Table 1). All patients were randomized to either one of both 
treatment arms. Patient characteristics are shown in Table 2. Nineteen patients were considered 
ineligible (11 from arm CABA and 8 from arm BUD, see Table 3). For the primary endpoint, 227 patients 
were considered eligible (CABA n=113, BUD n=114). 
The median number of cabazitaxel cycles was six in both treatment arms. Reasons for 
discontinuing the study are shown in Table 4. In three patients, diarrhea was one of the reasons for 
study discontinuation. Three patients in arm B received no budesonide, 12 patients (11%) only in 
one cycle and 96 patients (84%) received two cycles of cabazitaxel with concomitant budesonide. 
Three patients received >3 cycles with concomitant budesonide. For twenty-five patients (12%), a 
dose reduction was made in cycle 2. In one of these 25 patients, diarrhea was the reason for dose 
modification. 
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Table 1. Patient inclusion per participating medical center
City hospital     Number of included patients
Alkmaar Medical Center of Alkmaar                2
Amsterdam Antoni van Leeuwenhoek Hospital/ Dutch Cancer Institute 15
Breda Amphia Hospital 11
Delft Reinier de Graaf Hospital                    9
Delfzijl Ommelander Hospital Delfzicht                1
Deventer Deventer Hospital            3
Dordrecht Albert Schweitzer Hospital 6
Eindhoven Catharina Hospital 8
Geldrop St. Anna Hospital 5
Groningen Martini Hospital 2
Haarlem Kennemer Gasthuis 5
Hoofddorp Spaarne Hospital 14
Leeuwarden Medical Center of Leeuwarden          6
Leiden Leiden University Medical Center 2
Leidschendam Medical Center Haaglanden Antoniushove       5
Maastricht Maastricht University Medical Center 5
Rotterdam Erasmus University Medical Center 50
Rotterdam Sint Franciscus Gasthuis 52
Tilburg Tweesteden Hospital 17
Vlissingen Admiraal de Ruyter Hospital 13
Zutphen Gelre Hospital 7
Zwolle Isala Hospital 8
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Table 2. Patient characteristics
Group CAbA Group bud Total
Total 113 (100%) 114(100%) 227 (100%)
Median age at baseline 69 68 68
Range 49-85 51-83 49-85
Age >64 years 84  (74%)     84  (74%)  168  (74%)
Age ≤64 years 29  (26%)   30  (26%) 59  (26%)
WHO performance status [0-5]
WHO 0                         49 (43%)     43 (38%) 92 (41%)
WHO 1                        64 (57%)     69  (61%) 133 (59%)
Not reported                             -           2 (2%) 2 (1%)
Average number of stools baseline
≤1                          67 (59%)    55 (48%) 122 (54%)
1-2 21 (19%)     34 (30%)     55 (24%)
2-3 7 (6%)      6 (5%) 13 (6%)
3-4 3 (3%)      3 (3%)      6 (3%)
>4                            1 (1%)      2 (2%)      3 (1%)
unknown                             14 (12%)     14 (12%) 28 (12%)
Type of castration
Surgical 12 (11%) 19 (17%) 31 (14%) 
Chemical 101 (98%) 95 (83%) 196 (86%)
Number of prior chemotherapeutic regimens*
1 102 (90%) 105(92%) 207 (91%)
2 11 (10%) 7 (6%) 18 (8%)
3 - 1 (1%) 1 (0%)
4 - 1 (1%) 1 (0%)
Median 1 1 1
Range 1-2 2-3 3-4
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Group CAbA Group bud Total
Prior therapy with abiraterone                            
No 82 (73%)     74 (65%) 156 (69%)
Yes 31 (27%)     40 (35%)  71 (31%)
Prior therapy with orteronel (TAK 700)
 no                            106 (94%)    106 (93%)  212 (93%)
 yes                           7 (6%)      8 (7%) 15 (7%)
Chemotherapy within the last 4 weeks before randomization
 no                            78 (69%)     81(71%)   159 (70%)
 yes                           3 (3%)      3 (3%) 6 (3%)
 missing 32 (28%)     30 (26%) 62 (27%)
Prior irradiation back, abdomen and/or pelvis
no                            53 (47%)     55 (48%) 108 (48%)
yes                          60 (53%)   59 (52%) 119 (52%)
*Experimental chemotherapeutical therapies included
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Table 3. Reasons for Ineligibility 
Reason for ineligibility Group CAbA Group bud Total
No cabazitaxel in study context* 3 7 10
Initial cabazitaxel dose <25mg/m2 5 1 6
Treatment started before randomization 1 0 1
Death before start therapy 1 0 1
Long treatment delay after randomization∧ 1 0 1
Total 11 8 19
*due to disease progression and worsening of patient conditions. ∧due to ASAT and ALAT > 2 upper limit of 
normal without liver metastases there was a time of two months between randomisation and start of 
cabazitaxel therapy. 
Table 4. reasons for patients going off-protocol
Primary reason Group CAbA Group bud Total
Withdrawal of consent 0 1 1
Progression of disease 47 34 81
Toxicity 16 22 38
Death 5 5 10
Other 9 16 25
Unknown 14 17 31
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Effects of budesonide on the incidence and severity of diarrhea 
In group CABA, 14 out of 113 patients (12%) had grade 2-3 diarrhea in one of the first two 
cycles of cabazitaxel treatment (see Table 5). In group BUD, 21 out of 114 patients (18%) had grade 2-3 
diarrhea in either one or both (n=2) of the first two cycles of cabazitaxel treatment (P = 0.21). Seven 
patients (3%) (CABA n=5, BUD n=2) were hospitalized for diarrhea during cabazitaxel treatment. Grade 
3 diarrhea occurred in 4% of patients. The incidence of grade 3 diarrhea was not different between 
group CABA (n=5) and group BUD (n=4) (P=0.72). Interestingly, no grade 4 diarrhea was observed. Data 
from patients’ diarries is shown in Table 6.
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Table 5. effect of budesonide on diarrhea
Group CAbA Group bud Total P-value
Total 113 (100%) 114 (100%) 227 (100%) .
Grade 2-3 diarrhea 14 (12%) 21 (18%) 35 (15%) 0.21
Grade 3 diarrhea 5 (4%) 4 (4%) 9 (4%) 0.27
hospitalization with diarrhea 5 (4%) 2 (2%) 7 (3%) 0.25
Table 6. Patient diaries’ information
Minimum number of stools per day Group CAbA Group bud Total
0 79 (70%)     75 (66%) 154 (68%)
1 17 (15%)     19 (17%) 36 (16%)
2 2 (2%)       4(4%)  6 (3%)
3 -           1(1%) 1 (1%)
unknown 15 (13%) 15 (13%) 30 (12%)
Maximum number of stools per day
Number of patients                     98 99 197
Median  (range)                    3.00  (1.00-13.0)         3.00 (1.00-40.00)* 3.00(1.00-40.00)*
1 4 (4%)      3 (3%) 7 (3%)
2 27 (24%)     27 (24%)   54 (24%)
3 31 (27%)     25 (22%)    56 (25%)
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Effects of cabazitaxel and/or budesonide on PSA response
 PSA decrease of at least 50% was seen in 30% of all patients (38/113 patients in arm A versus 
31/114 in arm B). Concomitant use of budesonide had no effect on PSA response (P=0.29).
Effects of budesonide on other cabazitaxel-induced serious adverse events 
Budesonide had no effect on neutropenia, leukopenia, thrombocytopenia, nausea, vomiting, 
alopecia and motor and sensory neuropathy during the first two cycles (see Table 7). No correlation 
was seen between the occurrence of neutropenia and grade 2-4 diarrhea (P=0.32).
 
 
Minimum number of stools per day Group CAbA Group bud Total
4 15 (13%)     19 (17%)     34 (15%)
5 10 (9%)      9 (8%) 19 (8%)
6 3 (3%)      9 (8%)    12 (5%)
7 2 (2%)      4 (4%)      6 (3%)
8 1 (1%)      2 (2%)      3 (1%)
9 2 (2%)      -      2 (1%)
10 2 (2%)      -           2 (1%)
13 1 (1%)     -           1 (0%)
40 -           1 (1%)      1 (0%)
unknown 15 (13%)     15 (13%) 30 (13%)
Average number of stools per day
Number of patients                         98 99 197
Median (range)                        1.32 (0.40-3.98)        1.50 (0.39-4.31)     1.37 (0.39-4.31)
* One patient reported a maximum of 40 stools.
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Effects of budesonide on cabazitaxel pharmacokinetics
Between May 2011 and August 2011, 21 Caucasian patients were included in the 
pharmacokinetic study. Two patients were excluded after inclusion due to a decline in clinical 
performance status. One patient received only one course of cabazitaxel. The other 18 patients were 
evaluable for PK analyses. The median age at study entry was 66 (range 46-75) and 53% of patients 
received radiotherapy prior to cabazitaxel treatment. No statistically significant difference in mean 
dose-corrected AUC (0-24h) was found between the courses with concomitant budesonide (4.6 
ng*h/mL, SD 1.2) and without concomitant budesonide (4.2 ng*h/mL, SD 1.1, P = 0.21) (see Table 8). 
Therefore, budesonide co-administration had no was considered to be safe for investigation in the 
phase II study. 
Table 7. effect of budesonide on adverse events
Group CAbA Group bud Total P-value
Total 113 (100%) 114 (100%) 227 (100%) .
Neutropenia 55 (49%)     57 (50%) 112 (49%) 0.84
Leukopenia 47 (42%)     49 (43%) 96 (42%) 0.83
Thrombocytopenia 4 (4%)      4 (4%) 8 (4%) 0.99
Neuropathy, motor 5 (4%) 6 (5%) 11 (5%) 0.77
Neuropathy, sensory 29 (26%)     36 (32%) 65  (29%) 0.32
Alopecia 10 (9%) 13 (11%)     23 (10%) 0.52
Nausea 36 (32%)     36 (32%) 72 (32%) 0.96
Vomiting 20 (18%)     17 (15%) 37 (16%) 0.57
Table 8. Pharmacokinetic effect of budesonide on cabazitaxel exposure
Course without budesonide Course with budesonide P-value
AuC mean (sd) 4.16 (1.11) 4.6 (1.24) 0.21
AuC median (range) 4.48 (2.46-6.2) 4.43 (2.15-6.93)
All units are: ng*h/mL. AUC: area under the curve, SD: standard deviation.
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dIsCussION
The registration trial of cabazitaxel (TROPIC) reported all grades of diarrhea in 47% of 
cabazitaxel-treated patients (1). We thus aimed to find methods to reduce the incidence and severity 
of cabazitaxel-induced diarrhea in order to preserve patients’ quality of life as well as to avoid toxicity 
related dose-reductions and premature discontinuation of a potentially highly effective chemotherapy 
regimen. Our initial PK-study showed that budesonide had no negative effects on the exposure of 
cabazitaxel, and therefore the open-label multicentre phase II trial (CABARESC) was initiated.  
In this phase II trial, the incidence of diarrhea was markedly lower than expected, based on 
the data from the TROPIC trial (1). Diarrhea also appeared quite manageable, since only 7 patients 
(3%, versus 6% in TROPIC) required hospitalization for diarrhea and moreover only 2 patients reported 
diarrhea grade 2-3 in both cycles. Diarrhea was the reason of dose-reduction in only one case and thus 
not dose limiting. Moreover, diarrhea was never the sole reason for stopping treatment.
As mentioned, grade 3 diarrhea was reported in only 4% of patients and grade 4 was not 
reported at all, compared to 6% grade 3-4 diarrhea reported in the TROPIC trial (1). In the UK early 
access program and in the Spanish expanded access program similar grades were reported (6, 7, 8). 
These data, including those for our trial, add to the accumulating evidence that real-world toxicity of 
cabazitaxel is less than that experienced in the TROPIC trial (1).
The effects of budesonide on cabazitaxel-induced diarrhea were smaller than anticipated. 
This may partly be due to the lower incidence of grade 2-4 diarrhea in the control group than expected 
(15% versus 25% respectively). To avoid underestimation of the incidence and severity of diarrhea, 
patients also reported their stools in a diary. However, most patients report a maximum of <4 stools, 
maximally defined as grade I diarrhea. 
Chemotherapy-induced diarrhea is thought to be predominantly secretory with an exudative 
component and to be due to drug-toxicity on rapidly dividing cells of the intestinal epithelium (9-11). 
It is possible that cabazitaxel-induced diarrhea has no inflammatory foundation and that budesonide 
did therefore not result in a clinically meaningful effect. 
 
CONClusIONs
In this study, the incidence of cabazitaxel-induced diarrhea is notably lower than anticipated, 
not dose limiting, and appears manageable in routine clinical practise. The addition of budesonide to 
cabazitaxel therapy however had no influence on the incidence of diarrhea. 
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Chapter 9
Summary
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suMMAry 
The taxanes paclitaxel, docetaxel and cabazitaxel are used in the treatment of patients with 
solid tumors. These compounds are known for their anti-cancer effect, but also for their impact on 
quality of life, as taxanes are notorious for causing toxicity. For example, taxanes may cause neutropenia, 
neurotoxicity, fatigue, nausea, and vomiting. These toxicities can be dose limiting or cause premature 
therapy determination. It would therefore be convenient to be able to predict which patients will 
suffer from taxane-induced toxicity. Understanding the pharmacokinetics and pharmacodynamics of 
taxanes would therefore aid in the individualization of taxane therapy as the exposure is linked to 
efficacy as well as toxicity. However, multiple factors may be able to influence the pharmacokinetics 
and pharmacodynamics of a drug. Identifying these factors would allow us to act on possible 
consequences. In this thesis, we looked into different factors influencing the pharmacokinetics as well 
as the pharmacodynamics and toxicity of taxanes. We aimed for a more individualized approach of 
taxane therapy, reducing toxicity while optimizing efficacy. 
In Chapter 2, we looked into the role of solvents in the pharmacokinetics of taxanes. Because 
taxanes are known to be poorly soluble in water, solvents Kolliphor EL (KEL; or Cremophor EL (CrEL)) 
and Polysorbate 80 (PS80) are used for the formulations of these drugs. Previous research has showed 
that solvents influence the distribution of taxanes and that the hepatic elimination of paclitaxel was 
diminished when the formulation of this drug contained KEL (1,2). Previous literature also showed 
that the Organic Anion Transporting Polypeptide (OATP) 1B-type transporters take up taxanes for 
hepatic elimination (3). Using this knowledge, we hypothesized that the presence of solvents in taxane 
formulation would also affect the uptake of taxanes by OATP1-type transporters.  Cell lines as well as 
wild-type and OATP1B2-knock out mice were used for these pharmacokinetic experiments. Studies 
were done in absence or presence of the solvents CrEL and PS80. Results show that cabazitaxel is not 
transported by OATP1B1, OATP1B2, and OATP1B3. The uptake of paclitaxel and docetaxel is reduced in 
the presence of solvents CrEL and PS80. As a result, mice with an OATP1B2 deficiency had significantly 
lower clearance of paclitaxel in absence of solvents only. In other words, the effect of solvents on 
the uptake of paclitaxel by OATP1B2 masked the effect of OATP1B2 deficiency. This study confirms 
our hypothesis that solvents affect taxane pharmacokinetics, the hepatocellular uptake of taxanes by 
OATP1B2 in specific. 
 Patients treated with paclitaxel are at risk for neutropenia and subsequently for severe 
(opportunistic) infections and sepsis. Knowing which patients are prone to suffer from neutropenia 
could help in anticipating on this problem (for example resulting in close monitoring of these 
patients). In Chapter 3, we investigated whether genetic variation in drug metabolizing enzymes and 
transporters would be able to identify patients prone for hematological toxicity. Instead of using a 
candidate-gene approach, we used the drug metabolizing enzymes and transporters (DMET) platform, 
a chip containing 1936 single nucleotide polymorphisms (SNPs) in 225 genes encoding for enzymes 
and transporters involved in drug metabolism and transport. We identified a 10-SNP predictive model 
for neutropenia in 279 paclitaxel-treated patients. The sensitivity of this model was limited (43%). 
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We aimed for improved sensitivity by developing a genetic model predictive of neutropenia in the 
3-weekly treated patients only. This resulted in a model with an ability to identify 79% of patients with 
paclitaxel-induced neutropenia. 
Also for docetaxel neutropenia is a frequent clinical problem and a dose-limiting toxicity. 
In Chapter 4 we described that in our population of 213 docetaxel-treated patients, we saw that 
patients with severe neutropenia had a significantly lower docetaxel clearance than patients with 
normal neutrophil counts. We developed a model that could predict neutropenia with 70% sensitivity. 
Since the exposure to docetaxel correlates with its toxicity, we also developed a model predicting low 
docetaxel clearance (and thus high exposure) (4). Patients with low clearance (defined as 1 standard 
deviation below the mean clearance) could be correctly identified in 80% of cases. These models, as 
also the models for paclitaxel, did not reach statistical significance. Raising the assumption that genetic 
variation within patients only is not enough to accurately predict taxane-induced toxicity and to do so, 
the effects of non-genetic factors on the pharmacokinetics and pharmacodynamics of taxanes must 
be taken into account. 
 To look into all known and clinically relevant factors influencing docetaxel pharmacokinetics, 
an extensive literature search was performed. Chapter 5 summarizes current knowledge on factors 
influencing docetaxel pharmacokinetics and therefore (potentially) also efficacy.  To sum, liver 
impairment and hormonal factors should be taken into account in docetaxel therapy. Liver impairment 
decreases docetaxel clearance. Hormonal factors such as castration status and menopausal status also 
influence docetaxel pharmacokinetics. This review confirmed that the value of pharmacogenetics in 
predicting docetaxel pharmacokinetics is still limited. Drug-drug interactions on the other hand are of 
clinical relevance, especially with drugs inhibiting Cytochrome P450 3A4. 
 Since the first introduction of cabazitaxel, multiple new drugs for the treatment of castration 
resistant prostate cancer (mCRPC) were brought onto the market for the treatment of these patients. 
Both androgen receptor targeted drugs abiraterone as well as enzalutamide are frequently used in 
the treatment of mCRPC. However, with the introduction of these new therapies, it remained unclear 
what the most effective treatment continuum would be. For a long time, it was indistinct whether the 
efficacy of cabazitaxel was affected by preceding therapy with androgen receptor targeted drugs. In 
Chapter 6, we studied the effects of preceding abiraterone and/or enzalutamide therapy in patients 
with mCRPC on cabazitaxel efficacy. In this study, data was collected from 114 mCRPC patients that 
had been treated with cabazitaxel (in the prospective CABARESC trial). All were treated after a regimen 
of docetaxel therapy. Looking at prostate-specific antigen response and overall survival as a measure 
for cabazitaxel efficacy, we showed that preceding therapy with abiraterone or enzalutamide does not 
affect cabazitaxel efficacy. Based on these data, cabazitaxel seems to be useful at any stage of post-
docetaxel mCRPC treatment. 
In Chapter 7, a method for the quantitative measurement of cabazitaxel has been developed 
using liquid chromatography/tandem mass spectrometry (LC-MS/MS). Using this method, cabazitaxel 
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levels can be determined in human lithium heparinized plasma samples. This method was then used 
in the clinical trial determining the effect of the corticosteroid budesonide on the pharmacokinetics 
of cabazitaxel, preceding the CABARESC study (Chapter 8). In accordance with the hypothesis this 
particular study showed no clinically relevant effects of budesonide on the pharmacokinetics of 
cabazitaxel. Subsequently, we used budesonide to test the hypothesis that co-administrating this 
corticosteroid with cabazitaxel would diminish the incidence and severity of cabazitaxel-induced 
diarrhea. 
Budesonide was chosen for this purpose because of its low systemic availability and thus 
fortunate safety profile. This drug was previously shown to decrease the severity of irinotecan-induced 
diarrhea (5, 6). We hypothesized that the locally anti-inflammatory effect of budesonide would prevent 
the occurrence of cabazitaxel-induced diarrhea. We included 227 evaluable mCRPC patients in our 
study, of which half received budesonide for two courses, starting 2 days before the first cabazitaxel 
administration. Analyses of the data showed that the incidence of cabazitaxel-induced diarrhea was 
lower than reported previously. Diarrhea was no dose limiting toxicity and well manageable in routine 
clinical practise. Budesonide had no significant effect on the incidence and severity of cabazitaxel.
To conclude, multiple factors may influence the pharmacokinetics and pharmacodynamics 
of taxanes. Some of these factors are clinically relevant and should be taken into account when 
administering a taxane to a patient with cancer. Factors such as hormonal status deserve more thorough 
investigation, as its effects seems to be under-exposed but potentially important. The combination of 
patient-bound and environmental factors with genetic factors could potentially increase the value 
of predictive models in a clinical setting. The ultimate goal should be to increase quality of life by 
diminishing taxane-induced toxicity, as well as to optimize taxane-efficacy. 
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150
NederlANdse sAMeNVATTING
De afgelopen jaren zijn de anti-kanker middelen paclitaxel, docetaxel en cabazitaxel veel gebruikt voor 
de behandeling van verschillende soorten kanker. Deze drie chemotherapeutica noemen we ook wel 
‘Taxanen’. Taxanen kunnen overlevingswinst bieden aan patiënten met onder andere borstkanker, 
longkanker en prostaatkanker. Aan de behandeling met deze middelen zitten echter ook nadelen. 
De toediening van taxanen resulteert in sommige gevallen in ernstige bijwerkingen. 
Voorbeelden daarvan zijn gevoelsstoornissen aan handen en voeten, vermoeidheid, haarverlies, 
misselijkheid en diarree. Van tevoren valt echter niet goed te voorspellen welke patiënten last zullen 
krijgen van deze bijwerkingen. Ook valt niet goed te voorspellen hoe groot de blootstelling aan het 
medicijn precies zal zijn. Dit valt te wijten aan een grote variatie in de farmacokinetiek van taxanen. 
Farmacokinetiek is de verzamelnaam voor de opname, verdeling, omzetting en uitscheiding van 
een medicijn door het lichaam. Voor taxanen is aangetoond dat er een verband bestaat tussen de 
blootstelling aan het geneesmiddel en zijn werkzaamheid en bijwerkingen. Taxanen staan daarnaast 
bekend om hun kleine ‘therapeutische breedte’, wat zoveel wil zeggen als: er is maar een klein verschil 
tussen de meest effectieve dosering en een dosering die te hoog of te laag is, wat kan resulteren in 
veel bijwerkingen of een suboptimaal effect van de therapie. Als patiënten een te hoge blootstelling 
hebben aan een taxaan doordat ze het middel langzaam uit het lichaam verwerken en uitscheiden, is 
het voorstelbaar dat deze mensen meer last zullen hebben van ernstige bijwerkingen dan patiënten 
die het middel snel verwerken en uitscheiden. Andersom geldt dat mensen die het geneesmiddel heel 
snel kwijt zijn, een groter risico lopen op een suboptimaal effect van de therapie. Het is daarom nuttig 
om de blootstelling van patiënten aan taxanen te kunnen voorspellen om zo een optimale dosering te 
kunnen berekenen. Op dit moment worden patiënten gedoseerd op basis van hun lengte en gewicht. 
Gebleken is dat deze strategie de variatie in de farmacokinetiek tussen patiënten niet reduceert. 
Naast farmacokinetische variatie is er ook een grote variatie in de ‘farmacodynamiek’ van 
taxanen. Met farmacodynamiek bedoelt men de werking van het geneesmiddel op het lichaam. 
Hieronder vallen de bijwerkingen van geneesmiddelen, maar ook zijn werkzaamheid. Deze variatie 
tussen patiënten hangt deels samen met de variatie in farmacokinetiek. Om bijwerkingen te 
verminderen en de effectiviteit van de therapie te verbeteren zou het dus ook relevant zijn om de 
farmacodynamiek voor individuele patiënten te kunnen voorspellen. 
Naar alle waarschijnlijkheid zijn er meerdere factoren die de farmacokinetiek en 
farmacodynamiek van taxanen beïnvloeden. In dit proefschrift wordt een multifactoriële benadering 
besproken welke als doel heeft inzicht te creëren met betrekking tot factoren die de farmacokinetiek 
en farmacodynamiek van taxanen beïnvloeden. Met andere woorden, dit proefschrift beschrijft 
onderzoek naar factoren die zowel de bijwerkingen van taxanen als de blootstelling aan taxanen en 
daarmee mogelijk de effectiviteit beïnvloeden. 
Zoals genoemd zijn de taxanen ondanks hun gemeenschappelijke noemer wel degelijk 
verschillend van elkaar. Neem bijvoorbeeld alleen al het middel waarin zij zijn opgelost omdat de 
taxanen zelf heel lastig in water op te lossen zijn. Paclitaxel is oplosbaar in water omdat Cremophor, 
een oplosmiddel, is toegevoegd aan de formulering van paclitaxel. In een andere variant van de 
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paclitaxel formulering is paclitaxel gebonden aan een eiwit. Docetaxel en cabazitaxel zijn beide 
wateroplosbaar gemaakt door aan de formulering het oplosmiddel Polysorbaat 80 toe te voegen. 
Deze oplosmiddelen blijken echter de farmacokinetiek en daarmee de blootstelling aan taxanen te 
beïnvloeden. Omdat taxanen met name worden afgebroken door de lever en de opname van taxanen 
in de lever geschiedt middels specifieke ‘transport-’ eiwitten is de invloed van deze oplosmiddelen op 
transport-eiwitten in de lever onderzocht in hoofdstuk 2. Dit onderzoek bevestigt de rol van transport-
eiwitten in de afbraak van paclitaxel en docetaxel en laat zien dat het toevoegen van oplosmiddelen 
aan deze middelen resulteert in een verminderde werking van de transporter eiwitten in de lever. Dit 
betekent dat de oplosmiddelen dus leiden tot een verhoogde blootstelling aan paclitaxel en docetaxel. 
Naast de invloed van de oplosmiddelen van taxanen lijkt de variatie in farmacokinetiek en 
-dynamiek tussen patiënten toch een multifactoriële grondslag te hebben. Men heeft zich afgevraagd 
of ons genetisch materiaal (DNA) en de verschillen tussen mensen mogelijk ook een rol spelen in de 
verschillen tussen patiënten in farmacokinetiek. Voor zowel docetaxel als paclitaxel zijn eerder studies 
gedaan naar enkele stukjes van DNA (genen). Echter, geen van deze genen verklaarde de verschillen in 
farmacokinetiek en –dynamiek volledig. In dit proefschrift staan meerdere onderzoeken beschreven 
(hoofdstuk 3 en 4) die zich hebben gericht op de invloed van genetische variatie op de farmacokinetiek 
en –dynamiek van taxanen. In deze studies is geprobeerd om grote aantallen genen in kaart te brengen 
en de variatie tussen mensen in verband te brengen met de blootstelling aan taxanen en het risico 
op bijwerkingen. Zo is geprobeerd de bijwerkingen en de blootstelling aan paclitaxel en docetaxel 
te voorspellen middels genetische modellen. In deze modellen zijn genetische variaties geïncludeerd 
die mogelijk verklarend zouden zijn voor de verschillen in kinetiek en dynamiek in patiënten. Gebruik 
makend van deze modellen konden de meeste patiënten met een hoog risico op een laag aantal witte 
bloedcellen en een lage klaring en dus een hoge blootstelling geïdentificeerd worden. Echter waren 
deze modellen niet voorspellend genoeg, wat betekent dat ze (nog) niet in de kliniek gebruikt kunnen 
worden. 
Naast genetische factoren en het feit dat farmacokinetiek ook voorspellend kan zijn voor de 
toxiciteit van taxanen is in dit proefschrift ook gekeken naar andere factoren die van invloed zijn op 
de farmacokinetiek van docetaxel (hoofdstuk 5). Dit is gedaan door middels bestaande literatuur in 
kaart te brengen wat we weten van factoren die de farmacokinetiek van docetaxel beïnvloeden. Uit 
dit onderzoek kwam naar voren dat met name leverenzym-stoornissen ervoor zorgen dat docetaxel 
minder goed afgebroken kan worden, en dat daarmee de blootstelling aan docetaxel hoog is. Ook het 
geslacht en de lichaamsbouw van de patiënt bleek van invloed op de farmacokinetiek. Daarnaast is 
naar aanleiding van dit onderzoek het advies gegeven goed op te letten met het gebruik van andere 
medicatie en alternatieve geneesmiddelen. Deze middelen kunnen namelijk de afbraak van docetaxel 
beïnvloeden en daarmee de blootstelling aan deze anti-kanker therapie en potentieel dus ook de 
effectiviteit en toxiciteit. 
Voor cabazitaxel is ook onderzocht of andere medicijnen de effectiviteit van deze chemotherapie 
beïnvloeden. Cabazitaxel wordt op dit moment gebruikt in de behandeling van uitgezaaide 
prostaatkanker. Voor deze groep patiënten zijn er de afgelopen jaren vele medicijnen bijgekomen die 
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hun overleving kan verlengen. Voorbeelden van deze medicijnen zijn abiraterone en enzalutamide; 
beide middelen welke zijn gericht op een eiwit waaraan mannelijke hormonen zich kunnen binden. 
Mannelijke hormonen kunnen de groei van een prostaattumor bevorderen. Het was echter nog 
onduidelijk of de volgorde van het toedienen van deze verschillende medicijnen van invloed is op hun 
effect. In hoofdstuk 6 is een studie beschreven waarin gekeken is of de behandeling met abiraterone 
of enzalutamide voorafgaand aan de behandeling met cabazitaxel van invloed is op het effect van 
cabazitaxel op de ziekte. Dat onderzoek is gedaan door mannen met prostaatkanker die behandeld 
waren met abiraterone of enzalutamide, en daarna cabazitaxel toegediend kregen, te vergelijken met 
mannen welke direct cabazitaxel kregen. Ze werden vergeleken in tijd van overleving en daarnaast 
werd gekeken naar het Prostaat Specifiek Antigeen (PSA), een maat voor activiteit van de ziekte. Beide 
parameters waren niet verschillend in beide groepen, wat betekent dat voorafgaande behandeling 
met abiraterone of enzalutamide de effectiviteit van cabazitaxel niet vermindert. 
Bij de registratiestudie van cabazitaxel viel op dat bijna de helft van de mannen last had 
van diarree. Een klein deel van deze groep moest daarbij zelfs in het ziekenhuis opgenomen worden. 
Om de ernst en het voorkomen van diarree te verminderen is in de studie beschreven in hoofdstuk 
8 een ontstekingsremmer toegevoegd aan de behandeling met cabazitaxel. Patiënten slikten elke 
dag een corticosteroïd (budesonide). Voorafgaand aan deze grote studie bleek uit een kleiner door 
ons uitgevoerd onderzoek dat budesonide geen (negatief) effect heeft op de farmacokinetiek van 
cabazitaxel. In hoofdstuk 7 staat beschreven hoe de concentraties van cabazitaxel bepaald kunnen 
worden in het plasma van patiënten behandeld met dit middel. In de studie naar de effecten van 
budesonide op het vóórkomen en de ernst van diarree in patiënten die met cabazitaxel behandeld 
werden, bleek dat budesonide geen duidelijk positief effect had op het voorkomen van diarree en dat 
de diarree goed onder controle te houden was.  
Toekomst visie
 De inzichten met betrekking tot de farmacokinetiek en farmacodynamiek van taxanen welke 
in dit proefschrift naar voren zijn gekomen kunnen in de toekomst gebruikt worden om deze kennis 
verder uit te breiden. Het uiteindelijke doel zal zijn elke patiënt een individuele dosis toe te kennen 
van het taxaan waarmee zij behandeld worden, om zo een optimale balans tussen effectiviteit en 
bijwerkingen te kunnen bewerkstelligen. Meerdere factoren blijken een invloed te hebben op de 
farmacokinetiek en farmacodynamiek van taxanen. Sommige van deze factoren zijn klinisch relevant 
en moeten meegenomen worden in de besluitvorming bij therapie met taxanen. Factoren als 
hormonale status verdienen meer diepgaand onderzoek, omdat zij onderbelicht zijn maar potentieel 
belangrijk. De combinatie van patient- en omgevingsgebonden factoren met genetische factoren 
zouden potentieel de waarde van voorspellende modellen in de klinische setting kunnen vergroten. 
Het uiteindelijk doel zal zijn de kwaliteit van leven van met taxanen behandelde patiënten te vergroten 
door de bijwerkingen van taxanen te verminderen en het effect te optimaliseren. 
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Ik ben trots dat u vandaag dit boekje in handen heeft. Echter zonder de hulp, steun en input van velen 
was dit proefschrift er nooit geweest. Op deze laatste paar bladzijden van dit boekje wil ik dan ook 
een aantal mensen bedanken en vereeuwigen. Omdat het afronden van mijn proefschrift nagenoeg 
samenviel met het afronden van mijn studie maak ik van de gelegenheid gebruik ook aan (de mensen 
in) die periode te memoreren. 
Allereerst wil ik alle patiënten bedanken die geheel belangeloos hebben deelgenomen aan de studies. 
Velen van u reageerden vrijwel hetzelfde: “Ik doe het voor de mensen die er straks misschien wel wat 
aan hebben”. Ik heb bewondering voor het feit dat u in die fase van uw leven nog ruimte had voor 
andermans belangen. Ik ben u daarvoor dan ook zeer erkentelijk. Zonder mensen als u bestaat er geen 
vooruitgang in de oncologie. 
Dan wil ik uiteraard mijn promotoren bedanken. Prof. dr. A.H.J. Mathijssen, beste Ron, ik wil je 
bedanken voor het vertrouwen dat je mij als groentje gaf om met dit onderzoek te starten. Dank 
dat je altijd zo laagdrempelig te benaderen was om over praktische en wetenschappelijke zaken van 
gedachten te wisselen. Maar ook dat je met me mee dacht toen ik tussentijds aan mijn coschappen 
wilde beginnen en ik je er van verzekerde dat het proefschrift ook dan af zou komen, ook al zag je 
dat in eerste instantie niet zo zitten. Ik bewonder je  gedrevenheid en deskundigheid. Prof. dr. R. de 
Wit, beste Ronald, dankjewel voor de mogelijkheid aan dit promotietraject te beginnen. Bedankt dat 
ook jij met me mee wilde denken toen ik toch eerder de kliniek in wilde dan gepland, voor je visie en 
uiteraard voor je bijdrage aan dit proefschrift. Ook bedank ik je voor de politieke lessen die je me hebt 
meegegeven en de verschillende podia die je me geboden hebt om dit onderzoek te profileren.
Prof. dr. R.H.N. van Schaik, beste Ron, dankjewel voor de prettige samenwerking. Toen ik er eenmaal 
achter was dat ik gewoon met het manuscript naar je kantoor moest komen om zo de rode inkt te 
laten vloeien hadden we binnen no-time twee papers gepubliceerd. Ik heb veel gehad aan je feedback 
en je kennis, waarvoor dank.  
Prof. dr. A. Sparreboom, beste Alex, met name in de korte periode dat ik op het lab in 
Memphis mocht zijn viel het tempo waarin gewerkt wordt en de kennis over farmacologie die zich 
daar bevindt mij het meeste op. Je liet me tijdens de revisies van mijn stukken ook elke keer weer een 
nieuwe invalshoek zien en schroomde niet te benoemen dat een stuk soms gewoonweg nog niet goed 
genoeg was. Je hebt me daarmee gestimuleerd mijn schrijfvaardigheid maar zeker ook mijn kennis 
en diepgang verder te verbeteren. Ik voel mij dan ook vereerd dat je de plas bent over gestoken om 
aanwezig te zijn op mijn promotiedag.  
Prof. dr. T. van Gelder, beste Teun, bij onze eerste ontmoeting vond ik je stem zo bekend 
voorkomen maar ik wist niet goed waar ik je van zou kunnen kennen. Ik kwam er later achter dat ik 
daarvoor gewoon wat verder vooraan had moeten gaan zitten in de collegezaal.  Ik wil je bedanken 
voor het feit dat je vandaag front row zal zitten als opponent in de kleine commissie.   
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Beste dr. A. Huitema, ik wil u bedanken voor het zitting nemen in de grote commissie. Beste 
dr. R. van Soest, beste Robert, dank voor je inzet voor de Cabaresc studie en voor het zitting nemen in 
de grote commissie. Dear professor Sharyn Baker, thank you for attending my PhD defence as part of 
the dissertation committee. I am honored that you travelled so far to be here on this day. 
Ook wil ik een aantal personen bedanken die mij geïnspireerd hebben onderzoek te willen 
doen. Prof. dr. E. Zwarthoff, beste Ellen, je wist me te enthousiasmeren voor wetenschappelijk 
onderzoek. Ik ben je dankbaar voor de begeleiding die ik van je heb mogen ontvangen en je oprechte 
interesse in hoe het mij verging. Het cirkeltje is voor mij rond nu je zitting hebt genomen in de grote 
commissie, waarvoor veel dank.      
Beste dr. M. Bontenbal, de onderwijsprijzen die u in de afgelopen jaren hebt mogen 
ontvangen zijn er het bewijs van dat uw benadering van de oncologie door velen wordt gewaardeerd. 
Zo ook door mij. Dank voor de eerste adviezen en de lijntjes die u voor mij heeft gelegd destijds. Het is 
het begin geweest van wat nu voor u ligt.    
Beste dr. T. Zuiverloon, beste Tahlita, jij stimuleerde me in het onderzoek verder te gaan 
en pikte het als ik je weer eens aan het opjagen was. Ik zal je wijze lessen over het waarom van 
promoveren niet snel vergeten. Onze review was mijn eerste paper en ik ben er nog steeds trots op.
 
Het laboratorium Translationele Farmacologie was jaren mijn ‘thuisbasis’. Zonder mijn collega’s was 
er geen proefschrift geweest en was het met mijn geestelijke gesteldheid mogelijk ook anders gesteld 
geweest. 
Sander, naast mijn waardering voor je inzet voor de Cabaresc studie ben ik je ook een 
woord van dank verschuldigd voor je relativerende droge humor en de vele hilarische filmpjes die 
mijn leven rijker is geworden. Ook je IT deskundigheid kwam vaak zeer goed van pas als ik weer eens 
vast zat. Jacqueline, dankjewel voor je gezelligheid en je reistips! “Nee geen hakken in je backpack”. 
Peter, dankjewel voor je geduld en je kennis, alsmede voor al je werk. Je bescheidenheid maakt dat 
het misschien niet altijd opvalt hoe groot jouw toegevoegde waarde is, maar laat het bij deze dan 
zwart op wit staan. Inge, als vanzelfsprekend heb ik je werk maar ook je gezelligheid en hoe attent 
je altijd bent zeer gewaardeerd. Mei, ook jij bedankt voor je werk en de lekkere ei-vrije hapjes en de 
moeite die je daar elke keer weer voor deed. Patricia, als kamergenoot wil ik je graag bedanken voor je 
behulpzaamheid, jij staat altijd voor een ander klaar. Anne-Joy, dank voor je begeleiding en alle inside 
info die ik als student van je kreeg. Karel, voor jou geldt hetzelfde. Sorry dat je erfenis (lees: pieper) 
meteen in mijn eerste week in het riool belandde. Walter, Carolien, Marijn, Erik, Herman, Xander, Ton, 
Roelof, Leni en Bimla dank jullie wel voor jullie input en gezelligheid. Maaike en José, dankjewel voor 
alles, wat moeten ze/we zonder jullie! 
Alle coauteurs wil ik bedanken voor hun bijdrage aan het onderzoek in dit proefschrift. Alle artsen en 
(research) verpleegkundigen in de Daniel, op de Centrumlocatie en  in het gehele land, bedankt voor al 
jullie hulp en deelname in de 03-264 en de Cabaresc studie. Een aantal van de co-auteurs wil ik nog in 
het bijzonder bedanken. Beste Marcel, je was de drijvende kracht achter de DMET papers en daarvoor 
ben ik je zeer erkentelijk alsmede voor je geduld met mij. Samira, wat was het een gedoe om alle 
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samples gerund te krijgen, zonder jou was het niet gelukt! Beste Linda, Nelly, Tessa, René, Dana en alle 
andere leden van het Cabaresc studie team, heel erg veel dank voor alle uren die jullie in de Cabaresc 
hebben gestoken zonder te mopperen (in ieder geval niet waar ik bij was). Het was altijd een fijn idee 
te weten dat ik op jullie deskundigheid kon rekenen en dat aan alles werd gedacht. Nelly, als jij een 
stuk leest weet je zeker dat niets over het hoofd gezien wordt, hulde aan jouw kritische blik, het heeft 
de Cabaresc en ook mijn werk beter gemaakt. Beste dr. P. Hamberg, beste Paul, dankjewel voor alle 
energie en moeite ten aanzien van de Cabaresc studie. Zonder jullie en de patiënten uit het SFG was 
het einde van de studie nog niet eens in zicht geweest. Dear Shuiying and Alice, thank you for all the 
work in the OATP project. I hope you are both doing well and wish you all the best both in your career 
as well as personally.  
Lieve Ellen, ik denk dat ik wel kan zeggen dat we de meeste hoogte- en dieptepunten van de promotie 
rollercoaster samen hebben beleefd. Ook al zaten we niet op hetzelfde lab, het klikte vanaf moment 
één en na een paar weken deelden we al een kamer in Dublin. Je humor, opbeurende woorden, de 
nodige bakkies pleu-ahr, en een enkel frietje hebben me door de promotie-dipjes geholpen. “Wij 
komen er wel”! En zo is het (zelfs in dezelfde week)! 
Lieve Lisette, als kamergenoot was je er altijd om even te sparren en ook om de dagelijkse 
beslommeringen mee te bespreken. Hoogtepunt was uiteraard om jouw promotie als paranimf mee te 
mogen maken. Goede tweede is uiteraard jullie muisexperiment waar ik een nieuwe kant van mezelf 
ontdekte. In de afgelopen jaren ben je voor mij een vriendin geworden, een waarop je kunt bouwen. 
Dankjewel voor al jullie adviezen en steun meiden, zonder jullie was het niks geworden!  
Lieve meiden van jaarclub Santé: Anouk, Charlotte, Cleo, Danielle, Els, Ingeborg, Linda, Marjolein, 
Marije, Yvette en Sil, jullie hebben ervoor gezorgd dat Rotterdam mijn thuis werd. Ik hoop dat we nog 
heel vaak met elkaar op mooie dingen mogen proosten: Santé! 
 Lieve Anouk, geen poespas bij jou. Je oprechte interesse en nuchterheid waardeer ik zeer. 
What you see is what you get, dankjewel! Het maakt niet uit in welke steden onze huizen staan!
 Lieve Inge, al vanaf de clubvorming hadden we een klik en vele verenigingen verder is die 
er gelukkig nog steeds. De Zeil, Skadi, op elk weekendje waren we er, al moest men er niet gek van 
opkijken als we onze eigen planning hadden. Toch vonden we op het water niet altijd waar we naar 
op zoek waren. Dankjewel voor alle hilarische momenten die we hebben gedeeld en de steun en 
vriendschap die ik over de jaren heb mogen ervaren. 
Lieve Marije, dankjewel voor je vriendschap. We kunnen het tijdens onze etentjes altijd 
zo goed hebben over alle dingen die ons bezig houden, ook al is dat soms in totaal verschillende 
werelden. Het blijft altijd waardevol en heerlijk verfrissend!
Lieve Sil, als medico’s van de club mochten we al snel ervaren hoe het was om uit je (stapel)
bed gehaald te worden voor een medisch noodgeval. Groene klompen (hoe ironisch) aan de kant: met 
een stabiele zijligging en een lepel kregen wij iedereen weer op de been. Zowel op de velden, in de 
kroeg en op het water zijn wij een goed team.  Dankjewel voor je vriendschap!  
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Lieve Katrien en Judith, dank jullie wel dat jullie mij als groentje in Hotel de Botel hebben opgenomen 
en Rotterdam hebben laten zien. Daarbij kwamen later ook Saar, Naomi en Iris. Lieve meiden, ik heb 
genoten van de gezelligheid, de verhalen, het gezonde koken (ook dank namens mijn moeder) en dat 
jullie er altijd waren om even bij binnen te lopen. We lopen tegenwoordig wat minder makkelijk bij 
elkaar binnen, maar mijn deur staat nog altijd voor jullie open!
Lieve Yvonne, we gaan al jaren terug. Van brugwuppen met te grote rugzakken naar nu. De afstand 
maakt dat we elkaar soms een tijdje minder zien, maar het is altijd weer als vanouds. Je vriendschap 
is me heel dierbaar. Ik heb je altijd bewonderd om je discipline en het feit dat de onfortuinlijke 
loting onze vriendschap nooit een seconde in de weg heeft gestaan. Ik hoop dat we nog vele jaren 
vriendschap mogen delen!
Lieve Mus, dank voor alle keren dat je er voor me was, naar me luisterde alsof je het niet al tien keer 
eerder had gehoord, en het nog onthield ook. Dankjewel voor je humor en je vriendschap. Ik zal 
nooit meer vergeten hoe we in ons eerste jaar bijna de collegezaal uitgezet zijn omdat we niet meer 
bijkwamen van de lach, hoe we in Bulgarije op de OK stonden en vele avonden in onze stamkroeg sleten 
waar ze op de vraag of ze Engels spraken gewoon, “Houston, we’ve got a problem!” antwoordden. Ik 
ben dan ook heel blij dat je naast me wil staan op mijn promotiedag. 
Last but not least wil ik mijn familie bedanken. Zonder jullie was alles anders geweest. 
Lieve familie Nieuweboer, zonder jullie aanwezigheid zijn de feestjes niet compleet, dank 
voor jullie interesse in mij, ik hoop dat we elkaar nog vele jaren mogen volgen en zien. Lieve Monique, 
Carlien en Joris, elke keer als we elkaar zagen was het weer wat anders wat ik aan het doen was, 
dankjewel dat jullie het probeerden bij te houden en met me mee hebben geleefd. 
Lieve tante Danielle en oom Jaap, dank voor alles wat we tot nu toe met elkaar hebben 
mogen delen en dat jullie er altijd (voor me) zijn! Ik waardeer jullie warmte en interesse in mij en vind 
het altijd een feestje om elkaar weer te zien.
Lieve Oma, dankjewel voor uw niet aflatende interesse en trots. U heeft heel wat kaarsjes 
opgebrand de afgelopen jaren en ons vanaf kleins af aan gestimuleerd onze hersenen te gebruiken met 
memory en kruiswoordpuzzels maar toch was de ‘bolletjes’ kant van het rapport altijd het belangrijkst. 
Ik ken geen andere oma’s die hun kleinkinderen achter op de fiets het woord ‘anticiperen’ bij brengen, 
uiteraard voorafgaand en gevolgd door heel hard vals zingen. 
Lieve Frederieke, dankjewel voor de fijne zus die je bent en dat je mijn paranimf wilde 
zijn. We hebben al zoveel mooie dingen mogen beleven. Je weet ook telkens weer een feitje of een 
herinnering op te vissen die ik dan al lang weer vergeten ben. Ik hoop dat we de komende jaren nog 
veel meer herinneringen mogen maken en delen!
Lieve Sander, jij hoort er voor mij bij alsof het nooit anders is geweest. Toch is dat wel zo, 
want het staat me nog heel helder voor de geest dat je moeder in groep acht uitleg kwam geven over 
het beroep van apotheker en in plaats van capsules salmiak snoepjes gebruikte. Het heeft ongetwijfeld 
wat in mijn getriggerd. Wie had dat gedacht, van schoppend schooljoch naar zwager?!
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Lieve Frank, ik ben blij dat ik geneeskunde heb kunnen afronden, want mijn tweede 
studiekeuze was toch op de second best business school geweest (als ik jou mag geloven althans). Ik 
bewonder je doorzettingsvermogen en je loyaliteit en wil je bedanken voor het zijn van de fijne broer 
die je voor mij bent. Als jij er niet bent wordt er echt minder gelachen aan tafel (behalve door mij dan, 
want ik lach ook om mijn eigen grappen natuurlijk..). 
Lieve Mam, je hebt me geleerd hard te werken, maar je hebt me ook laten zien dat alles 
relatief is. Dankjewel dat je altijd naar me luistert. Je bent er altijd op de belangrijke momenten, 
maar ook op de doodgewone momenten heb jij de gave om er altijd wat feestelijks van te maken. 
Ook na een drukke werkweek trek jij alles uit de (koel)kast als we weer met elkaar aan tafel zitten. 
Ik ken niemand anders die altijd de champagne koud heeft staan voor een onverwacht feestelijk of 
anderszins memorabel moment! Je hebt me geleerd het leven te vieren. Dankjewel voor al je adviezen 
en je goede voorbeeld. 
Lieve Pap, dokter Spock is inmiddels dokter Nieuweboer geworden maar zal voor jou 
waarschijnlijk altijd dokter Spock blijven. Jouw nuchtere kijk op het leven heeft me geleerd wat 
belangrijk is en om dicht bij mezelf te blijven. Je weet me regelmatig een andere kijk op dingen te 
geven. Dankjewel dat ik altijd op je kan bouwen.
Lieve Pap en Mam, ik draag dit boekje aan jullie op. Laat het symbool staan voor het feit dat 
jullie me hebben geleerd door te zetten en af te maken waar ik aan begonnen ben. “Kan ik niet ligt op 
het kerkhof”. Jullie hebben me het vertrouwen gegeven dat als ik ergens voor ging ik het dan ook kon 
bereiken. Het is een fijn gevoel te weten dat ik altijd op jullie steun en liefde kan rekenen. Dankjewel 
voor alles wat jullie me hebben (mee)gegeven. 
Lieve Bart-Jan, dankjewel voor je niet aflatende steun en liefde. Ik ben je dankbaar voor wie je bent en 
voor alles wat je voor mij betekent. In het bijzonder voor je stabiliteit en rust, je relativeringsvermogen, 
je geduld, je humor en je onverflauwde vertrouwen in mij, zelfs als ik dat zelf (even) niet had (all of the 
above...). Ik hoop dat we nog heel veel samen mogen vieren!
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